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Abstract
Chagas disease is a neglected chronic condition with a 
high burden of morbidity and mortality. It has considerable 
psychological, social, and economic impacts. The disease 
represents a significant public health issue in Brazil, with 
different regional patterns. This document presents the 
evidence that resulted in the Brazilian Consensus on Chagas 
Disease. The objective was to review and standardize 
strategies for diagnosis, treatment, prevention, and control 
of Chagas disease in the country, based on the available 
scientific evidence. The consensus is based on the articulation 
and strategic contribution of renowned Brazilian experts with 
knowledge and experience on various aspects of the disease. 
It is the result of a close collaboration between the Brazilian 
Society of Tropical Medicine and the Ministry of Health. It 
is hoped that this document will strengthen the development 
of integrated actions against Chagas disease in the country, 
focusing on epidemiology, management, comprehensive 
care (including families and communities), communication, 
information, education, and research.
Keywords: Chagas disease. Epidemiology. Control. 
Diagnosis. Treatment. Health care. Consensus. Brazil.
INTRODUCTION
General aspects of Chagas disease epidemiology, with 
specific focus on Brazil
Chagas disease, an infectious condition with an acute and 
chronic phase, is classified as a neglected disease by the World 
Health Organization (WHO)(1) (2). As a result of human poverty, 
it presents high morbidity and mortality load in endemic 
countries, including Brazil, with focal expression in different 
epidemiological contexts(1) (2) (3) (4). The geographic distribution 
of the disease is limited primarily to the American continent due 
to the distribution of more than 140 species of insect vectors 
(Triatominae, Hemiptera, Reduviidae); hence, it is also called 
American trypanosomiasis(5). Gradually, however, the disease 
has reached non-endemic countries; this as a result of an intense 
process of international migration and as the mode of disease 
transmission has changed(6) (7) (8) (9) (10) (11) (12) (13).
The World Health Organization (WHO) estimates that 
approximately 6-7 million people are infected worldwide, 
mostly in Latin America(14).Recent estimates for the 21 Latin 
American countries, based on data from 2010, showed that 
5,742,167 people were infected by Trypanosoma cruzi, of 
which 3,581,423 (62.4%) were living in the countries of the 
Southern Cone Initiative against Chagas disease, especially 
Argentina (1,505,235), Brazil (1,156,821), Mexico (876,458), 
and Bolivia (607,186)(5). However, these data differ from 
the estimates of other research groups using other methods 
to define T. cruzi infection in many countries; this hinders 
accurate establishment of the prevalence of Chagas disease in 
the Americas. Nevertheless, the authors agree that the number 
of infected individuals is still very significant in the health and 
social context of the continent, requiring priority and attention 
from the countries(15) (16).
Table 1 represents changes in epidemiological parameters 
specific to Latin America in the recent years(5) (17).
Thus, despite advances in vector control and quality 
assurance of blood transfusions in many of these countries, 
especially from intergovernmental initiatives started in the 
1990s(3) (4) (10) (11) (18), Chagas disease remains a relevant public 
health problem in Latin America, showing different regional 
patterns of epidemiological expression. The challenges are 
magnified by the lack of access to diagnosis and systematic 
treatment; according to 2015 estimates >80% of individuals 
affected by Chagas disease globally had no such access. This 
supports the high impact of morbidity, mortality, and the social 
cost of this illness.
Uncontrolled human migration, environmental degradation, 
climate change, high population concentrations in urban areas, 
and precarious socio-economic conditions (housing, education, 
sanitation, and income, among others) are determinants and 
social conditioning factors for the transmission of T. cruzi(1) (10) 
(11) (19) (20) (21) (22) (23). Infected populations are vulnerable to varying 
degrees of neglect, expressed by overlapping and increased 
exposure to other diseases, conditions and injuries; lower 
coverage for preventive interventions; a higher likelihood of 
illness; less access to a network of health services, to secondary 
and tertiary health care, and to other services; poor quality of 
primary care services; lesser likelihood of receiving essential 
treatments; and greater likelihood of developing severe forms 
of the disease with increased risk of progression to death(24).
From this perspective, it is essential to obtain greater 
knowledge concerning the epidemiological scenario of Chagas 
disease and its transmission dynamics, involving people who are 
Parameters – estimates 1990 2000 2006 2010
Number of deaths/year >45,000 21,000 12,500 12,000
Number of infected individuals 30,000,000 18,000,000 15.000.000 5,742,167
New cases/year – vector transmission 700,000 200,000 41.200 29,925
Total population at risk 100,000,000 40,000,000 28,000.000 70,199,360
TABLE 1
Changes in mortality, prevalence, and incidence of vector-borne transmission of Chagas disease in 21 endemic countries in Latin America, in the years 1990, 
2000, 2006, and 2010.
Source: Adapted from the Pan American Health Organization, 2006(17) (TDR/WHO, PAHO, WHO); World Health Organization, 2015(5).
  5
Rev Soc Bras Med Trop 49:Supplement I, 2016
2nd Brazilian Consensus on Chagas Disease, 2015
infected or are at risk of infection, different parasite populations, 
vector species, and T. cruzi reservoirs. This integrated 
knowledge is central to the search for consistent and sustainable 
management actions, monitoring, and coherent health and social 
control programs that are efficient and effective(1) (10) (11) (25) (26) (27).
Despite a clear need for more evidence, more than 105 
years since the discovery of the disease by Carlos Ribeiro 
Justiniano Chagas (1909) there are still important gaps in 
technical, scientific, and political fields that must be overcome 
to effectively face this widely-neglected condition.
Brazil, with its continental dimensions, is undergoing major 
and rapid demographic, social, and environmental change, 
but serious socio-economic and regional inequalities persist. 
Here, diseases associated with social contexts of vulnerability 
and neglect still afflict a considerable part of the population(28). 
Gradually, however, a consistent improvement in the overall 
health status and life expectancy of the Brazilian population has 
been observed. This can be attributed to changes in the social 
determinants of health, advances in the control of infectious 
diseases, and implementation of a more comprehensive national 
health system with relevant social participation(28) (29).
Despite these social advances, it is recognized that the 
persistence of large social inequalities, that result in individual, 
programmatic and social vulnerabilities, is strongly related to 
Chagas disease. New health problems emerge, however, as 
the result of an intense urbanization process and changes in 
the social and environmental field; others tend to persist and 
coexist(28), requiring new healthcare response networks(30).
These demand specific actions, adjusted to new realities, 
focused on an integrated approach to the different components 
involved in the natural history of the disease: humans, vectors, 
reservoirs, and T. cruzi(3) (6) (15). The great extent and territorial 
diversity, with the specific ecologic, demographic, social, 
and economic dynamics of the regions, implies multiple 
epidemiological and operational clinical scenarios(3) (4) (15). 
In addition to the challenges, the coming years bring 
opportunities for shared, more concrete action in fighting Chagas 
disease. In 2015 the 17 new Sustainable Development Goals 
(SDGs) were released; these are based on the eight Millennium 
Development Goals (MDGs). The agenda, which was agreed 
to and consolidated in the framework document Transforming 
Our World: The 2030 Agenda for Sustainable Development, 
represents a historic and unprecedented opportunity for 
countries to seek new global paths(31). In a broader sense, in 
order to promote prosperity and well-being for all, to protect the 
environment and cope with climate changes(31), these decisions 
will determine the global course of action to confront and 
eliminate poverty. 
Chagas disease is part of the third objective of this 
document, which aims to ensure a healthy life and promote 
well-being for all, at all ages. The goal is to control the acquired 
immunodeficiency syndrome (AIDS) epidemic, to eradicate 
tuberculosis, malaria, and neglected tropical diseases and to 
combat hepatitis and waterborne and other transmitted diseases 
by 2030(31). The progress in specific indicator composition to 
monitor neglected tropical diseases in the world is highlighted, 
from the recognition of the number of people requiring 
interventions against this group of diseases. In addition, Chagas 
disease and other neglected tropical diseases also interface 
with the second (zero hunger and sustainable agriculture), fifth 
(gender equality), and sixth (drinking water and sanitation) 
objectives(31).
MORBIDITY AND MORTALITY
Trypanosoma cruzi infection
In Brazil, few population-based systematic studies have been 
conducted. This hinders accurate estimation of the magnitude 
of the impact Chagas disease throughout history.
Prior to the 1950s, Chagas disease was recognized as an 
eminently rural endemic disease, transmitted predominantly 
through vectors, occurring in areas of high social vulnerability. 
With industrialization, the disease became modeled in a new, 
urban epidemiological context, increased by internal migration 
within the country from rural to urban areas with consequent 
growth of cities(4).
Between 1975 and 1980, a national serological survey in 
the rural population of Brazil (except São Paulo), estimated 
the prevalence to be 4.2%, corresponding to 6.5 million people 
infected by T. cruzi(20) (32) (33). In 1996, it was estimated that the 
prevalence of T. cruzi infection in Brazil was at 3.1% in 1978 
and 1.3% in 1995, amounting to an estimated 1.96 million 
people infected(34). Subsequently, the Pan American Health 
Organization (PAHO) estimated that 21.8 million people in 
endemic areas in Brazil were at risk, given the estimated 1.9 
million (1.019% of the population) infected individuals(17). 
In 2014, the first systematic review and meta-analysis 
to estimate the prevalence of Chagas disease in Brazil was 
published. It included publications from the period between 
1980 and 2012, and estimated the pooled prevalence of Chagas 
disease at 4.2% [95% confidence interval (95% CI): 3.1–5.7], 
ranging from 4.4% (95% CI: 2.3–8.3) in the 1980s to 2.4% (95% 
CI: 1.5–3.8) after 2000(35). In that study, the highest prevalence 
was found in women (4.2%; 95% CI: 2.6–6.8), individuals 
over 60 years old (17.7%; 95% CI: 11.4–26.5), residents in the 
Northeastern (5.0%; 95% CI: 3.1–8.1) and Southeastern regions 
(5.0%; 95% CI: 2.4–9.9), and in mixed urban/rural areas (6.4%; 
95% CI: 4.2–9.4). It was estimated that 4.6 million people (95% 
CI: 2.9–7.2 million) would be infected by T. cruzi in Brazil. 
Emphasizing the limitation of the findings in the literature, 
the authors highlight the need for new studies, with a view to 
obtaining truer estimates(35).
From this and other studies, the most recent estimates in 
Brazil regarding the number of people infected by T. cruzi vary 
from 1.9 million to 4.6 million people(35) (36) (37), probably closer 
now to 1.0–2.4% of the population.
This epidemiological scenario brings challenges in the 
coming decades for the country to support control actions 
and establish a consistent plan in the Unified Health System 
[Sistema Único de Saúde (SUS)] for diagnosis, treatment, and 
comprehensive care of millions of people(38), combined with 
epidemiological surveillance adjusted to this reality(15) (22). It is 
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presumed that up to 30% of chronically infected people are likely 
to develop cardiac alterations and up to 10% may experience 
digestive, neurologic, or mixed alterations. Given this, there is a 
heightened need to structure a comprehensive network of timely 
health care for Chagas disease in the country(39).
In order to establish estimates for the number of people 
infected by T. cruzi, the publication Projeção da População do 
Brasil por Sexo e Idade para o Período 2000/2060 e Projeção da 
População das Unidades da Federação por Sexo e Idade para o 
período 2000/2030 (Projection of Brazil’s Population by Sex and 
Age for the Period 2000/2060 and Projection of the Federative 
Unit’s Population by Sex and Age for the Period 2000/2030) 
by the Brazilian Institute of Geography and Statistics [Instituto 
Brasileiro de Geografia e Estatística (IGBE)] was taken as a 
population-based reference. According to the IBGE the Brazilian 
population will continue to grow until 2042, when it will reach 
228.4 million people, mostly concentrated in urban centers. 
From there, it will gradually decrease and it will account for 
approximately 218.2 million individuals in 2060(40). 
Table 2 shows the relative projection to the estimates of 
the number of infected people by T. cruzi and the number of 
Chagas disease cases in the chronic phase with the cardiac and 
digestive form of the disease in Brazil, between 2015 and 2055, 
according to five-year periods. In 2015, for example, taking as 
a basis an estimated population of 204,450,649, it is estimated 
that between 1,426,994 and 3,357,633 of Brazilian individuals 
would be infected with T. cruzi. Of these, 142,699 to 335,763 
would potentially have the digestive form and 428,098 to 
1,007,290 would have the cardiac form of the disease. Moreover, 
an estimated 856,197 to 2,014,580 individuals would potentially 
present with T. cruzi infection in the indeterminate form.
Year
Estimate of the Brazilian 
population
Reference age range Estimated number of infected people Estimate of cases with the digestive form
Estimate of cases with the cardiac 
form
age range Population % infection 1.02%a infection 2.4%b infection 1.02%a infection 2.4%b infection 1.02%a infection 2.4%b
2000 173,448,346 ≥5 156,133,836 90.0 1,592,565 3,747,212 159,257 374,721 477,770 1,124,164
2005 185,150,806 ≥10 150,944,641 81.5 1,539,635 3,622,671 153,964 362,267 461,891 1,086,801
2010 195,497,797 ≥15 145,563,676 74.5 1,484,749 3,493,528 148,475 349,353 445,425 1,048,058
2015 204,450,649 ≥20 139,901,357 68.4 1,426,994 3,357,633 142,699 335,763 428,098 1,007,290
2020 212,077,375 ≥25 133,880,929 63.1 1,365,585 3,213,142 136,559 321,314 409,676 963,943
2025 218,35014 ≥30 127,334,466 58.3 1,298,812 3,056,027 129,881 305,603 389,644 916,808
2030 223,126,917 ≥35 120,096,221 53.8 1,224,981 2,882,309 122,498 288,231 367,494 864,693
2035 226,438,916 ≥40 112,013,898 49.5 1,142,542 2,688,334 114,254 268,833 342,763 806,500
2040 228,153,204 ≥45 102,983,115 45.1 1,050,428 2,471,595 105,043 247,160 315,128 741,479
2045 228,116,279 ≥50 92,984,144 40.8 948,438 2,231,619 94,844 223,162 284,531 669,486
2050 226,347,688 ≥55 82,097,220 36.3 837,392 1,970,333 83,739 197,033 251,218 591,100
2055 222,975,532 ≥60 70,485,475 31.6 718,952 1,691,651 71,895 169,165 215,686 507,495
TABLE 2
Projection of the prevalence estimates of T. cruzi infection and chronic-phase Chagas disease, cardiac and digestive forms,  
in Brazil, from 2000 to 2055.
Source: IBGE – Overall population estimates and by age group. Coordination of the Population and Social Indicators. Studies Management and Analysis of 
Demographic Dynamics(40). aParameters for estimates (minimum and maximum) of the prevalence of T. cruzi infection - PAHO, 2006(17); Martins-Melo et al., 
2014(35). bParameters for maximum estimates of the prevalence of Chagas disease in the chronic phase with cardiac form (× 30%) and digestive form (× 10%).
In addition to internal migration in Brazil, with the 
urbanization of Chagas disease its occurrence in migrants 
from endemic areas in countries not traditionally endemic has 
brought about an expanded discussion on the contexts of risk 
and vulnerability, with a challenge to develop control actions 
for these countries(3) (6) (7) (10) (11) (12) (13) (16) (18) (37) (41) (42). Multiple 
bio-ecological, socio-cultural, and political factors have been 
implicated in this process(10), demanding an increased need for 
human and social sciences research concerning the disease(43).
In 2005, it was estimated that there were a total of 501,036 
Brazilians in the United States, with a prevalence of infection 
by T. cruzi of 1.02%(17), or 5,106 cases(44). In a broader sense, it 
is estimated that the total of people infected by T. cruzi in that 
country could range from 300 thousand to just over 1.0 million(8) 
(9), with different impacts on the health system. It is worth noting 
that this is a non-endemic area(9) (45).
It is estimated that approximately 72,000 people infected 
by T. cruzi live in Europe(12). From analysis of the aggregated 
data of a systematic review and meta-analysis investigating the 
prevalence of Chagas disease in Latin American people living 
in Europe (Spain, France, Switzerland, Italy and Germany), it 
is estimated that the prevalence of this infection in Brazilian 
migrants is 0.6% (from 0.16 to 1.12%) or 4/954(13). Migrants 
from Bolivia had the highest prevalence of Chagas disease 
(18.1%), followed by Paraguayan migrants (5.5%). The 
prevalence among migrants from Argentina was 2.2%; there 
were no cases of Chagas disease detected among migrants 
from Uruguay, Venezuela, Panama, Guatemala, and Mexico(13).
The occurrence of other important international migration 
waves within Latin America, such as from Bolivia and Paraguay 
to Argentina and Brazil or from Colombia to Venezuela, is 
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recognized(10). On the other hand, from the second half of the 
twentieth century, it is especially emphasized the intensification 
of the movement of thousands of citizens from Latin America 
to countries in North America (mainly the United States, but 
also Canada), Europe (particularly Spain, among other nations), 
Asia (Japan), and Oceania (Australia), increasing the number of 
people with Chagas disease living in non-endemic countries(2) (7) 
(10) (12) (42). Overall, this migration process is associated with the 
search for improved living conditions for people from endemic 
countries living in conditions of serious social vulnerability(10).
In addition to Brazilians potentially infected by T. cruzi living 
abroad, a considerable number of people have migrated to Brazil 
from other endemic countries such as Bolivia; an estimated 80,000 
to 200,000 Bolivian migrants live in the State of Sao Paulo(46). This 
fact has prompted discussion, within the country, about public 
health policies consistent with the need for greater attention to 
this migrant population, including viewing the precarious life and 
work conditions to which they are subjected(46) (47).
In addition to the migration context, there is a clear shift 
in the prevalence of infection by T. cruzi to older age groups, 
which brings new challenges for the SUS. With the prevalence 
of chronic phase Chagas disease resulting largely from infection 
by vectors in the past, the probability of infectious and non-
infectious comorbidities has expanded. These comorbidities 
consist mostly of chronic degenerative conditions (especially 
diabetes mellitus, systemic arterial hypertension, and other heart 
diseases), human immunodeficiency virus (HIV) co-infection 
with T. cruzi, and other immunosuppressive conditions that are 
acquired or induced(2) (48) (49) (50) (51). The risks are amplified by 
longer survival combined with migration and the urbanization 
that had occurred over the past five decades(49). 
As for other infectious diseases, T. cruzi can behave 
as an opportunistic microorganism in individuals with 
imunosupression(2) (49) (50) (51) (52). Although the first case of T. cruzi 
and HIV co-infection was reported in the 1980s, the frequency 
of this co-infection and of specific reactivation; the clinical 
and laboratory features associated with co-infection; specific, 
adequate treatments for T. cruzi infection in the context of 
co-infection with HIV; and outcomes (survival and death) of 
co-infected individuals, persist as knowledge gaps at a global 
level(49) (52) (53).
In Brazil, we estimated the prevalence of co-infection 
to be 1.3%(48) (49) (52). Considering that in 2014 there were 
approximately 734,000 people living with HIV (without 
AIDS) in Brazil, corresponding to a prevalence in the general 
population of 0.4%,(51) there would be an estimated 9,542 
cases of T. cruzi/HIV co-infection. On the other hand, since 
the beginning of the AIDS epidemic in Brazil to June 2014, 
total of 757,042 AIDS cases were registered in the Brazilian 
Notifiable Diseases Information System [Sistema de Informação 
de Agravos de Notificação] (SINAN)(50); it is estimated that 
more than 9,842 of these would be co-infected. Therefore, it 
is estimated that there are 19,384 cases of T. cruzi/HIV-AIDS 
co-infection in Brazil, based on data up to June 2014, stressing 
that many of these cases probably died, are undiagnosed, or 
unrecognized as having co-infection. In Brazil, anti-T. cruzi 
antibodies testing is recommended for HIV-infected patients, 
taking into account their epidemiological risks(51). It is worth 
noting that, for surveillance purposes, since 2004 reactivation 
of Chagas disease has been added to the list of AIDS-defining 
illnesses, and has been an important marker, from the definitive 
diagnosis of Chagas myocarditis and meningoencephalitis(39) (49) 
(52) (54). Generally, such HIV co-infection occurs through sexual 
transmission in individuals previously infected with T. cruzi. 
A progressive decrease in the number of co-infection cases 
is expected in Brazil, since Chagas is gradually becoming 
restricted to higher age groups. 
In addition to the above co-infection, generally, despite the 
high morbidity and mortality of Chagas disease in Brazil, data 
relating to the specific epidemiological surveillance of human 
cases of the disease does not allow estimation of its magnitude, 
since it is only mandatory to report cases in the acute phase to 
SINAN. Furthermore, it is estimated that only 10–20% of acute 
Chagas disease cases are actually reported.
In the period 2000–2013 (data updated in May 2014), 1,570 
cases of acute Chagas disease were reported ̶ an average of 112 
cases per year. This figure was derived from records from most 
Brazilian states, with the exception of Mato Grosso do Sul and 
Federal District in the Central-West region and Paraná in the 
South. Most of these cases (1,430; 91.1%) were concentrated 
in the North, followed by the Northeast (73; 4.7%), South (28; 
0.2%), Central-West (27; 1.8%) and Southeast (12; 0.8%). 
It is noteworthy that the State of Pará was responsible for 75% 
of all cases in the country and 82% of cases in the Northern 
region(55).
With regard to the municipality of residence, there were 
163 reported cases of acute Chagas disease: 97 (60%) from 
the Northern region, 37 (23%) from the Northeast, 14 (9%) 
from the Central-West and, in smaller proportions, 9 (6%) and 
6 (4%) from municipalities of the Southern and Southeastern 
regions, respectively(55). This notification pattern is quite distinct 
from that of the 1990s(4) (18) (19), but still demarcates operational 
contexts of epidemiological silence in some areas.
Mortality
The burden of mortality related to Chagas disease in Brazil 
remains high, despite the introduction of control measures(3) (29) 
(35) (56) (57). A study conducted to quantify the mortality pattern 
of Chagas disease in the period 1981–1998 found that out of 
68,936 deaths in Brazilian individuals with a known birthplace, 
32,369 (32%) deaths occurred in states other than the deceased’s 
birthplace, varying from 0.3% in Rio Grande do Sul to 100% in 
Roraima and Amapá. Most (67%) of these deaths in migrants 
occurred in individuals of Minas Gerais (51%) and Bahia (16%). 
Mortality rates of residents within the period showed a consistent 
decline in the Southeast, South, and Central-West, but not in 
the Northern and Northeastern regions, where the median age 
at death was comparatively low(58). 
Later, from 1999 to 2007, Chagas disease was recorded as the 
cause of death on 53,924 (0.6%) of approximately 9.0 million 
death certificates from the Brazilian Mortality Information 
System [Sistema de Informações sobre Mortalidade (SIM)]: 
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for 44,537 (82.6%) it was recorded as the underlying cause 
and for 9,387 (17.4%) as an associated cause(59). Acute Chagas 
disease was recorded in the statement in 2.8% of deaths. The 
average number of deaths per year was 5,992, with an average 
standardized mortality rate of 3.36/100,000 inhabitants/
year, verifying a gradual reduction in the specific mortality 
rate of 26.4%. It is emphasized the decreasing tendency of 
a standardized mortality rate, especially in the Central-West 
region (-37.9%). The proportional mortality (for numerous 
reasons) was 0.6%, highest in the Central-West region (2.17%) 
where there was a reduction of 19.5%, with a significant 
decreasing tendency. However, in this study, there was a 
considerable increase of 38.5% in the Northeast region, with 
an increasing tendency. Risk factors identified in the bivariate 
analysis were older age groups and residence in the Central-West 
region. In the multivariate analysis, however, age over 30 years 
and residence in the States of Minas Gerais and Goiás and in 
the Federal District were identified as risk factors(59). It should 
be noted that more than 40% of expected deaths associated 
with Chagas disease in Latin America occurred in Brazil(56) (59). 
Another study of the same Brazilian population base 
examined 53,930 deaths, recorded between 1999 and 2007, 
where Chagas disease was mentioned as a cause of death. When 
analyzed as the underlying cause, Chagas disease was the fourth 
leading cause of death (10.8%) among all infectious diseases and 
parasites(56). Of the 53,930 recorded deaths, 37,800 (84.9%) were 
related to cardiac forms and 4,208 (9.4%) to digestive forms 
of Chagas disease. Acute cardiac involvement was noted in 
1,097 (2.5%) deaths; other organ involvement in 1,157 (2.6%); 
and finally, other clinical presentations of the disease (central 
nervous system involvement and no cardiac involvement 
in the acute phase) in 281 (0.6%). The associated causes of 
death with Chagas disease as the underlying cause included 
diseases of the digestive, circulatory, and respiratory systems. 
Direct complications of heart disease, especially conduction 
disturbances/arrhythmias and heart failure were identified in 
more than 35% of deaths, followed by shock (15%). Among the 
basic causes of death in which Chagas disease was mentioned 
as an associated cause, the most common diseases were of the 
circulatory and respiratory systems (59%), followed by cancer 
(11.6%) and digestive system diseases (10.6%). Cerebrovascular 
disease, ischemic heart disease, and hypertensive diseases 
were the main underlying causes of death in cases where 
Chagas disease had been identified as an associated cause. 
Chronic lung diseases and, in particular, chronic obstructive 
pulmonary disease also represented particularly important 
causes of death(56).
In an additional study from this same database, using 
different spatial analytical approaches, we identified a cluster 
of high mortality risk for Chagas disease involving nine States 
of Brazil’s Central-West region: Almost all municipalities from 
the States of Goiás and Minas Gerais, Federal District and 
some municipalities from the States of São Paulo, Mato Grosso, 
Mato Grosso do Sul, Tocantins, Piauí and Bahia. This area 
was indicated by the authors as a priority for integrated planning 
of actions to strengthen the network of attention focused 
on Chagas disease(60).
A study examining regional patterns and tendencies in 
Brazil over a longer time period (1979–2009), found that of 
27,560,043 deaths analyzed, Chagas disease was the underlying 
cause in 172,066 deaths(57). The proportional mortality of 
Chagas disease was 0.62% with a crude specific death rate of 
3.61 deaths/100,000 inhabitants/year and a specific mortality 
rate adjusted for age of 5.19 deaths/100,000 inhabitants/year. 
Nationally, there was significant reduction over the period, but 
with important inter-regional differences; there was significant 
reduction in the Southeast, South and Central-West regions, 
but significant growth in the Northeast and Northern regions(57). 
Another historical series, from 1980 to 2008, found that 
the proportion of deaths attributed to Chagas disease as the 
underlying cause remained stable in the period(29).
In the State of São Paulo from 1985 to 2006, there were 
40,002 Chagas disease-related deaths. Chagas disease was 
an underlying cause in 34,917 (87.3%) and an associated 
cause in 5,085 (12.7%). The mortality rate, according to the 
underlying cause, declined by 56.1%, but remained stable in 
terms of associated cause of death. There were 44.5% more 
deaths in men than in women, and 83.5% of deaths occurred 
in people over 45 years old. The main causes associated with 
those who had Chagas disease as underlying cause of death 
were: direct complications of cardiac impairment (conduction 
disorders, arrhythmias and heart failure). For Chagas disease 
as an associated cause, the most important underlying causes 
were ischemic heart disease, cerebrovascular disease, and 
neoplasms(61).
On the other hand, from the national database on mortality 
related to Chagas disease as the underlying cause, from 2000 
to 2010, it was found that most deaths (85.9%) occurred in 
males older than 60 years. These deaths were mainly caused 
by cardiac involvement, and the mortality rate of this clinical 
form of the disease decreased in all regions except in the North, 
where there was an increase of 1.6%. The Northeastern region 
had the lowest reduction, while the Central-West had the largest. 
It is noteworthy that the mortality rate related to the digestive 
form increased in all regions(61).
A pattern of aging and an expansion of ages at highest age 
ranges for the population affected by Chagas disease has been 
verified, not only by previous studies of mortality, but also 
by other population-based studies based on cases of cohorts 
followed through long periods of time(63) (64). 
Data from the Ministry of Health on deaths from acute 
Chagas disease indicate that in the period 2005–2013, the 
national average annual mortality rate over the 14 years was 
2.7% (37.9/14). In 2005, a high (20%) mortality rate was 
recorded. This coincided with an acute Chagas outbreak by 
oral transmission in Santa Catarina, at which time little was 
known about the etiology and management of the disease by 
this form of transmission. In 2006, the mortality remained high 
(5.9%), with subsequent reduction that has remained relatively 
constant (average of 1.7% from 2007 to 2013), ranging from 
0.5% in 2009 to 4.7% in 2011. It is worth noting that the lack 
of disease suspicion and the delay in establishing the diagnosis 
may worsen the clinical picture and the evolution of the disease, 
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and may affect the prognosis. For example, deaths occurred 
due to lack of timely intervention(55), particularly in terms of 
the cardiovascular forms of the disease.
In terms of mortality associated with co-infection of T. 
cruzi/HIV, approximately 9 million deaths were studied in 
the period 1999–2007. Seventy-four deaths were identified as 
related to T. cruzi/HIV co-infection; in 57 (77%) the underlying 
cause was AIDS, and in 13 (17.6%) the underlying cause was 
Chagas disease(53). Co-infection was associated with male 
sex (51.4%), Caucasian ethnicity (50%), age between 40 and 
49 years (29.7%), and place of residence in the Southeastern 
region (75.7%). The average age at death was significantly 
lower among co-infected (47.1 years) individuals than among 
those without co-infection (64.1 years)(53). These data probably 
indicate a underestimation the real impact of co-infection on 
mortality.
Epidemiological profile according to  
transmission modes
In more recent years (SINAN, 2000–2013), with the 
operational limitations as previously indicated, it was found that 
oral transmission was the most frequent mode of transmission 
every year (1,081; 68.9%), followed by vectorial transmission 
(100; 6.4%)(55). The persistence of the latter has been observed 
since 2006, the year that Brazil obtained certification for 
interrupting transmission of T. cruzi by Triatoma infestans. 
Transmission still occurs, albeit to a lesser extent, probably 
due to reduced visibility of these cases. Comparatively, WHO 
estimates, based on data from 2010, indicated that a total 
of 46 cases of Chagas disease per year in Brazil originated 
from vectorial transmission(5). Together, these data reinforce 
the likely underestimation of cases relating to this mode of 
transmission, both nationally and internationally. The mode 
of transmission was not identified in 372 (23.7%) reported 
cases; 93% (306 cases) of these were from the State of Pará. 
In 11 (0.7%) cases other modes of transmission (transfusion or 
accidental) were identified, and there were 6 (0.4%) cases of 
vertical transmission(55). Underreporting is also clear in the later 
mode of transmission. 
This change in the epidemiological pattern of transmission 
of Chagas disease is the combined result of the control 
measures undertaken over the last four decades and major 
environmental, demographic, economic, and social changes, 
and the concentration of the population in urban areas(4) (15) (33) 
(65). Thus, mechanisms directly related to the enzootic cycle 
of infection, such as extradomiciliary vector transmission or 
visitation of wild vectors to households, in addition to oral 
transmission (also mediated by vectors, in most cases), have 
to have relevance as main modes of T. cruzi transmission to 
human populations(22) (27) (65).
Vector transmission
In 1950 and 1951, the first Prophylaxis Campaign for Chagas 
disease was developed in Brazil, led by the then National Service 
for Malaria, reaching 74 municipalities on the border of the 
States of Minas Gerais and São Paulo with chemical vector 
control activities. By 1975, control activities were conducted 
intermittently, with varying territorial scope. The area at risk 
of vector transmission of Chagas disease in Brazil in the late 
1970s included 18 states, with more than 2,200 municipalities, 
which proved the presence of domiciled triatomine. Notably, the 
Amazon region was excluded from this risk area(4) (19) (20) (22) (66). 
Since then, with the intensification of control measures, the 
vectorial transmission of T. cruzi in Brazil has shown marked 
and systematic reduction. This was achieved by the development 
of systemized actions of chemical control of domiciled vector 
populations, introduced in 1975, with a range of coverage of 
the endemic area in 1983(20) (22) (66). These actions have taken 
place on a regular basis since then. However, their reach has 
progressively declined over the past two decades due to technical 
and political prioritization of changes, and due to political-
institutional reorganization in the country(20) (22).
This process, in an integrated manner, culminated with the 
Certification of Interruption of Chagas Disease Transmission 
of the main domiciled vector, T. infestans, granted in 
2006 by Pan American Health Organization/World Health 
Organization (PAHO/WHO) to countries of the Southern Cone 
Initiative(18) (22) (39). The control of vector-borne transmission had 
considerable impact in relation to congenital and transfusion 
transmissions(4) (10) (18) (23) (29). Despite the advances, the risk of 
vectorial transmission of Chagas disease persists. This has been 
evaluated from different perspectives(22), including the existence 
of indigenous species of triatomine with high potential for 
colonization; the presence of T. cruzi reservoirs and increasing 
proximity of human populations to these environments; and the 
persistence of residual foci of T. infestans, still existing in some 
municipalities of the States of Bahia and Rio Grande do Sul(22) 
(23) (39) (67). The impacts of the certification process achieved by 
Brazil in 2006 in relation to T. infestans generated concern about 
the demobilization of society in general and the imprecise way 
information was obtained and disclosed to society(68). 
Furthermore, additional studies and analyses have sought to 
evaluate further the operational processes involved in different 
strategies to control/eliminate of indigenous vector transmission, 
including the certification model and potential alternatives(69) 
(70) (71) (72). Data from the Ministry of Health on entomological 
surveillance (passive or active) specific to the period 2007–2011 
(Epidemiological Bulletin of Chagas Disease 2015) indicate 
a record catch of >770,000 triatomine in local homes and 
peridomestic contexts. Like human cases, considering the low 
coverage of entomological surveillance actions, this record 
probably comprises less than 10% of triatomine in or around 
residences. Also, according to data from the Ministry of 
Health, among the 62 species distributed in intradomicile and 
peridomicile spaces in Brazil, the following stand out as species 
of epidemiological relevance: Panstrongilus geniculatus, 
Panstrongilus lutzi, Panstrongilus megistus, Rhodnius nasutus, 
Rhodnius neglectus, Rhodnius robustus, Rhodnius pictipes, 
Triatoma infestans, Triatoma brasiliensis, Triatoma maculata, 
Triatoma pseudomaculata, Triatoma rubrovaria, Triatoma 
rubrofasciata, Triatoma sordida and Triatoma vitticeps.
According to the data from the Epidemiological Bulletin of 
the Ministry of Health on Chagas Disease, 591,360 (76.8%) 
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of the captured triatomine were examined for infection with 
T. cruzi; the natural infection rate was an estimated 2.7% 
(15,967 triatomine). The Triatoma vitticeps (52%), Rhodnius 
robustus (33.3%), and Panstrongylus lutzi (29.4%) species had 
the highest rates of natural infection. According to the data from 
the Ministry of Health, T. vitticeps appears more frequently in 
the Southeastern States (Minas Gerais and Espírito Santo), R. 
robustus in the Northern region (Tocantins, Amazonas, Acre, 
and Rondônia), and P. lutzi in the Northeastern region (Piauí, 
Bahia, Sergipe, Alagoas, Paraiba, Rio Grande do Norte, Ceará 
and Pernambuco)(55). 
In 2012, the investigation of two cases of acute Chagas 
disease recorded by vector transmission showed the involvement 
of wild species with high rates of natural infection in 
municipalities that were considered non-endemic for Chagas 
disease. One case occurred in the city of Ibitirama (Espírito 
Santo), where infected T. vitticeps adults are often found by 
local residents. The other case occurred in Mangaratiba (Rio de 
Janeiro), involving Triatoma tibiamaculata found to be infected 
with T. cruzi. These episodes reflect a nationwide reality; that 
parasite transmission cycles exist in wild environments close 
to human dwellings, which favors transmission(55).
For the period 2007–2011, the persistence of Triatoma 
infestans foci was identified in four municipalities of the 
State of Bahia (Itaguaçu da Bahia, Ibipeba, Novo Horizonte, 
and Tremedal) and 12 municipalities of Rio Grande do Sul 
(Ajuricaba Alegria, Coronel Barros, Doutor Mauricio Cardoso, 
Giruá, Humaitá, Ijuí, Independência, Porto Mauá, Salvador das 
Missões, Santo Cristo, and São José do Inhacorá)(55). Integrated 
actions of vector control mobilizing Federal, State, and Municipal 
governments have advanced towards the control of this triatomine.
Currently, the risk related to the transmission of T. cruzi in 
Brazil depends mainly on: I) the persistence of residual foci of T. 
infestans, with episodes found in some states, such as Bahia and 
Rio Grande do Sul; II) the existence of large number of species 
that were confirmed as indigenous or acting as potential vectors 
in the country, even though in some cases resident populations 
have been greatly reduced; III) the emergence of new species at 
risk of domiciliation (T. rubrovaria, P. lutzi); IV) the existence 
of endemic transmission in the Amazon Region, with still poorly 
characterized mechanisms of transmission such as domiciliary 
vectorial without colonization, extradomiciliary vectorial, and 
oral; and V) the occurrence of outbreaks and micro-epidemics 
of orally transmitted of T. cruzi infection(20) (33) (65) (67).
The major change in the epidemiological situation of the 
disease in the country has generated the need for a dynamic 
review of the control strategies adopted(4) (20) (23) (33) (65) (67). From 
this perspective, identifying areas with greater vulnerability to 
the synanthropic occurrence of triatomine has been important 
tool to reorient prevention, control, and surveillance actions(39) 
(67), and to optimize the use of available program resources(20). 
On the other hand, risk stratification associated with vector 
transmission has been proposed as an important strategy for the 
guidance and support of control measures in the country and has 
been incorporated, in different ways, by the control programs 
of states and municipalities(4) (20) (22) (39) (65). This stratification is 
based on three different scenarios or eco-epidemiological spaces 
of vector-borne transmission of T. cruzi(22):
• an area first considered endemic, with registered 
domiciliary vectorial transmission, which was submitted 
for an extended period to intensive chemical control 
operations, resulting in the almost complete elimination of 
the main vector (T. infestans), and the risk being currently 
limited to a more or less focal transmission, mainly 
by native species. This scenario includes the States of 
Alagoas, Bahia, Ceará, Goiás, Mato Grosso do Sul, Minas 
Gerais, Paraíba, Pernambuco, Paraná, Piauí, Rio Grande 
do Norte, Rio Grande do Sul, São Paulo and Sergipe, as 
well as the Federal District;
• an area previously considered harmless for human Chagas 
disease, in which the disease is now transmitted through 
mechanisms that before were considered extraordinary or 
improbable and are still poorly characterized but able to 
maintain endemic transmission of relatively low intensity 
to sustain endemic transmission (oral, extradomiciliary 
and domiciliary without vector colonization). This 
scenario includes the region covering the States of Acre, 
Amazonas, Amapá, Rondônia, Roraima and Pará; and 
• a transition area between the two previous scenarios, in 
which both coexist. This scenario includes the States of 
Maranhão, Mato Grosso, and Tocantins.
As previously discussed, the States of Santa Catarina, Rio 
de Janeiro, and Espírito Santo, although not covered by the 
proposal of the previous risk stratification, given the historical 
patterns observed from the entomological surveillance of 
the states, have registered autochthonous cases of Chagas 
disease(39) (55) (73) (74) (75) (76) (77).
The evaluation and systematic monitoring of this process 
should incorporate the possibility of colonization of the Amazon 
and other agricultural fronts (extensive cattle ranching and 
soybean cultivation, among others) by domiciliated vectors, with 
epidemiological importance in the areas of human migration(22) (65).
The great diversity of vector-borne transmission of 
T. cruzi inherent to the aforementioned scenarios or eco-
epidemiological spaces include(22) (65): I) the remote risk of 
reestablishment by introduced species, such as Triatoma 
infestans; II) focal transmission by native species known as 
vectors, such as Panstrongilus megistus, Triatoma brasiliensis 
and, less likely, Triatoma pseudomaculata and Triatoma 
sordida; III) domiciliation of some species typically considered 
as exclusively wild, and the risk that these then act as vectors 
in some areas, as in case of Triatoma rubrovaria in the State 
of Rio Grande do Sul and Panstrongilus lutzi in the States 
of the Northeastern region; and IV) the possibility of extra-
domiciliary transmission or triatomine house visitation (basic 
form of outbreak generation by oral transmission, at least in 
rural areas), as already observed with Rhodnius brethesi in the 
region of Alto Rio Negro, in the State of Amazonas, and with 
Rhodnius pictipes in the State of Tocantins. 
Given the coexistence of areas with different degrees of 
risk, surveillance and vector control actions should be adjusted 
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and based on established risks(22) (65). In addition to considering 
the operational capacity of municipalities, the stratification of 
a large traditionally endemic area is based on a set of variables 
that potentially influence the process of infestation and/or 
reinfestation, and therefore of transmission or reintroduction 
of vectorial transmission of Chagas disease in the house 
environment(22).
It is recognized that the process of simplification of fauna is 
the result of unplanned occupation of the environment, having 
the following potential consequences: I) lower diversity of food 
supply for triatomines in different habitats; II) a greater tendency 
of displacement of triatomines in search of food (hematophagous 
activity) from their original habitat, to feed on more eclectic 
mammals species that remained and expanded numerically; 
III) the populations of the parasite will also expand from these 
species of mammals with this environmental eclecticism, 
in general large reservoirs of T. cruzi(21) (78) (79) (80). As these 
animals (such as marsupials and rodents) have a high degree 
of synanthropy, the epidemiological risk becomes clear(79) (80).
T. cruzi is a multi-host flagellate parasite capable of infecting 
tens of species of wild and domestic mammals distributed in all 
phytogeographic regions in Brazil; it is found in the most diverse 
ecological niches, contributing, in each type of ecotope, to form 
singular modalities of natural transmission foci(21) (23) (27) (39) (78) (79) (80).
The integration of the reservoirs in the routine monitoring 
process should be taken into account given that domestic animals 
are not confined and can also act as a link between wild and 
domestic transmission routes(80) (81). As with wild mammals, the 
importance of domestic animals (for example, dogs and cats) 
as reservoirs of T. cruzi varies in different places, and they can 
be used as sentinel populations of transmission of T. cruzi in a 
given area(21) (81). In general, they are always exposed and their 
infection usually precedes human infection(78). Therefore, the 
presence of domestic animals infected with T. cruzi in a given 
area indicates that transmission is occurring in areas where 
these animals circulate, which reinforces the need to widen 
control actions(81).
The research of entomological and reservoirs must be 
associated with sustained environmental surveillance actions(39). 
To this end, the understanding of the processes of habitat 
selection by triatomines is fundamental for the construction 
of epidemiological evidence, in order to plan and develop 
local systems of epidemiological surveillance and control, 
thus reinforcing the role of surveillance(22) (39) (82). However, 
operational failures identified in the detection of vectors can 
generate critical classification errors and, therefore, prevent the 
scope of the actions, hampering the composition of scenarios 
and dynamics of these insects in their habitat(70) (71) (82).
Assuming that no sampling technique is perfect, some 
studies in Brazil have applied methods that explicitly incorporate 
the failures in the detection of infestation foci in the research of 
the ecology and the surveillance of vectors of Chagas disease 
in different environments, including the Amazon and Northeast 
region(70) (71) (82). This approach has and will increasingly enable 
future improvement of the estimates of eco-epidemiological 
indicators and may significantly strengthen the strategies for 
integrated monitoring and control of vectors(70) (71) (83) (84). The 
failures were observed in areas with well-established triatomine 
infestation, where active searches by trained and motivated 
agents usually detect approximately 40–60% of intradomiciliary 
and extradomiciliary infestation outbreaks, while undetected 
foci are not eliminated(70). In addition, from the analysis of the 
monitoring process by means of active searches conducted by 
control agents, its sensitivity is estimated at approximately 20% 
for locations with low intensity infestation (few outbreaks, with 
few triatominae) and at approximately 40% in locations with 
more intense infestation(71). 
In addition to this approach, the integrated use of spatial 
analysis techniques to extend the analytical capability, with 
insertion of spatial and temporal dimensions of the transmission 
of Chagas disease, has shown great potential, in particular by 
the significant development of portable electronic equipment 
and software for data processing and analysis(70) (85) (86) (87). 
In the past two decades, several studies have been published 
describing the different degrees of resistance of triatomine 
populations to insecticides(88). However, the actual factors behind 
the emergence of these phenotypes are unknown and the impact 
of this on the development of standardized strategies for vector 
control are unclear(89) (90). This new context will require endemic 
countries to build networks of cooperation between laboratories 
for the analysis of resistance in triatomine populations in a 
standardized manner, integrating this activity in the process of 
epidemiological surveillance(88).
Oral transmission
In Brazil, vectorial transmission of Chagas disease by 
its principal vector, T. infestans, is under control. However, 
oral transmission of T. cruzi has become increasingly 
epidemiologically relevant, particularly in the Amazon 
Region(11) (23) (39) (76) (91) (92). Transmission by the oral route is 
considered a primary mechanism, in particular in the wild 
cycle(93); it will occur regardless of control actions undertaken(21) 
(39). It presents a common feature in the early enzootic cycle of 
this parasite: ingestion of vectors and reservoirs of infection by 
susceptible mammals(21). In the case of humans, this transmission 
occurs in a sporadic and circumstantial manner, through 
food contaminated with the parasite, mainly from triatomines 
or their feces, with records since the 1960s(93). Therefore, the 
analysis of this epidemiological context refers indirectly to 
vectors. 
In Brazil, most cases of orally transmitted Chagas disease 
have been reported in the Amazon as outbreaks in families or 
multifamily contexts(11) (23) (91) (92). Outside the Amazon region, 
few events have been investigated; most were related to sugar 
cane juice, the likely food carrier in the oral transmission of 
these cases(76) (93). A recent review of the subject identified 
records of outbreaks or micro-outbreaks in Brazil, in the States 
of Rio Grande do Sul, Pará, Paraíba, Santa Catarina, Bahia, 
and Ceará. Other countries with records included Venezuela 
and Colombia(76).
The Ministry of Health reported 112 outbreaks nationally 
between 2005 and 2013, involving all 35 municipalities in 
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the Amazon Region. The probable source of infection was 
food contaminated with T. cruzi, including: açaí, bacaba, jaci 
(Syagrus), sugar cane juice, and palm hearts of babaçu nuts. 
Most of the outbreaks occurred in the States of Pará, 75.9% (85 
outbreaks) and Amapá, 12.5% (14 outbreaks) and, to a lesser 
extent, in the States of Amazonas, 4.5% (5 outbreaks), Tocantins, 
1.8% (2 outbreaks), and Bahia, 1.8% (2 outbreaks)(55).
The process of surveillance of Chagas disease and acute oral 
transmission was potentiated by the increased sensitivity of the 
surveillance system. The first officially investigated outbreak of 
orally transmitted Chagas disease in Brazil occurred in Santa 
Catarina in 2005, probably linked to the intake of sugar cane juice 
contaminated with T. cruzi(55). Between 2007 and 2013, it should 
be emphasized that more than 50% of orally transmitted Chagas 
disease cases presented with symptoms between August and 
November, a period that coincides with the açaí harvest in Pará(55).
Available experimental evidence suggests that oral transmission 
may occur from trypomastigote, epimastigotes, and probably 
amastigotes forms of T. cruzi and cell masses, originating from 
mammals or contaminated vectors, as well as, accidentally, 
through artificial cultures of the parasite(21) (23) (94). Depending on the 
predominance of a large group or lineage of T. cruzi transmitted, 
as well as of the inoculum in question, there is a diversity in 
pathogenicity, histiotropism, morbidity, and mortality(21). In 
relation to the mechanism of oral transmission of T. cruzi, the 
following possible scenarios have been identified(21) (39) (93) (94):
• ingestion of triatomine feces or urine of or even infected 
triatomines, on the assumption that these are processed or 
carried along with food, as verified in episodes investigated 
in which the infection was assigned to the consumption of 
acai fruit, typical of the Brazilian Amazon Region(92); 
• intake of food or drinks contaminated with metacyclic 
trypomastigote forms in the secretion of the anal gland or 
in the urine of infected marsupials of the genus Didelphis;
• intake of suspensions of T. cruzi in pipettes in the context 
of research or diagnostic laboratories;
• intake of breast milk from mothers diagnosed with: acute 
Chagas disease, T. cruzi-HIV co-infection in the AIDS 
stage, documented reactivation of Chagas disease, or 
bleeding from fissures of the nipples.
Other speculative situations of exposure include(21) (39) (93) (94): 
• ingestion of raw or poorly cooked meat or blood from 
infected mammals, especially wild animals;
• consumption of the blood of infected animals for 
therapeutic purposes, as performed by some indigenous 
groups in the Amazon. This has been reported in some 
regions of Colombia, where the intake of blood of 
armadillos and skunks has been observed;
• contamination of equipment used in the handling of 
carcasses of infected mammals;
• ingestion of triatomines by primitive or exotic habits. 
It is noteworthy that the feces of infected triatomines can 
retain infectious potential for a few hours in environments with 
high humidity. Therefore, they can potentially contaminate food 
directly or indirectly, by the feet and oral cavity of secondary 
carriers, like flies and cockroaches. Experimental studies have 
shown that the parasite can remain viable for ≥24 hours in foods 
such as milk or sugar cane juice if stored at room temperature. 
Although gastric juice is able to destroy a considerable number 
of parasites, some are able to escape this through chemical 
mechanisms of external protection, allowing the parasites to 
penetrate the intestinal mucosa(21) (92).
Although oral transmission is generally associated with 
outbreaks, it can also occur in isolated cases(21) (39). In fact, we can 
identify two main profiles of outbreaks, according to the place 
of occurrence: urban and rural. Urban outbreak derives from the 
consumption of semi-industrialized and commercialized açaí, 
reflecting an issue of sanitary surveillance, associated with food 
safety and good food handling practices. In rural outbreaks, there 
is the participation of various types of food prepared locally 
by hand, generally by family or people of the social network/
community of a given family.
For research and surveillance purposes, food recall is a useful 
tool to identify the possibility of suspect food intake. It allows 
one to identify the source, place of preparation and consumption 
of suspect food, and to list all the people who may have ingested 
the suspect food(21) (39) (92). The focus of surveillance actions and 
control should therefore include the productive chain, based on 
good food handling practices(21) (39). 
Transmission by blood transfusion and transplantation  
of tissues/organs
The transmission of T. cruzi in blood transfusions was 
amplified by the urbanization of Chagas disease in Brazil 
and in other endemic countries in Latin America(3) (4) (10) (95) (96). 
The risk of transmission by blood transfusion is dependent on 
various factors: I) the presence of the parasite in the blood or 
blood component transfused; II) type and number of infected 
blood products transfused; III) immune status of the recipient; 
IV) quality of the clinical-epidemiological screening; V) level 
of coverage of the serologic screening of donors; and VI) 
sensitivity of serologic tests used to screen blood donation 
candidates(4) (23) (95) (96). 
Given that the majority of potential blood donors are 
aged 18–35 years—the age group with the lowest number 
of candidates potentially infected with T. cruzi—and that, in 
recent years, the obligation of clinical, epidemiological, and 
serologic status screening has been established in most endemic 
countries, the risk of transfusion transmission of Chagas disease 
has been largely reduced in Latin America as a whole(4) (23) (95) 
(96). In Brazil in the 1950s, the estimated average prevalence 
of positive serology for T. cruzi among potential blood donors 
was 8.3%. This decreased to 6.9% in the 1960s and 1970s, 
dropping to 3.2% in the late 1980s and early 1990s(96). A Health 
ministry report from January to June 1994 stated an estimated 
prevalence of Chagas disease through blood transfusion, by the 
public blood donation network to different geographic regions 
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of the country, of 0.75%(95). In 2006, this estimate was 0.21%, 
a reduction of more than 95% compared with previous data(17). 
Most recent WHO data from 2010, estimated this prevalence 
to be 0.18% in Brazil(5). 
In Brazil, not only the safety of blood transfusion has 
improved, but also the process of hemovigilance, with the 
establishment of a national system integrating blood banks and 
epidemiological and sanitary surveillance(97) (98). With this, one can 
classify the rare, but possible cases of Chagas disease transmitted 
by blood, associated with the residual blood transfusion risk and 
any failures within the process. The same applies for situations 
associated with screening of candidates for donation of tissues 
or organs. For both, sanitary inspection in hematology and 
transplantation services (hospitals or blood banks) are instituted, 
as is communication and integrated action with haemovigilance(97) 
(98), recalling that the transfusion transmission can only be 
determined if the infected person received blood or some other 
component within the 120 days before the onset of symptoms(97).
A similar trend in the reduction of the risk of transmission 
from blood transfusions has been observed in other endemic 
countries, to a greater or lesser degree. For non-endemic 
countries, in the last decade several strategies have been adopted 
to prevent and control transfusion transmission of Chagas 
disease. Nations like the United States, Canada, Spain, France, 
the United Kingdom, Switzerland and Australia, for example, 
have already introduced strategies of universal or selective 
serologic screening of blood donation candidates(99).
In case of organ transplants, endemicity patterns of areas 
of origin and residence should be considered, both for donors 
and recipients, in order to outline the best approach possible for 
each case in terms of screening and management of possible 
infection by T. cruzi(100).
Vertical transmission (congenital)
Vertical transmission of Chagas disease is still relatively 
important in Brazil, despite the absence of systematic preventive 
measures against this type of transmission in the country. To 
assess its impact and also the impact of vector control, between 
2001 and 2008 a new national serologic survey was conducted, 
now having as a reference population 105,000 children aged 
0–5 years(101). The estimated prevalence of children infected 
with T. cruzi was 0.03% (32 cases). Of these, 20 (0.02%) 
had concomitant maternal positivity, suggesting congenital 
transmission [coming from the States of Rio Grande do Sul 
(12), Minas Gerais (3), Paraná (1), Pernambuco (1), Alagoas 
(1), Bahia (1), and Acre (1)]. In the other 11 (0.01%) cases, only 
the child tested positive, indicating probable vector transmission 
[derived from the State of Piauí (2), Ceará (2), Paraíba (2), 
Alagoas (2), Rio Grande do Norte (1), Amazon (1) and Paraná 
(1)]. This study was the first to identify regional differences in 
the congenital transmission of Chagas disease in Brazil, possibly 
related to the existence of T. cruzi TcV and TcVI(101). Moreover, 
it points to the absence of Chagas disease transmission by a 
sustained domiciliary vector in the country(39) (101).
Official data from the Ministry of Health concerning 
epidemiological surveillance by reporting cases of acute Chagas 
disease indicate consistency with the findings obtained in the 
aforementioned survey: 50% of notifications of this form of 
transmission were from the State of Rio Grande do Sul(55).
The overall estimate of the prevalence of T. cruzi infection 
in pregnant women ranges from 1 to 40%(102) (103) (104), and 
approximately 1.8 million women of childbearing age in Latin 
America are infected(17). The latest data from WHO estimate that 
1,124,930 women aged 15–44 years are infected with T. cruzi(5). 
A recent meta-analysis estimated the global risk for congenital 
T. cruzi infection in children born to infected mothers as being 
5% (range: 0–28.6%)(101). In Latin America, more than 15,000 
cases per year of congenital Chagas disease are estimated to 
occur(17). More recent studies estimate that 8,668 children are 
vertically infected(5). On the other hand, in non-endemic areas, 
the availability of evidence to estimate incidence is even more 
limited(5) (17) (104). In North America, for example, the estimate is 
of 2,000 cases of congenital Chagas disease per year(45).
A systematic review with meta-analysis of studies 
conducted in Brazil estimated the prevalence of infection in 
pregnant women to be 1.1% with a vertical transmission rate 
of 1.7%(106). According to data from the Brazilian Live Birth 
Information System [Sistema  de Informações sobre Nascidos 
Vivos (SINASC)], 2,861,868 live births were recorded in the 
country in 2010. From these data it was estimated that 34,629 
pregnant women would be infected with T. cruzi this year; the 
number of congenitally infected children would thus range 
from 312 to 1,073 (average: 589 cases)(106). These data are 
consistent with those of an epidemiological survey conducted 
in the State of Minas Gerais in 1998, extrapolated to the 
Brazilian population(107), and with the global estimate provided 
by the WHO of 571 Brazilian children infected by vertical 
transmission in 2010(5). In 2006, PAHO estimated that 5,000 
Brazilian children would be vertically infected(17). Considering 
the gradual reduction in fertility rates in Brazil, it is estimated 
that over the next few decades, vertical transmission will be 
substantially reduced, with possible elimination as public health 
problem for the country in the next 10 to 20 years.
A recent retrospective study from a referral hospital of the 
Federal University of Goiás [Universidade Federal de Goiás 
(UFG)] analyzed 1,211 individuals born to mothers known to be 
infected by T. cruzi and identified a rate of vertical transmission 
of 2%, consistent with previous estimates. This suggests that 
the presence of TcII in the study area may be associated with 
lower rates of transmission than TcV, which predominates in the 
southern regions of Brazil and other Southern Cone countries, 
where the vertical transmission rates are generally known(108). 
Despite existing scientific evidence, important gaps remain in 
terms of the role of genetic diversity of T. cruzi in relation to 
the evolution of the chronic phase of the disease, the risk of 
congenital transmission or reactivation, and the occurrence of 
oral outbreaks transmission(27).
In Brazil, congenital Chagas disease is considered acute 
and therefore its registration is mandatory(20) (39). However, 
surveillance for Chagas disease specifically in pregnant women 
or exposed/infected children has not yet been established in 
the country. On the other hand, it is recognized that provision 
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of anti-T. cruzi treatment to non-pregnant infected women of 
childbearing age may be an effective strategy to reduce vertical 
transmission in future pregnancies(41) (109). It should also be noted 
that vertical transmission may be repeated in every pregnancy(104).
Accidental transmission
Accidental transmission has been recorded in different 
contexts: triatomine laboratories, vector capture actions in 
endemic areas, experimental work with infected mammals and 
cultures, aerosols of infected materials, surgical infection and 
infection during collection of blood samples from people with 
acute infection. In these cases, safety deficiencies are evident 
in the transportation of contaminated materials, among other 
factors(93). Risk factors include ignorance, inattention, lack or 
misuse of personal protective equipment, inadequate facilities 
and equipment, poor lighting, lack of training, non-compliance 
with standard precautionary measures, and non-adoption of 
routine technical protocols(93) (110).
The process of monitoring and control must include the 
development of continuing education actions in health and 
supervision, to check the proper use of personal protective 
equipment and, if applied, the communication of work accidents 
within the demarcated processes for the health surveillance of 
workers(39) (93) (110).
Epidemiological surveillance
Epidemiological surveillance is a set of strategic actions that 
provide knowledge, detection, or prevention of any change in 
determinants and conditioning factors of individual or collective 
health, in order to recommend and adopt measures for the 
prevention and control of diseases and disorders(39). In the case 
of Chagas disease, it includes necessarily integrated actions 
involving human cases, vectors, and reservoirs, interfacing 
closely with the health care network, with emphasis on primary 
care or primary health(4) (15).
Systematized below are the main elements in Brazil for the 
development of surveillance processes for human cases and for 
entomological surveillance. Several questions related to this 
process have already been presented and previously discussed.
Chagas disease cases surveillance
Epidemiological surveillance actions for Chagas disease in 
Brazil have the following main objectives(20) (39):
• to detect early cases of acute Chagas disease, with the 
aim to treat newly diagnosed cases timeously and to apply 
preventive measures of occurrence to new cases;
• to conduct epidemiologic investigation of all acute 
cases, aiming to identify the form of transmission and, 
consequently, to institute appropriate control measures;
• to monitor T. cruzi infection in humans, through periodic 
serologic surveys in key populations, and by means of 
adopting a national screening process of blood donation 
candidates in blood donation centers;
• to monitor the profile of morbidity and mortality of 
Chagas disease in the country, outlining scenarios for 
strengthening the healthcare network for infected people;
• to maintain the elimination of vector transmission by T. 
infestans and to monitor/control other important species 
involved in transmission to humans; 
• to integrate health surveillance and environmental actions 
(regarding vectors and reservoirs) with epidemiological 
surveillance activities.
The change in the epidemiological patterns of the disease 
in the country required structuring of Chagas Epidemiological 
Surveillance in the Northern region due to oral transmission. 
There is a clear need to closely interfacing with the Health 
Surveillance, with the aim to improve prevention and control 
measures, besides the definition of reference flows for the 
diagnosis, treatment and monitoring of disease complications. 
The high percentage of cases in the Health Ministry database 
with an undetermined mode of transmission suggests a 
weakness of the surveillance process and indicates the need 
for improvement in the opportunity of surveillance activities 
regarding the detection and investigation of suspect cases(55). It 
also reinforces the need for quality health surveillance actions 
in the SUS, potentiated through continuing education activities 
and monitoring and evaluation by the health teams.
The occurrence of suspected cases of acute Chagas disease 
in Brazil requires immediate notification (within 24 hours after 
suspicion) using a specific instrument, the Acute Chagas Disease 
Research Sheet, which is standardized throughout the national 
territory. For epidemiologic surveillance purposes, the following 
case definitions have been established(39): 
1. Suspected case of acute Chagas disease
• Person with persistent fever (more than 7 days) with one or 
more of the following clinical manifestations: swelling of 
the face or limbs, rash, lymphadenopathy, hepatomegaly, 
splenomegaly, acute cardiomyopathy (tachycardia and 
signs of heart failure), hemorrhagic manifestations, 
jaundice, Romaña’s sign, inoculation chagoma, or:
• He/she has had a direct contact with triatomines or their 
excreta; or
• He/she has received blood/blood products or transplanta-
tion of cells/tissues/organs contaminated with T. cruzi; or
• He/she has ingested food suspected of being contaminated 
with T. cruzi; or
• He/she is a newborn, from an infected mother.
2. Confirmed case of acute Chagas disease
Laboratory criteria
• Parasitologic: T. cruzi circulating in the peripheral blood 
identified by direct parasitologic examination.
• Serologic: suspected case with serology reactive with anti-T. 
cruzi IgM antibodies by the indirect immunofluorescent 
antibody test (IFA); or serology reactive with anti-T. cruzi 
immunoglobulin G (IgG) antibodies by indirect IFA, with 
change in IgG concentration of at least two titers after a 
minimum interval of 21 days in preferably paired samples; 
or seroconversion by any of the methods [enzyme-linked 
immunosorbent assay (ELISA), indirect hemagglutination 
(IHA) or indirect IFA].
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Clinical-epidemiological criteria
Cases of acute Chagas disease should always be confirmed 
by laboratory diagnosis. Only in specific situations can 
clinical-epidemiological criteria be used for suspected cases, 
such as during an outbreak of the disease in the acute phase 
by oral transmission. Such cases have initial negative or non-
reactive serologic and parasitologic test results but possess an 
epidemiological link to confirmed cases of acute Chagas disease 
by laboratory criteria.
3. Discarded case of acute Chagas disease
This refers to a suspected case with negative or non-reactive 
laboratory test results, or in whom another illness is diagnosed. 
Due to the limited clinical expression presented in many cases 
in the acute phase and the long, silent course of the disease, the 
reported case can be discarded as being a chronic case or a case 
of disease reactivation.
4. Definition of a case according possible forms of 
transmission in Brazil
Reserved for confirmation of cases of acute Chagas disease 
characterized according to the probable form of transmission.
Confirmed case of Chagas disease by oral transmission
Case in which other routes of transmission are excluded, with 
epidemiological evidence of a food as a common source of 
transmission, and usually the simultaneous occurrence of 
more than one case with an epidemiological link (origin, 
customs, and cultural elements).
Confirmed case of Chagas disease by vector transmission
Case in which other routes of transmission are excluded, with 
clinical evidence (Romaña’s sign or inoculation chagoma) 
and/or epidemiological evidence of triatomine occurrence 
at the site of the infection. Typically, this is observed as an 
isolated case.
Confirmed case of Chagas disease by laboratory accident
Case that had contact with T. cruzi cultures, exposure to 
contaminated triatomine feces or blood (human or animal 
cases) containing infective forms of the parasite. Usually, 
this occurs in laboratory scientists, health professionals, or 
researchers.
Confirmed case of Chagas disease by vertical transmission
Newborn from mother with positive parasitologic 
examination or reactive serology with T. cruzi and 
presenting:
• Positive parasitologic examination from birth; or
• Serologic examination reactive from 9 months of 
age (before that, maternal antibodies may still be 
present in the child) and no evidence of infection 
by other forms of exposure to T. cruzi. 
In addition to the surveillance of current outbreaks for 
the specific surveillance of Chagas disease in Brazil, with the 
revision of the case definition for epidemiological surveillance 
of AIDS in the country, from January 2004 throughout the 
national territory, reactivation Chagas disease (myocarditis and/
or meningoencephalitis) has been introduced as indicative of 
AIDS for SUS(49) (54).
Although so far, these are not the subject of epidemiologic 
surveillance in Brazil(54), individuals with the chronic form of 
Chagas disease should be confirmed, considering the evaluation 
of people with no indicative picture of febrile illness in the last 
60 days and the presence of one of the following tests(39):
• Serology: Anti-T. cruzi IgG reactive by two methods 
based on different principles [ELISA, indirect fluorescent 
antibody technique (IFAT) or IHA]; or
• Xenodiagnosis (artificial or indirect): positive for T. cruzi; 
or
• Positive blood culture for T. cruzi in blood samples or 
cerebrospinal fluid; or, even from postmortem samples.
It is noteworthy that the current epidemiological context 
in Brazil brings to debate the expansion of the focus and 
approaches of epidemiological surveillance in the human 
population for Chagas disease in its chronic phase, considering, 
among other factors, the possibility of increased sensitivity of 
epidemiological research actions of other cases in the family, 
social network and communities (in the acute phase or chronic), 
as well as the design of spatial contexts of transmission (past 
or recent, active or not) in a manner integrated with vectors 
and reservoirs. At the same time, consideration should be 
given to expanding the criteria for the specific treatment of 
Chagas disease, considering that millions of infected Brazilian 
citizens would clearly benefit(15) (59). Therefore, these questions 
bring the need to overcome operational problems of the health 
care network, which should be prepared for longitudinal 
management of this chronic condition. There is also a need 
to guarantee sustainable production of medicines, given the 
potential increase in the demand for specific treatment, and 
international agreements(38). Extensive national discussion is 
therefore ongoing, to assess the inclusion of surveillance through 
mandatory reporting of human cases in the chronic phase in 
order to qualify the actions of both epidemiology and control, 
and health care.
Entomological surveillance
Entomological surveillance for Chagas disease should 
be implemented throughout the country, supported mainly 
on two pillars: passive surveillance, with the participation 
of the population in the notification of triatomine; and active 
surveillance, carried out by entomological teams of the 
municipalities in partnership with regional health states, without 
necessarily being based on prior notification by the resident(39). 
The entomological surveillance has been enhanced with 
a community-based support, responsible for the network of 
Triatomine Information Posts (TIPs), which is being slowly 
consolidated in the country(22). The home research by the 
institutional technical team has been recommended in a 
more systematic and comprehensive form, depending on 
the existing risk. However, few municipalities have adopted 
this approach, and those that developed it, generally, have 
low sensitivity in active search, not detecting at least half 
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of infestation foci. Systematic review addressing impacts of 
community participation in the entomological surveillance 
process found that the development of strategies to ensure 
such participation should be incorporated as a component of 
entomological surveillance process. This study emphasizes that 
only the standardized chemical control seems to be consistently 
effective in eliminating foci of infection(85). It was strengthened, 
therefore, the necessary participation of individuals, families 
and communities of endemic areas in all stages of this process, 
from the planning to actions evaluation, considering the social 
dimensions in which they fall(18) (43) (85), and recognizing the need 
for empowerment and participation of these populations.  
The strategies adopted must be appropriate to the reality of 
each location, since passive surveillance with the participation 
of the population is a priority in Brazil and is suitable for 
the vast majority of scenarios, safeguarding the necessary 
and prompt response by the services to the demands of the 
population(85). On the other hand, active surveillance should be 
carried out obligatorily in municipalities with residual foci of 
T. infestans(23) (39). 
Amplification of T. cruzi transmission, registered in areas 
previously considered harmless or with no risk for transmission 
of Chagas disease, such as the Amazon region, required greater 
attention to the epidemiologic surveillance teams(76) (91) (92). In 
several Brazilian regions, environmental changes favoring the 
adaptation of vectors to artificial environments, thus establishing 
new spaces for the appearance of disease, have been observed(22) 
(23) (39) (65) (66). Similarly, it has also been observed the domiciliation 
of secondary species, even in a much smaller scale to that seen 
previously to the control of T. infestans(22) (23) (39) (66). 
The emergence or re-emergence of Chagas disease in Brazil 
characterizes a new epidemiological profile that is independent 
of the intradomiciliary transmission by T. infestans. Thus, the 
control of transmission of T. cruzi, in the current scenario, 
should be examined under a new perspective. Surveillance 
attention is extremely important, especially mainly maintaining 
the functioning of sensitive entomological surveillance in 
the municipalities, in addition to health and environmental 
educational actions.
Challenges for Brazil
In Brazil, the SUS is based on core values and principles 
within society, such as universality, equity, integrity, social 
participation and control, which should be the foundation for 
policies and programs of public interest. The country is one 
of the main endemic areas of Chagas disease in the world, in 
various contexts of great complexity for prevention and control. 
Due to the high morbidity and mortality burden associated with 
Chagas disease and their relative invisibility in society, the 
government must ensure its prioritization for public health and 
mobilize necessary resources and capabilities with other state 
actors or non-governmental organizations to its confrontation, 
by strengthening the singular role that primary care plays for 
the national health system.
National estimates of millions of people infected by T. cruzi 
indicate the great responsibility of the country in the technical-
scientific and political fields, not only for the prevention of new 
cases, but especially in the implementation of better decisions 
and benefits for patients with disease that are both acute and 
chronic. Brazil and the other Latin American countries have a 
key role in conducting this process and implementing the action 
commitments internationally agreed under the seals of PAHO 
and WHO. The emerging social movement should be valued 
and promoted, in order to seek the sustainability of actions for 
coping.
The health surveillance activities for Chagas disease, 
based on primary health care, should have as principles: 
territorialization, intersectoriality, focus on people and not 
the disease, formation of multidisciplinary teams, focus on 
the needs and expectations of the population and finally, 
the search quality. The qualified and ethical approach of 
families affected by Chagas disease should be integrated with 
promotion and prevention actions, health care for diagnosis 
and timely treatment, but also to physical, psychological and 
social rehabilitation. Similarly, for transversal epidemiological 
surveillance activities in these territories. Therefore, new pacts 
and agendas must be built, by inserting the Chagas disease as a 
relevant issue, aimed at ensuring access to inputs necessary for 
the diagnosis and treatment of the disease in the SUS.
Therefore, in addition to the elements presented previously, 
the country must continually review the current goals and 
focuses of epidemiological surveillance of Chagas disease, 
considering the accumulation of scientific evidence and 
successful experiences. The social and human development 
must be strongly linked to promote strategic research focusing 
on overcoming science, market and public health system 
failures(111), with a broad popular participation and the emerging 
social movement in Chagas disease. The establishment of the 
International Federation of Associations of People Affected 
by Chagas Disease (FINDECHAGAS), with the important 
participation of various representations of Brazil and other 
countries, strengthens the possibility of raising and catalyzing 
discussions and decisions from a technical and political point of 
view based on evidence, to reach the true control and prevention.
The Ministry of Health, in partnership with states, Federal 
District and municipalities, has played a key inducer role and 
should be guaranteed the strengthening and sustainability of 
the National Program for Chagas Disease Control, to enable 
the scientific evidence, many of which are summarized in 
this Consensus, in fact be applied in the different realities of 
the SUS. It is worth to reiterate its strategic role to ensure the 
sustainability of research funding for control and prevention of 
Chagas disease in Brazil, more adjusted to different situations 
and contexts in the country(83).
The expansion of epidemiologic surveillance activities, in 
addition to acute cases of Chagas disease, integrating cases of the 
disease in the chronic phase, has to be incorporated strategically 
in this perspective, expanding network access to health care for 
diagnosis, timely infection treatment and potential complications 
of the disease. The antiparasitic treatment should be guaranteed 
to all cases that have indication for its use, and new safe and 
effective treatment options must be continuously pursued.
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The priority areas for the development of monitoring 
programs should be designed for both current and future 
epidemiological scenarios, encompassing the redefinition 
of instruments and tools with innovative character for 
the development of monitoring procedures, integrating 
environmental aspects, reservoirs, vectors, parasites and human 
population. The macroecologic and eco-geographic perspective 
should be integrated into the planning of actions in the country, 
in coordination with the other nations of the Southern Cone 
Initiative against Chagas disease.
Considering the risk contexts outlined for Brazil, it should be 
defined the role of other forms of surveillance and how these will 
be integrated into existing processes of surveillance, including: 
hemovigilance, technovigilance, pharmacovigilance, vertical 
transmission, accidents with biologic materials, transplants, 
HIV/AIDS infections, other immunosuppressive conditions, 
unusual acute events, such as outbreaks and microepidemics, 
among others.
It should be emphasized that the integration of Chagas 
disease control program to other communicable disease 
control programs (vectorial programs or not) is required and 
non-communicable chronic diseases in the country - all linked 
mainly to the Secretariat of Health Surveillance [Secretaria 
de Vigilância em Saúde (SVS)], as well as with other areas of 
the Ministry of Health: Secretariat of Science, Technology and 
Strategic Inputs (SCTIE), Secretariat of Health Care (SAS), 
Secretariat of Strategic and Participative Management (SGEP), 
Secretariat of Labor Management and Education Health 
(SGTES), and Special Secretariat of Indigenous Health (SESA), 
aiming to strengthen intersectorial actions for the effective 
control of Chagas disease.
Faced with such prospects, it is justified the construction of 
this consensus, which, in addition to focusing on the Brazilian 
reality, could be a reference tool, encouraging and mobilizing 
all actors involved in the global fight against Chagas disease.
Vertical transmission of Trypanosoma cruzi
Vertical transmission (from mother to child) of T. cruzi 
remains a reality, even with the favorable impact of vector 
control actions and the qualification of the transfusion process 
in several countries, including(104) (105) (112) (113) included in Brazil(20) 
(106) (107). The existence of infected women in childbearing age, 
in endemic countries or not, supports this risk, which tends to 
be reduced over the next two decades.
In Brazil, in 2011, according to SINASC data were collected 
about 3 million live births. Based on the estimated prevalence of 
1% of T. cruzi infection in women between 25 and 44 years of 
age(17) and a risk of vertical transmission estimated as maximum 
of 1% for the State of Minas Gerais, it is estimated that up to 300 
children were born infected that year(107). Detection of vertical 
transmission is complicated in practice, since the vast majority of 
congenital cases is totally asymptomatic(4) (10) (102) (104) (113) (114) (115) (116).
It is a complex issue, considering the existence of little 
scientific evidence of population base. In Brazil, as congenital 
Chagas disease is considered acute, its notification is compulsory 
within the epidemiological surveillance activities.
Diagnosis and management of Trypanosoma cruzi  
infection during pregnancy
It is recommended to carry out a serologic assessment 
(screening) for T. cruzi infection in all pregnant women living in 
or are from endemic areas, preferably during their first prenatal 
visit (20) (117). The Technical Group on Prevention and Control of 
Congenital Transmission and Case Management of Congenital 
Infections (IVa) of WHO Programme on Control of Chagas 
disease also recommends that screening for those women who 
have a history of having received blood transfusions performed 
in endemic areas or who were born in these areas(104). Although 
transmission depends fundamentally by maternal parasitemia, 
there is no clear evidence on which women may actually be 
transmitting the infection, which emphasizes the importance 
of prenatal screening(112) (116) (117).
The transmission may occur at any time during pregnancy, 
possibly being greater in the third quarter, with increasing 
parasitemia(116) (118). On the other hand, the timely diagnosis of 
infection during pregnancy allows a more qualified care to the 
infected pregnant women, who should be monitored throughout 
gestation.
Reports of accidental exposure to benznidazole in pregnant 
women do not indicate adverse effects on the newborn. 
However, given the evidence of teratogenicity demonstrated 
in animals, the specific antiparasitic treatment of infection by 
T. cruzi is contraindicated during pregnancy and not 
recommended during breastfeeding(20) (115), and should be given 
only after these periods(112). Accidental exposure to antiparasitic 
drug during pregnancy is not a criterion for interrupting the 
gestation(115).
Studies point to the possible benefit of antiparasitic 
treatment, with better evolution of Chagas disease(116) (119) (120) 
(121) (122) and reduction of the risk of vertical transmission in 
future gestations(109) (116). High maternal parasitemia is associated 
with an increased risk of vertical transmission and abortion(103) 
(115). Pregnant women who are in the acute phase of Chagas 
disease should be evaluated case by case, preferably with the 
participation of experts, to define the risk-benefit of indicating 
the antiparasitic treatment. The pregnant women with chronic 
Chagas disease must be accompanied in referral centers for 
high-risk pregnancy, as they may present the need for high-
complexity care.
The evidence of T. cruzi infection does not justify the 
abdominal delivery indication (Cesarean),(115) since the congenital 
T. cruzi infection may result in delayed uterine growth, detected 
in ultrasound, and premature delivery(102) (115) (116) (123).
The importance of carrying out all the recommended 
evaluations during prenatal care, including anti-HIV testing is 
emphasized. The coinfection of T. cruzi and HIV in pregnant 
women increases the risk for congenital transmission of T. cruzi, 
by high parasitemia, also implying an increased morbidity and 
mortality(20) (116) (120) (123) (124).
After the delivery, the woman should be evaluated as to 
the conduct of Chagas disease, from the clinic of this disease, 
aiming at an appropriate specific treatment.
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Diagnosis and management in exposed children 
The risk of vertical transmission of T. cruzi depends on 
the level of parasitemia, maternal immune status, infecting 
strain and placental factors, and might occur at any stage of 
disease(41) (104) (113) (115) (116).
Although most cases are asymptomatic, in some cases 
prolonged fever, hepatosplenomegaly, respiratory failure, 
prematurity, low birth weight and stillbirth may occur. Signs 
of meningoencephalitis and myocarditis were observed in 
coinfection with HIV(102) (104) (113) (114) (115) (123). Therefore, they 
have been recommended as routine assessments in children 
with clinical signs of congenital Chagas disease: complete 
blood count, serum biochemistry, urinalysis, chest X-ray, 
electrocardiogram (ECG), echocardiogram, and cerebral and 
abdominal ultrasonography(115).
The strategy employed for the diagnosis of T. cruzi infection 
depends essentially on the child’s age. Children exposed to T. cruzi, 
by vertical transmission, have circulating maternal IgG antibodies 
that can be detected by routine serologic testing up to 9 months 
of age, and their detection in this period, does not necessarily 
characterize a congenital infection. In turn, the persistence of 
unaltered titers of anti-T. cruzi antibodies in children from 9 months 
old, is indicative of congenital infection, and the absence of these 
antibodies removes the possibility of infection in children(104) (123).
The diagnosis in suspected cases of Chagas disease by 
vertical transmission (excluding other forms of transmission), 
because it is an acute infection, should be confirmed using direct 
parasitological methods (fresh examination, micro-hematocrit, 
leukocyte cream and/or Strout method) in cord blood or of the 
newborn in the first 30 days of age (preferably in the first week 
of life), with evaluation of two or three samples in the absence 
of signs and symptoms to expand sensibility(20) (104) (123).
For symptomatic children or newborn from mother presenting 
an acute T. cruzi infection or reactivation in the presence of 
coinfection with HIV/T. cruzi, these parasitological tests should 
be performed repeatedly and, if negative, parasitological methods 
of enrichment and/or molecular (in research laboratories) have 
been used. However, these are not accessible and standardized 
for use in the routine of health services(115) (125). 
In case of negative parasitological/molecular tests in the first 
months or in the impossibility of using parasitological methods, 
it is recommended to search for anti-T. cruzi IgG antibodies after 
the ninth month in two tests(20) (104) (123) (125)). Conventional reagent 
serology in children during this period is strongly indicative of 
congenital transmission, especially when excluding possibilities 
of vector transmission and transfusion(20). 
In Brazil, the inclusion of serologic tests searching IgG for 
T. cruzi in the National Newborn Screening Program (heel prick 
blood test) is recommended, especially in endemic areas for T. 
cruzi infection, representing an useful and low cost strategy(20) (107). 
The search for anti-T. cruzi IgM antibodies has a low 
sensitivity and there are still difficulties to standardize this 
technique and obtain controls. The use of serological methods 
employing recombinant antigens, such as the Shed Acute Phase 
Antigen (SAPA), it may be used if available. There are reports 
that anti-SAPA maternal antibodies disappear earlier than 
conventional antibodies in about three months(126).
Once the diagnosis of T. cruzi infection has been established, 
the child must be treated with benznidazole (10–15mg/kg/
day in two or three doses for 60 days); this is a well-tolerated 
regimen(20) (104) (115). There is a clear need to develop formulations 
in suspension that are more suitable for this treatment, despite 
the recent advance in providing pediatric tablets (12.5mg) for 
these clinical situations. Treatment is mandatory in all cases 
of congenital infection, since it treatment is highly efficacious 
and safe for the vast majority of children. In addition, studies 
show a high cure rate (≥ 95%) when treatment is started before 
1 year of age, already in the first weeks of life(104) (112) (115) (127).
Clinical and laboratory evaluation (blood count testing) 
should be performed at the beginning of the treatment and 30, 
60, and 90 days after the use of benznidazole. In children with 
the clinical syndrome of Chagas disease, other complementary 
assessments should be carried out according to the table presented. 
The cure control must be performed with serologic tests every 
six months with titration until the child has two consecutive non-
reactive serologic test results. Persistence of positive serology or 
evidence of positive parasitologic tests may indicate treatment 
failure and the child must be monitored and evaluated for possible 
complications of the disease. In refractory cases, benznidazole 
therapy may be repeated or may be substituted with nifurtimox 
(up to 15mg/kg/day in two or three doses, for 60 days).
In newborns from infected mothers and asymptomatic, 
whenever possible, T. cruzi research should be performed. 
Those with initial negative parasitologic examination or not 
carried out must be submitted at nine months after birth, for 
the research with serologic tests of anti-T. cruzi IgG antibodies 
or conventional serology for infection by T. cruzi(107) (117) (127). 
A reactive serologic test after this age necessarily implies the 
need to initiate antiparasitic treatment. On the other hand, no 
evidence of positive serology excludes infection.
It is not recommended to suspend breastfeeding of infants 
whose mothers have Chagas disease in the chronic phase - 
except in cases where there is bleeding by nipple fissure, when 
the interruption of breastfeeding in the affected breast would 
be appropriate - or in situations of high parasitemia, such as in 
reactivation of Chagas disease or in women in the acute phase of 
the pathology(112) (115). If exposed to breast milk of mother with acute 
or chronic infection with the presence of nipple cracks, the infant 
should be monitored for the acquisition of T. cruzi infection during 
the exposure period, using the same parasitologic and/or serologic 
criteria described above. In some of these cases, heat treatment 
of milk prior to administration to infants can be considered(112). 
In T. cruzi/HIV coinfection, it is recommended that all 
infected mother is advised not to breastfeed, considering 
that breastfeeding, regardless of the association with Chagas 
disease, it is associated with an additional 7–22% risk of HIV 
transmission. Meanwhile, in cases of acute maternal infection 
by HIV, breastfeeding increases the likelihood of vertical 
transmission of HIV to 29%. In Brazil, the mother is entitled 
to receive infant milk formula, at least until your child reaches 
6 months of age(128). Figure 1 shows the general flow diagram 
for the approach of T. cruzi infection in the mother/child pair.
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Pregnant women living in an area 
endemic to Chagas disease
1st prenatal consultation
Two anti-T. cruzi serologicala tests 
in the pregnant women - different 
methods [ELISA / indirect IFA / IHA]
At
 b
irt
h Confirmed infection by T. cruzi 
(according to diagnostic flowchart)a
Discarded infection by T. cruzi 
(according to diagnostic flowchart) a, b
Forward to high-risk prenatal 
care - evaluate the commitment 
of the pregnant woman (clinical 
evaluation and ECG) b, c
Routine/normal prenatal follow-up
Assess T. cruzi 
infection in the 
newborn
In the postpartum period
Refer the mother for medical 
control of the disease and 
therapeutic evaluation
Absence of 
clinical alterations 
suggestive of 
congenital infection
Perform anti-T. cruzi 
serology in the  
remaining children (if any)
Assessment of T. cruzi d
Positive 
result
Negative 
result
Treatment of infection 
by T. cruzi
Assessment of T. cruzi 
again (one week  
after birth)
Assess other 
causes of 
congenital infection
Positive result Negative result with 
clinical alterations
Negative result 
without clinical 
alterations
Child serology (2 tests after 
9 months age) e
Confirmed congenital infection 
by T. cruzi (according to 
diagnostic flowchart)a
Discarded congenital infection 
by T. cruzi (according to 
diagnostic flowchart a)
a  Follow flowchart to confirm the diagnosis of infection by T. cruzi (see section on laboratorial diagnosis of infection by T. cruzi, in this Consensus)
b If the complementary exams do not confirm changes, o prenatal assistance can be done within the routine procedures of the Basic Health Unit (primary health care).  If signs/symptoms 
suggestive of Chagas disease are present, one should continue prenatal assistance in a reference care unit for high risk pregnancies.
c Evaluation of the fetus by obstetric ultrasonography, one should look for signs of restricted uterine growth and other signs common in the TORCH group (Toxoplasmosis, Other infections, 
Rubella, Cytomegalovirus, and Herpes).
d Parasitological tests are recommended in the first days of life of the child.
e After the 9th month of life use serological tests for the diagnosis of infection.
FIGURE 1. Flowchart for investigating and managing T. cruzi infection in both the mother and child.
Presence of 
clinical alterations 
suggestive of 
congenital infection
ELISA: enzyme-linked immunosorbent assay;  IFA: immunofluorescent antibody test; IHA: indirect 
hemagglutination; ECG: electrocardiogram
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LABORATORY DIAGNOSIS OF 
TRYPANOSOMA CRUZI INFECTION
In Brazil, an attempt to establish the etiologic diagnosis of 
Chagas disease should be made in all suspected cases, both in 
the acute phase and in the chronic phase(20) (39) (129). Therefore, it 
is essential to integrate epidemiologic, clinical, and laboratory 
evidence, in order to increase the degree of predictive and 
diagnostic accuracy. The complementary diagnosis of infection 
by T. cruzi through various laboratory techniques should follow 
defined criteria, depending on the stage of the disease. The 
following recommendations for diagnosis include the current 
Brazilian regulations.
Laboratory criteria to define the diagnosis  
of Chagas disease 
Acute phase
Parasitologic criterion
Parasitologic examination is the most appropriate at 
this stage. This criterion is defined by the presence of T. 
cruzi trypomastigotes, identified by direct examination of 
the peripheral blood (with or without centrifugation) using 
microscopy (with or without staining)(39) (129) (130) (131) (132).
Simultaneous performance of different modalities of 
direct parasitological examinations is recommended - fresh 
examination of trypanosomatids, concentration methods, or 
thick smear or smear stained slide. When the results of the 
fresh examination and concentration methods are negative in 
the first collection, new collections must be carried until the 
case definition and/or the disappearance of the symptoms of 
the acute phase, or until the confirmation of another diagnostic 
hypothesis(20) (39) (133).
Serologic criterion
The serologic criterion is based on indirect methods for 
diagnosis that may be performed when parasitologic tests are 
negative but clinical suspicion persists. Such methods have 
complementary usefulness, and should always be performed 
in suspected or confirmed cases of acute Chagas disease(39) (134). 
When the parasite is not identified by direct observation, 
verifying the presence of anti-T. cruzi IgM antibodies in the 
peripheral blood is considered suggestive of the acute stage, 
particularly when combined with the patient’s epidemiologic 
context and clinical events(39) (135). This represents a more 
complex technique and is most suitable in the late acute phase, 
when repeated direct examinations are negative(129) (133) (134).
Seroconversion to T. cruzi infection is defined by an initial 
non-reactive serum sample for anti-T. cruzi IgG antibodies, 
followed by a reactive sample collected 2–4 weeks later, based 
on an assay that includes both samples simultaneously(133) (134).
Alternately, an increase of at least two titers between two 
reactive samples taken 2–4 weeks apart, in a clinical and 
epidemiologic context suggestive of acute Chagas disease, may 
also be considered diagnostic of acute Chagas disease(39) (132) (133) (134).
In situations where vertical transmission is possible, the 
strategy used for the diagnosis of infection by T. cruzi would 
depend on the child’s age; this is discussed in a specific part of 
this document. It is noteworthy that every case of congenital 
transmission means an acute case of Chagas disease and, as 
such, should be reported and managed(104).
Chronic phase
Parasitologic criterion
Due to the low parasite burden in the blood in the chronic 
phase of Chagas disease, parasitologic methods of enrichment/
multiplication, blood culture(136) (137) and xenodiagnosis(138) have 
demonstrated low sensitivity, which implies the absence of 
diagnostic value when the result is negative(20) (133) (139). When 
positive, the results are useful, mainly to monitor the specific 
treatment, or in unusual cases where serology presented 
inconclusive results(129) (134).
Serologic criterion
In the chronic phase, the diagnosis is essentially serologic, 
and must be performed using a test with high sensitivity in 
conjunction with another having high specificity(20) (39) (132) (133) (134).
An individual is considered in the chronic phase of infection 
if anti-T. cruzi IgG antibodies are detected by means of two 
serologic tests with different principles/methods having different 
antigenic preparations. Other diseases (for example, visceral 
leishmaniasis, virchowian (lepromatous) hanseniasis, and 
autoimmune diseases) should be considered in the differential 
diagnosis(140) (141) (142).
Principles and Guidelines for the Laboratory  
Diagnosis of Trypanosoma cruzi Infection
Parasitologic diagnosis in the acute phase
The parasitologic diagnosis of Chagas disease at this stage 
is mainly based on the identification of the parasite, and its 
sensitivity depends on the level of parasitemia. In the acute 
phase, the number of parasites in the peripheral blood is high. 
It is recommended that, if presented with a suspected case of 
Chagas disease in the acute phase, different methods of direct 
parasitologic examination be used for immediate and repeated 
reading, in order to clarify the diagnosis(20) (39) (104) (132) (133) (134).
The fresh search for trypanosomatids is quick and easy to 
perform, and is more sensitive than staining the smear. The 
ideal situation is to collect them from a febrile patient within 30 
days of symptoms onset(134). The examination can be performed 
directly under the microscope with a drop of blood between 
the slide and cover slip. Blood collection should be carried out 
simultaneously for techniques of blood concentration.
The concentration methods are quick and inexpensive 
(Strout’s method, micro-hematocrit and buffy coat). They 
are recommended as the first choice of diagnostic test for 
symptomatic cases with more than 30 days of evolution, due 
to the decline in parasitemia with time. Blood samples should 
be examined within 24 hours due to possible lysis of the 
parasites(129) (134).
Direct examination of a stained thick blood drop or blood 
smear can be used, but this has lower sensitivity than the 
methods described above. However, in the Northern region 
of Brazil, belonging to Legal Amazon, this method is widely 
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used; it is convenient and able to be integrated into malaria 
diagnostic actions(20) (39). It also represents an important method 
for verification and morphologic characterization, especially in 
geographic areas where the infection by T. rangeli can coexist 
with T. cruzi.
It is emphasized that in cases with high parasitemia ̶ 
as in the acute phase of the disease, but also in transfusion 
transmission and in immunocompromised individuals  ̶ parasites 
can be incidentally found on blood smear when performing a 
differential leukocyte count(20) (39) (49) (52) (100).
In cases where a strong clinical and epidemiological suspicion 
of acute phase T. cruzi infection exists but direct parasitologic 
examinations are negative, molecular diagnosis using 
polymerase chain reaction (PCR) methods with hybridization 
has shown promising results. However, these are in-house 
tests, performed by only a few research/reference centers. The 
methods, protocols, and operating procedures should follow the 
recent recommendations for the standardization for the PCR 
use(143) (144). In Brazil, due to the absence of defined protocols 
and standard operating procedures, as well as of commercial 
kits to be routinely used in health surveillance, PCR cannot be 
considered an isolated diagnostic method to confirm or discard 
cases of acute or chronic Chagas disease(39).
Serologic diagnosis in the acute phase
In Brazil, there are currently difficulties in performing 
serologic tests in patients in the acute phase, due to the lack of 
registered commercial kits approved by the Brazilian National 
Health Surveillance Agency (ANVISA) and difficulty in 
obtaining positive controls for IgM(20) (39) (133). Therefore, it has 
been traditionally recommended that indirect IFA methods are 
performed in reference laboratories to detect IgM(145) in addition 
to the conventional techniques already in use, such as indirect 
IFA to detect IgG, IHA(146), and ELISA(147).
Parasitologic diagnosis in the chronic phase
Indirect conventional methods for the isolation and 
identification of T. cruzi (xenodiagnosis and blood culture) have 
low sensitivity; sensitivity can be increased through repetition(20) 
(129) (133) (148) (149). A negative test does not rule out the possibility 
of infection, but a positive test has an absolute diagnostic value. 
The PCR at this stage, despite being limited by the lack of 
standardized protocols, is indicated when serologic tests present 
an indeterminate result or to determine cure after antiparasitic 
treatment. PCR should be performed by laboratories with 
recognized competence, carried out by experts in the field(150).
Serologic diagnosis in the chronic phase
Diagnosis in the chronic phase is essentially serologic, 
and should be performed using a test with high sensitivity 
(ELISA with total antigen or indirect IFA) in conjunction 
with another method with high specificity (IHA)(129) (133) (134). 
Known conventional tests (IHA, indirect IF, and ELISA)
(131) can determine the diagnosis in almost 100% of cases. 
Unconventional tests (with recombinant antigens, for example) 
may preferably be used in parallel with another conventional 
test(151).
Performing reactions in eluates from collected blood on filter 
paper is not recommended to diagnose the infection, although 
these are usually used in the screening steps of epidemiological 
investigations(152). The Guerreiro and Machado reaction (or 
complement fixation) for Chagas disease does not meet the 
standards currently required. Since it is not commercially 
available, it is also not indicated(20) (129).
The chemiluminescence test also allows the identification of 
IgG antibodies. While some kits are available on the market, the 
technique is still not recommended by the Ministry of Health 
of Brazil(133).
The recent evaluation of 11 rapid test kits used for serologic 
diagnosis of Chagas disease indicates the potential of these 
methods. However, further studies should be conducted in the 
laboratory and in the field to confirm these data, in particular 
assessing their reproducibility in the context of limited resources 
or the use of whole blood in the real contexts of endemic and 
non-endemic areas(153).
The following flowchart (Figure 2) summarizes the steps 
for the laboratory diagnosis of T. cruzi infection in the chronic 
phase of the disease.
ACUTE PHASE OF CHAGAS DISEASE
Acute Chagas disease is becoming a less frequent event in 
endemic countries, including Brazil, where control of vector 
(especially by T. infestans) and transfusion transmission has 
altered the epidemiological scenario(20) (39). On the other hand, 
the occurrence of cases and outbreaks by oral transmission, 
transmission by domiciliary vectors without colonization and 
by extradomiciliary vectors, especially in Amazônia Legal, 
has gained epidemiological importance(20) (21) (39) (76) (154) (155) (156).
Urbanization and globalization of Chagas disease due to 
large migrations, both in endemic and non-endemic countries, 
has contributed to making the epidemiological scenarios even 
more complex. In addition, reactivation episodes of Chagas 
disease associated with immunodeficiencies have become 
emerging challenges for health systems(20) (39) (49) (157) (158) (159). In 
this sense, the epidemiological investigation of the mode of 
transmission of Chagas disease is of particular importance, not 
only in order to determine actions to be implemented, but also 
because the different routes potentially lead to specificity in the 
clinical expression of the acute disease(20) (39) (76) (132).
Clinical and complementary examination aspects 
Acute phase of Chagas disease by vectorial transmission 
The clinical picture is characterized by the appearance of 
a set of manifestations of variable intensity after an incubation 
period that is inversely proportional to the load of the inoculum 
and the inoculation route. There may be a lesion at the inoculation 
site(20) (21) (39) (76) (91) (155) (160). The clinical picture of acute illness in 
cases of vectorial transmission is polymorphic, ranging from the 
classical description  ̶ a sign of infection at the inoculation site, 
fever, subcutaneous edema, lymphadenopathy, hepatomegaly, 
splenomegaly, and evidence of myocarditis and meningoencephalitis 
 ̶ to asymptomatic and oligosymptomatic situations(20) (76) (91) 
(160). The incubation period may vary from 4 to 15 days.
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Plasma or serum samples
2 tests, different methods 
(ELISA, indirect IFA/IHA)
1 test reactive
1 test non-reactive
Both 
reactive
Both 
reactive
Positive result
Both 
non-reactive
Negative resultInconclusive
Collect new sample
Repeat 2 tests, different methods 
(ELISA, indirect IFA/IHA)
Both 
reactive
1 test reactive
1 test non-reactive
Positive result Negative resultInconclusive result
Forward samples to reference 
laboratory
FIGURE 2. Flowchart of steps for the laboratory diagnosis of T. cruzi infection in suspected cases of chronic Chagas disease.
The portal of entry is the ocular conjunctiva (Romaña 
sign) in 50% of cases and the skin (inoculation chagoma) 
in 25% of cases; it is unknown in the remaining 25% of 
cases(160). However, it is assumed that the ocular route is the 
most frequently diagnosed as it is easy to recognize, both by 
the affected individual and the healthcare team. The Romaña 
sign is essentially characterized by unilateral, painless, elastic 
edema of the eyelids with satellite lymph node reaction (mainly 
pre-auricular). Often, the swelling spreads to the ipsilateral side 
of the face; its degree is variable and can be severe enough to 
cause total occlusion of the palpebral fissure. The presence of 
the Romaña sign is an excellent marker for the diagnosis of the 
acute phase, allowing recognition of many cases(20) (160) (161). In 
terms of the skin, the inoculation chagoma presents as a hard, 
erythematous, slightly painful nodule surrounded by elastic 
edema. It is also accompanied by satellite lymph node reaction 
and, sometimes, ulceration. It can be found on any region of 
the body, especially exposed parts(20) (160).
Along with these signs of entry, general symptoms such as 
fever, malaise, headache, asthenia, and pyrexia appear. Fever 
is an initial symptom is almost all cases; it usually does not 
exceed 39°C; although it can be higher, especially in children. 
The thermal curve is not characteristic; the temperature record 
may show a continuous or relapsing and intermittent pattern, 
with significant increases in the late afternoon(160) (162). 
Around the second week of the disease, generalized or 
localized edema may appear (on the face or lower limbs), 
regardless of the inoculation site or presence/absence of cardiac 
failure(160). Its consistency can be elastic or soft; the elastic is 
observed only in young children. The pathogenesis of this edema 
is unclear; several hypotheses have been suggested. 
Usually, lymph nodes are slightly to moderately increased 
in size, isolated, mobile, smooth, painless, and firm. Of those 
accessible to palpation, lymphadenopathy is most commonly 
found in the cervical, axillary, and inguinal regions; this 
manifestation occurs early in disease(160).
ELISA: enzyme-linked immunosorbent assay  
IFA: immunofluorescent antibody test  
IHA: indirect hemagglutination
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Hepatomegaly and splenomegaly, alone or in combination, 
are often observed. In general, the increase in liver and spleen 
volume is small or moderate, the consistency does not change, 
the edge and the surface are smooth and, sometimes, there is 
pain on palpation of the liver. These signs are an early part of 
the clinical framework(160) (163).
Although less common, other features (neurologic and 
cutaneous) may be present. Neurologic manifestations refer to 
signs of meningoencephalitis (vomiting, agitation, convulsions, 
opisthotonos, neck stiffness, etc.), which is mainly observed 
in young children. Meningoencephalitis may present with 
abnormal cerebrospinal fluid (CSF) findings. The characteristic 
examination findings are clear CSF, increased cellularity with 
mild lymphocytosis (<100 cells/mL), low glucose and slightly 
increased protein levels; it is possible to see trypomastigote 
forms of T. cruzi after centrifugation of CSF, using specific 
staining methods(20) (160).
Cutaneous manifestations (rare in Brazil and relatively 
frequent in Argentina) include rashes (morbilliform, urticariform, 
and macular) called esquizotripanides and hematogenous 
chagomas (usually flat formations). These affect skin and 
subcutaneous tissues without changing their color; are non-
adherent to the deep planes; usually painless; and of variable 
size, from that of a coin to large plaques(160) and, according to 
Lugones (2001), they are more palpable than visible(162).
The heart presents changes of greater or lesser severity; 
with a moderate frequency. However, the clinical, radiologic, 
or ECG manifestations involved are not significant, are not in 
keeping with the histologic findings, and may even be absent. 
On the other hand, it is necessary to bear in mind that serial 
radiologic and electrocardiographic examinations are required 
in the short-term, seeking signs of cardiac impairment, given 
the transience of some of the manifestations(20) (21) (160) (164).
The symptoms of acute Chagas myocarditis are essentially 
identical to those of acute myocarditis of other etiologies, 
sometimes being masked by other clinical manifestations. 
Tachycardia is often reported and, generally, not dependent on 
the degree of temperature increase; in most cases this is observed 
early. A systolic murmur with functional blow characteristics 
can be detected in the mitral area. Excitability arrhythmias are 
only occasionally found. Heart failure, when present, is global; 
its symptomatology is no different from that related to other 
etiologies. There may be a degree of arterial hypotension(160) (164). 
Already in the first weeks of infection, radiologic and/or 
electrocardiographic changes, of greater or lesser significance, 
may be observed. These tests are not always simultaneously 
abnormal. Practically, if one test result is abnormal it has 
the same diagnostic value as both being abnormal, as both, 
individually, reveal disorders with the same frequency. When 
performed in combination and serially, however, these allow 
more frequent demonstration of impairment(160) (164). Therefore, 
the study of cardiac function by echocardiography is indicated 
in cases with signs and symptoms of myocarditis.
Radiologically, the heart size can be normal or may be 
mildly, moderately, or severely increased. Cardiomegaly 
is global, predominantly as a result of enlargement of the 
ventricles, but in some cases, due to a dilation of only the left 
ventricle. The exudate in the pericardial cavity contributes to 
increase the heart shadow(160) (164).
The electrocardiographic changes most frequently 
encountered are sinus tachycardia, decreased QRS complex 
voltage, first-degree atrioventricular block (AVB), primary 
alteration of ventricular repolarization, and increased electrical 
systole. Arrhythmias, except for first-degree AVB, are only 
occasionally observed(160) (164).
The chronologic asynchrony between the appearance of 
echocardiography findings and the occurrence of acute phase 
is not a reason not to perform this examination. In a study 
conducted in Venezuela that followed 58 patients in the acute 
phase, the ECG findings proved to be abnormal in 27 (52%); 
the most important finding was pericardial effusion, present in 
42% of the cases, ranging from mild to moderate intensity in 
17 patients and severe in 5; in 11 (21%) patients earlier and/or 
apical dyskinesia was demonstrated, and in 3 (6%) patients, left 
ventricular dilation was observed(165). A study of 158 patients 
with acute Chagas disease in the Amazon (most cases due to oral 
transmission) revealed the presence of 108 changes, with more 
than one alteration present in the same individual(91). The main 
abnormal findings were pericardial effusion (from small to large 
volume), mitral or tricuspid valve regurgitation, and symmetric 
hypertrophy of the left ventricle. Occasionally, accentuation of 
sinus tachycardia was observed, in contrast to the reduction in 
intensity or disappearance of acute manifestations, including 
fever; this was previously reported by Chagas(76) (91) (160). 
The main nonspecific laboratory abnormalities found are, in 
order of frequency: anemia, leukopenia, relative lymphocytosis, 
and an increase, from mild to moderate, of aminotransferases. 
Also described are thrombocytopenia and, more rarely, 
thrombocytosis and atypical lymphocytosis(21) (76).
The complete blood count reveals that the total leukocyte 
count is generally increased, although it may be normal or 
slightly decreased, with intense lymphocytosis, plasmacytosis, 
and related neutropenia. A high percentage of atypical 
lymphocytes and leukocytoid cells appear after the second 
week of the disease. As the disease evolves to chronicity, these 
changes disappear, and eosinophilia emerges(20) (21) (39) (160).
Acute phase of Chagas disease by blood transmission
In the acute phase of transfusion transmitted Chagas 
disease, the clinical syndrome is practically identical to that 
seen when transmitted by triatomines, except for the absence 
of an inoculation chagoma. Similarly, it must be assessed with 
complementary examinations. The incubation period can range 
from 30 to 112 days, being a little longer than that observed 
in vector-borne transmission, although much shorter periods 
(such as 8 days) or longer periods (such as 120 days) have been 
observed(160) (166). Chagas disease must always be considered in 
cases presenting with a fever of unknown origin, particularly 
if the patient under investigation has received a transfusion in 
a remote or hyperendemic region(166).
Fever is the most common symptom, affecting 80–100% of 
cases. It is often the only symptom found. Lymphadenopathy 
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and splenomegaly are also frequently observed, while anemia/
pallor, perimalleolar and periorbital edema, skin rash, and 
hepatomegaly appear in <50% of cases(166).
Acute phase of Chagas disease by oral transmission
Oral transmission of Chagas disease has been reported in the 
Amazon and extra-Amazon regions(76) (91) (94) (167) with peculiar 
clinical characteristics when compared to vectorial transmission, 
and sometimes with regional differences(21). The major clinical 
differences between the descriptions of past endemic areas and 
the Amazon region (in which oral transmission prevails) is the 
clinical presentation of high morbidity, highlighting the regional 
epidemiological characteristics regarding the occurrence of a 
more efficient mode of transmission than the vectorial route(76) 
(94). Evaluation by non-specific complementary tests is generally 
similar to that previously seen.
Evidence suggestive of inoculation (Romaña sign and 
inoculation chagoma)  ̶ typical of the disease induced by vector 
transmission  ̶ is rarely described in cases of oral transmission, 
emphasizing the clinical differential diagnosis between the two 
forms of transmission and the low frequency of contact between 
humans and non-domiciled vectors in this region(91) (94) (160).
The incubation period ranges from 3 to 22 days. The main 
signs and symptoms recorded in acute Chagas disease are, in 
order of frequency: prolonged fever, headache, pallor, myalgia, 
skin rash, and edema of the face and lower limbs(21) (39). The 
characteristic signs and symptoms of cardiac impairment 
include tachycardia without fever, palpitations, dyspnea, and 
chest pain(76).
Fever is the predominant manifestation in almost all cases. In 
general, it is characterized by daily high temperatures, from the 
morning until the late afternoon. This continues for an average 
of 18 days (range: 3–25 days). In individuals manifesting 
prolonged fever, the fever is initially high (38.7–39.0ºC) 
and is accompanied by chills and generalized pain. After 
approximately 12–15 days, it begins to settle; the temperatures 
range between 37.0ºC and 37.8ºC, occur daily, and the fever 
usually disappears in the afternoon(76) (91).
Pallor (anemia) occurs from the beginning of the febrile 
syndrome, in particular on days 3–5, and lasts 20–25 days. 
Myalgia can be intense; it is often described as an acute stabbing 
pain, or similar to that experienced in dengue fever (generalized 
and confused with polyarthralgia)(91) (168).
When Chagas disease is induced by oral transmission, 
skin rash appears as an important sign and is associated with 
abundant parasitemia. It occurs more frequently than when 
Chagas disease is caused by vectorial transmission. In general, 
it presents as a macular rash that is not itchy or painful. It occurs 
on around days 4–8 of disease, usually affecting the chest, back, 
lower limbs, and neck, and sparing the face and palmoplantar 
regions. It is relatively transient and most often goes unnoticed 
by the patient, found only on physical examination(91) (169) (170).
The edema of the lower limbs generally appears after 
approximately 12 days of illness and lasts until day 20, 
coinciding with the disappearance of fever. Invariably, it has 
the characteristics of inflammatory edema, inelastic and slightly 
painful. It affects the malleolar region or the entire lower limb. 
Facial edema can occur in the same period; it has no specific 
features(76) (91).
In most cases, acute myocarditis may start slightly before 
the disappearance of fever, on average from day 15 to 20 of the 
disease. The main signs and symptoms are dyspnea, palpitations, 
tachycardia (without fever) and, possibly, precordial chest pain 
simulating myocardial infarction. Myocarditis is one of the 
most common complications among patients in the acute phase. 
ECG and echocardiographic examinations should be performed 
immediately after diagnosis(76) (160) (164). 
Among patients evaluated in the Amazon, 52.3% had 
altered ECG findings, consisting of diffuse changes with 
ventricular repolarization abnormalities (VRA), low voltage 
of the QRS complex, deviation of the electrical axis to the left, 
and sinus tachycardia, demonstrating some involvement of 
milder conduction system of the heart and, more often, diffuse 
signs of inflammation. Cardiac electrical conduction disorders 
are more evident in adults. Myopericarditis, evidenced by the 
presence of VRA and pericardial effusion (seen on ECG and 
echocardiography, respectively) is important in both adults and 
children(154) (160) (164). In outbreaks outside the Amazon Region, 
a high frequency of pericardial effusion was observed(155), 
emphasizing the need for early diagnosis in view of severe 
evolution if not promptly diagnosed and treated.
Pericardial and/or pleural effusion may occur in more than 
50% of cases infected via the oral transmission route, suggesting 
that pericarditis may be more important than involvement of the 
cardiac electrical conduction system during the acute phase(154) 
(160) (164).
Painful nodules of lower limbs may be associated with 
edema, and have been invariably recorded in lower limbs of 
women. The presence of erythema nodosum has been frequently 
observed in cases of oral transmission. Similar descriptions 
in children were also recorded in an Argentinian case series, 
in which some skin and subcutaneous lesions were labeled as 
hematogenous or metastatic chagomas(169) (171).
Other manifestations associated with this form of transmission 
can be present, such as epigastric pain, jaundice of the skin and 
mucous membranes, hepatomegaly, and lymphadenopathy. 
Lymphadenopathy is common in children, affecting especially 
cervical lymph nodes chains; it is not generalized. Splenomegaly 
and diarrhea are rare events(91) (94).
It has been reported that 13.3% of cases are severe. 
Severity is almost always related to manifestations of acute 
myocarditis and severe gastrointestinal bleeding. The presence 
of gastrointestinal bleeding might represent the portal of entry(94), 
with the inflammatory infiltrate containing amastigotes. There 
are rare reports of acute meningoencephalitis(172). Hemorrhage 
represents a critical scenario of the epidemic that occurred in 
the City of Navegantes, in the State of Santa Catarina (Southern 
region of Brazil), providing differential diagnosis for severe 
diseases that presented a jaundice-hemorrhagic condition, such 
as leptospirosis, dengue and hantavirosis(76). The mortality rate 
was significant among adults aged over 50 years (5.6%).
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In just over half (54.1%) of the cases in the Amazon, the 
diagnosis was confirmed by parasitologic examination(154) (156) (169). 
Therefore, in cases with negative parasitologic tests, but with strong 
clinical suspicion, concomitant serologic testing is recommended, 
considering in particular their higher sensitivity after the first month 
of clinical history.
Specific treatment
Specific and immediate treatment is indicated in the acute 
phase, with long-term follow-up to identify the treatment 
response serologically(76) (156) (169). For more details, see the 
specific treatment part of this Consensus.
A case series was reported of 179 patients treated with 
benznidazole in the acute phase of Chagas disease induced 
by oral transmission who were followed-up under a research 
protocol for an average period of 5.6 years. A serologic response 
to treatment was found in 26.3% of patients, most evident 
four years after treatment; 2.7% developed a chronic mild-to-
moderate cardiomyopathy; and 73.7% had persistently reactive 
serology, although with a significant decrease in the levels of 
antibodies(156).
Reactivation of Chagas disease
The management of cases with reactivation of Chagas 
disease, in the context of immunosuppression, is an important 
and emerging public health problem in all countries where 
people with chronic Chagas disease reside. In particular, the high 
congenital transmission rate (>50%) in T. cruzi/HIV coinfected 
pregnant women is highlighted in the literature. It is advised, 
therefore, that careful follow-up with clinical assessment and 
periodic direct search for the parasite be conducted in these 
women(20) (173) (174) (175).
Reactivation of chronic Chagas disease in previously 
infected cases is defined as positivity of the following tests, 
regardless of the presence of other signs and symptoms(159):
1. Parasite detected by direct microscopic examination 
of blood or biological secretions: cerebrospinal fluid, 
pleura, pericardium, ascitic fluid, among others. In terms 
of sensitivity, parasite search in buffy coat or micro-
hematocrit specimens or sediment from other materials 
is more sensitive than fresh direct search in biological 
material or smear. The thick blood smear is more difficult 
to perform and interpret, and can only be carried out by a 
trained technician.
2. Histopathologic examination of tissue lesions (panniculitis, 
myocarditis, encephalitis, enteritis, colpitis, among others), 
with parasite nests within the acute inflammatory infiltrate.
Reactivation of Chagas disease was first reported in patients 
immunocompromised by hematologic neoplasms(176). From the 
late 1980s and early 1990s, cases of reactivation of Chagas 
disease began to be reported in HIV-infected individuals(159) 
(175) (177) (178) (179) (180). In the largest prospective study of T. cruzi/
HIV coinfection (n = 53 patients), the rate of reactivation was 
20.8%(175). Considering only followed-up patients and excluding 
hospitalized patients diagnosed with reactivation, this value was 
approximately 10%(175). 
In kidney transplant recipients, the rates of transmission 
(from infected donors) and reactivation (in chronically infected 
patients submitted to transplantation) are 18.7% and 21.7%, 
respectively(181). In the context of heart transplant recipients, a 
reactivation rate of 26.4–40% was found(182) and, although use 
of infected donor hearts is prohibited, this has been reported in 
the absence of donor screening in non-endemic countries(157) (158).
In Brazil, in addition to prohibiting the use of infected donor 
heart and intestine in transplants, it is recommended not to use 
other transplant organs from donors with infection; exceptional 
situations should be discussed on a case-by-case basis with 
specialized teams(183).
The rate of reactivation in recipients of allogeneic 
hematopoietic stem cell(184) and liver(185) transplants is 27.3%, 
and 18.7%, respectively. The use of corticosteroids in 
association with increased parasitemia and a possible effect with 
immunosuppressive drugs to treat mesenchymal diseases have 
been recorded, without a well-defined causal relationship(186).
Diagnosing reactivation of Chagas disease
Clinically, the most common manifestations of reactivation 
are fever, panniculitis (subcutaneous nodules), myocarditis, 
meningoencephalitis, stroke, and symptoms such as anorexia, 
myalgia, malaise, and diarrhea. Case series studies suggest that 
reactivation associated with HIV infection has a higher morbidity 
and mortality than other causes of immunosuppression, such as 
in transplant recipients, where the monitoring of organ recipients 
is suggested, with high success rate for some groups(181) (184). 
In reactivation associated with HIV infection, 
meningoencephalitis (74% of the cases), myocarditis (17.1%), 
and both occurrences (7.9%) have been reported(48) (49) (159) (175) (187). 
Oligosymptomatic forms forms were diagnosed in mothers 
who gave birth to children with severe Chagas disease and in 
patients with prolonged fever in long-term follow-up, with good 
therapeutic responses to benznidazole. Other rare manifestations 
of reactivation in immunosuppressed patients have been observed, 
such as erythema nodosum, myelitis, peritonitis, and colpitis(49) (159).
Complementary examinations, such as computed 
tomography and/or magnetic resonance imaging of the brain, 
are fundamental to localize lesions; to differentiate other 
diagnostic possibilities, such as neurotoxoplasmosis and 
primary lymphoma of the central nervous system; and to assess 
whether it is possible to perform a lumbar puncture to obtain 
CSF for examination to confirm the diagnosis, by recognizing 
the presence of the parasite (and subsequent cultivation). 
These tests are more sensitive when performed on CSF than on 
peripheral blood. CSF examination reveals discrete pleocytosis 
(with predominance of lymphocytes and monocytes), average or 
slightly reduced glucose level, and a mild-to-moderately raised 
protein level(48) (49) (159).
In reactivation disease, myocarditis is manifested as heart 
failure induced by arrhythmia, cardiogenic shock, and low 
response to symptomatic drugs for congestive heart failure. 
Echocardiography and other complementary examinations to 
assess cardiac function are indicated(49) (159) (175). Diagnosis is 
facilitated when there is a concomitant increase in parasitemia 
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in peripheral blood; however, reactivation can occur in the tissue 
without systemic repercussions(49) (159). 
The reactivated form of Chagas disease, in its manifestations 
of meningoencephalitis and/or myocarditis, is officially 
considered in Brazil as indicative of severe immunodeficiency 
in individuals over 13 years, and have been included as AIDS-
defining conditions since January 2004(54).
For epidemiological surveillance purposes, cases of 
reactivation of Chagas disease are those that present a definitive 
diagnosis of T. cruzi infection by parasitologic diagnosis through 
direct investigation of blood or body fluids (CSF, pericardial, 
or peritoneal fluid), associated with:
• Meningoencephalitis: Brain injury image with mass effect 
(magnetic resonance imaging or computed tomography, 
with or without injection of contrast medium, showing 
ring enhancement); and/or
• Acute myocarditis: Arrhythmias and/or heart failure 
diagnosed by electrocardiography and echocardiography.
Factors associated with the reactivation  
of Chagas disease
A CD4+ T lymphocyte count <200 cells/mm3 is observed in 
>80% of cases of reactivation(49) (159) (175). Reactivation is rarely 
seen in patients with a CD4+ T lymphocyte count >350 cells per 
mm3(48) (49). Available data do not suggest the importance of HIV 
viral load as prognostic factor for reactivation or as factor related 
to the severity of the cases. On the other hand, HIV viral load 
increases have been observed in the context of reactivation(49) (159).
Regarding the role of the protozoan, prospective studies 
have shown the importance of high parasitemia (observed by 
quantitative methods) as a predictive factor of reactivation (50% 
of cases). In addition, the participation of different subpopulations 
of T. cruzi in the genesis of clinical manifestations of reactivation 
is discussed; this remains controversial in the literature(48) (49) (159).
In heart transplant situations, factors associated with 
reactivation are the number of rejection episodes, the presence of 
neoplasms, and tangentially, the use of mycophenolate mofetil(182).
Evolution and prognosis of reactivated  
Chagas disease
If early treatment is not provided, most patients with AIDS 
and reactivation of Chagas disease die before or shortly after 
diagnosis(159) (175). Of patients who complete at least 30 days of 
treatment, about 80% survive(159). The prognosis in cases of 
HIV infection and reactivation of Chagas disease was reserved 
before the advent of highly active antiretroviral therapy 
(HAART), with an estimated average survival of 10 days(20). 
In immunocompromised patients, the severity depends on 
the degree of immunosuppression, the parasite load and the 
sensitivity of the isolated parasite to antiparasitic treatment. 
The outcomes recorded in kidney transplant recipients were 
favorable, due to monitoring, diagnosis, and early treatment. The 
clinical picture is quite severe in newborn infants with congenital 
infection from born to T. cruzi/HIV coinfected mothers; the 
morbidity and mortality is high(173) (174) (175).
CHRONIC INDETERMINATE FORM OF 
CHAGAS DISEASE
The indeterminate chronic form (ICF) of Chagas disease is 
particularly relevant as it is the most prevalent clinical form the 
disease. It has a benign nature and low evolutionary potential 
in the short and medium term(19) (20) (39) (188) (189) (190) (191). With 
the reduced incidence of acute Chagas disease and improved 
clinical management, the duration of survival of patients with 
chronic Chagas disease has increased, reflecting a tendency to 
proportional reduction of ICF with advanced age(19) (189) (192) (193) (194). 
On the other hand, since the last Brazilian Consensus in 2005(20), 
no applicable strategy of clinical or complementary evaluation 
to the classic concept of ICF has been proposed.
Diagnostic criteria
Patients are considered to have ICF if in a chronic phase 
of Chagas disease with positive serology and/or positive 
parasitologic examination for T. cruzi(188) (189) but no typical clinical 
syndrome specific of the disease; conventional ECG results; 
and normal radiologic examination of the chest, esophagus, and 
colon(188). No other complementary examinations in addition to 
those previously listed, are required to define ICF. The expression 
indetermined chronic form was first used by Carlos Chagas and 
stablished by its use(195) (196) (197) (198). The reference of this term, 
mainly in the context of scientific research, was consolidated by 
Brazilian researchers in 1984(20) (142) (188) (199).
In field and operational studies, for asymptomatic cases with 
normal physical examination, conventional ECG, and chest and 
esophagus radiography findings, the term ICF was used without 
performing radiologic investigation of the colon(19) (189) (190) (191). 
This conduct is justified, taking into account the low availability 
and feasibility of these complementary tests in the real context 
of the national health systems in endemic regions.
Treatment and clinical follow-up
Specific antiparasitic treatment is indicated for all cases 
with ICF (see specific section on antiparasitic treatment in this 
Consensus)(20) (39). 
While the ECG finding is normal, the prognosis of cases 
with ICF of Chagas disease is similar to the general population, 
since serial repetition of these examinations can detect evolution 
to a cardiac form of Chagas disease(20) (189) (192) (197). Based on this 
key concept, is not recommended performing other routine 
complementary tests while the ECG finding is normal(19) (20) (189) (190) (191). 
Cases with ICF should be advised not to donate blood, and in 
principle, tissues or organs(20) (39). Due to the benign nature of ICF, 
the (still common) practice of requesting specific serologic exams 
for Chagas disease in pre-employment assessments for labor 
purposes and periodic examinations conducted by institutions 
and/or public or private companies, is not justified(192) (200) (201) (202). 
As for other complementary tests, these may be ordered according 
to the specific labor activities that the individual will perform. 
Similarly, in these cases, temporary or permanent removal from 
work activity is not recommended(192) (200) (201) (202) (203). 
Engaging in usual, regular physical activity is not 
contraindicated in patients with ICF. For professional activities 
  27
Rev Soc Bras Med Trop 49:Supplement I, 2016
2nd Brazilian Consensus on Chagas Disease, 2015
involving individual and collective risk that may require high 
demand of physical effort and/or psychological stress, the 
adoption of a complementary specific cardiologic evaluation 
is recommended. There is no restriction of sexual activity for 
patients with ICF(192) (200) (201) (202).
ICF carriers must be assessed annually, preferably in the 
primary healthcare services, by means of medical evaluation 
and conventional ECG (20) (202). If disease evolution is observed, 
these cases should be referred to more specialized healthcare 
services with the aim to provide the patient with a more precise 
direction (to define the appropriate investigation and treatment 
interventions) for the integrated management with primary 
health care teams (up- and down-referral).
Indeterminate chronic form does not interfere with the 
management of associated diseases and does not justify neglecting 
the follow-up and treatment of comorbidities that may possibly be 
present(49) (197) (203) (204). If immunodeficiency (acquired or induced) 
occurs in patients with ICF, special attention should be given to 
possible reactivation of Chagas disease (see specific section on 
reactivation of Chagas disease)(20) (49) (159). The surgical risk for the 
patient with ICF does not differ from that observed in the general, 
uninfected population(20) (194) (200) (202) (203).
Regarding pregnant women infected with T. cruzi with this 
classification, attention should be paid to the possibility of 
vertical transmission, and opportunities should be created for 
adequate assessment of the newborn infant (see specific section 
on vertical transmission)(20) (39) (202). Women with ICF should not 
restrict breastfeeding, except in the presence of fissures and/or 
bleeding of the nipple/areola(20) (202).
It is emphasized that health professionals should avoid the 
adoption of any practice that may induce stigma or prejudice. 
Health services should provide space and resources for advice, 
clarification, and orientation of the population regarding 
the characteristics of this form of disease. It is strongly 
recommended that this approach is led by a multidisciplinary 
team(20) (189) (190) (191) (193) (202). 
CARDIAC FORMS OF  
CHAGAS DISEASE
Chronic Chagas heart disease is the most prevalent 
symptomatic clinical form, responsible for the high burden of 
morbidity and mortality, with great impact on social and medical 
systems(4) (19) (20). Recently, the notion has been considered that 
the pathogenesis of myocardial injury in the chronic phase of 
Chagas disease depends mainly on parasite persistence and 
the unfavorable immune system response to this incessant 
infectious stimulus(205) (206) (207) (208). Among the most peculiar 
characteristics of chronic Chagas heart disease, the following 
are highlighted: Its inflammatory and intensely fibrosing nature, 
presence of complex ventricular arrhythmias in association with 
disturbances in atrioventricular and intraventricular formation 
and conduction of the electrical stimulus, high incidence of 
sudden death and thromboembolic events, and right ventricular 
dysfunction and ventricular aneurysms(209) (210) (211) (212) (213) (214).
Acute Chagas disease and consequently, acute Chagas 
myocarditis, was previously restricted to vectorial transmission 
of Chagas disease, now rare in Brazil. However, their 
epidemiological importance in Brazil and other countries, 
endemic and non-endemic, has expanded due to reactivation 
of the disease in immunocompromised individuals, favored 
by the spread and chronicity of HIV infection, as well as by 
the increased access to organ transplantation. In addition to 
this scenario, there is the challenge posed by Chagas disease 
in the Amazon, attributed to oral transmission. As a result of 
changing the epidemiological profile of disease transmission, 
cases of acute Chagas heart disease, which currently present 
clinical and specific epidemiological aspects, has again 
increased(76) (91) (92) (169) (170).
The importance of the composition of a resolute healthcare 
network for people with Chagas disease, in particular the role 
of primary care as the first contact and provider of secondary 
prevention of the disease, is emphasized. From the recognition 
of the context of clinical cases, this primary health care network 
should be integrated into the matrix/reference network for more 
complex situations.
Acute Chagas heart disease 
1. Acute Chagas myocarditis associated with oral 
transmission
In Amazônia Legal, especially, a systematic record exists 
of cases with the acute form of Chagas disease, occurring in 
sporadically, in outbreaks, or in micro epidemics, where the 
main form of transmission is oral, involving food contaminated 
with triatomine feces(21) (76). The clinical presentation differs from 
classical acute Chagas myocarditis (vectorial) mainly by the 
absence of evidence of a portal of entry (inoculation chagoma), 
the involvement of community groups or families in outbreaks, 
and having no identified predilection for a specific age group 
or for disease severity(91) (169).
Clinical manifestations of acute disease associated with oral 
transmission are variable, ranging from asymptomatic cases 
up to those developing severe heart failure, cardiogenic shock, 
and even death. It can also manifest as a nonspecific infectious 
syndrome, with prolonged fever (usually for more than three 
weeks). The manifestations of acute myocarditis are described 
in Figure 3(215).
Laboratory and radiologic examinations
Chest radiography may be normal or may show varying 
degrees of cardiomegaly and pleural effusion. The ECG readings 
are altered in most acute cases. The main ECG findings are 
non-specific changes in ventricular repolarization, followed 
by prolonged QTc interval, left atrial overload, low voltage of 
QRS complex, AVB, bundle branch block, sinus tachycardia, 
and atrial fibrillation(216). ECG can detect pericardial effusion, 
atrioventricular valve regurgitation, increase in the size of 
the heart chambers, presence of thrombi, and changes in left 
ventricular systolic function.
Treatment
Pharmacological management of acute Chagas myocarditis 
is even recommended for the treatment of heart failure in 
patients with acute myocarditis of other etiologies: Routine use 
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• Dyspnea of variable intensity 
• Tachycardia (even without fever)
• Palpitations
• Chest pain
• Raised jugular venous pressure
• Soft heart sounds 
• A gallop rhythm
• Heart murmurs in the apical region and tricuspid area
• Pericardial effusion
• Hypotension
• Cardiac tamponade
• Tachyarrhythmias (atrial fibrillation)
• Bradyarrhythmias (atrioventricular block)
• In children: tachypnea, irritability, sweating, vomiting, anorexia, hepatomegaly, and edema of the lower limbs
FIGURE 3. Key signs and symptoms of acute Chagas myocarditis
of a combination of three types of drugs [diuretics, angiotensin 
converting enzyme inhibitors (ACEI) or angiotensin II AT1 
receptor blockers (ARBs), and beta-blockers] is always 
combined with specific treatment of T. cruzi infection (using 
benznidazole or nifurtimox)(203). 
The natural history of the acute phase of Chagas myocarditis, 
induced by oral transmission of Chagas disease, is still not fully 
known. The most severe cases, with ventricular dysfunction, 
pericardial effusion, and atrial fibrillation, tend to have worse 
outcomes in the acute phase, requiring treatment in an intensive 
care environment.
2. Acute Chagas myocarditis in immunocompromised 
individuals
Individuals infected with T. cruzi, when exposed to 
immunosuppressive agents or who have other concomitant 
diseases such as cancer and other infections, particularly HIV 
infection, may experience reactivation of Chagas disease. The 
frequency of this reactivation is not fully known. However, in 
a prospective study in which cases were evaluated pre- and 
post-antiretroviral therapy, the occurrence of reactivation was 
observed in 20% of the cases(48).
The heart appears to be involved in approximately 30–40% 
of cases of reactivation of Chagas disease in individuals 
coinfected with HIV. However, the incidence of myocarditis 
alone does not seem to be common. Cardiac involvement is 
usually characterized by acute myocarditis, with diffuse or focal 
cardiac involvement. Clinically, it is characterized by signs and 
symptoms of heart failure (tachycardia, edema, hepatomegaly) 
or severe arrhythmias. In some cases, only electrocardiographic 
changes are observed; in others, myocarditis is confirmed 
only by histopathologic examination of endomyocardial 
biopsy material. Anatomopathological examination reveals 
acute myocarditis with intense inflammatory infiltrate, 
cardiac fiber injury with focal necrosis, and large numbers 
of amastigote forms of the parasite(217). In cases where there 
was previous cardiac involvement (for chronic Chagas heart 
disease), there may be overlapping reactivation Chagas disease 
cardiomyopathy and decompensation of preexisting Chagas 
heart disease. Determining if the clinical picture is solely due to 
reactivation of Chagas disease, myocarditis associated with HIV 
itself, or the overlap of the two conditions, is complex(218). Acute 
myocarditis due to the reactivation of T. cruzi infection might 
be also confused with the natural progression and worsening of 
chronic Chagas heart disease. The differential diagnosis between 
these two conditions is important in terms of deciding whether 
or not to administer the specific treatment of T. cruzi infection, 
as many patients do not tolerate the medication. High levels of 
parasitemia are indicative of reactivation. However, there is no 
record of patients who developed low parasitemia(219).
Diagnosis
Confirmation of reactivated Chagas disease in patients 
with immunosuppression is performed by parasite detection in 
peripheral blood and other body fluids (cerebrospinal fluid, cavity 
effusions, etc.), by direct observation methods, or in sites of organ 
damage (heart, skin, etc.) in individuals with co-infection(48).
Treatment
There are no specific treatment measures for this group. 
Treatment should follow evidence-based recommendations 
developed for the treatment of heart failure in general. 
Acute decompensated heart failure, resulting from the 
hemodynamic effects of heart failure, is associated with 
neurohumoral activation and symptoms of congestion and/
or low cardiac output. Early recognition of this condition and 
the implementation of appropriate therapeutic measures for 
heart failure, associated with the specific treatment for T. cruzi 
infection, can reduce the high rate of mortality observed in 
cases of myocarditis induced by reactivation of Chagas disease 
in immunocompromised patients.
Chronic Chagas cardiomyopathy 
Definition
Chronic Chagas cardiomyopathy (CCC) is defined as the 
presence of ECG changes suggestive of cardiac involvement 
typical of Chagas disease in symptomatic and asymptomatic 
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individuals. Since ECG examination is easily accessible and 
has high sensitivity and specificity (around 90%), the modified 
conventional ECG is used, a priori, to diagnose CCC in people 
chronically infected with T. cruzi(20). Cardiac involvement in 
the chronic phase of Chagas disease includes a wide spectrum 
of manifestations, ranging from the presence of clinically 
unapparent abnormalities to severe forms, such as end-stage 
heart failure, thromboembolic complications, refractory 
ventricular arrhythmias, and sudden death.
Taking as a reference only conventional 12-lead ECG, it is 
possible to establish, in a simplified way, the degree of cardiac 
involvement in routine evaluation of the patient with chronic 
Altered conventional electrocardiogram
Significant non-specific changes: 
Sinus bradycardia (HR> 40 bpm) 
Low voltage, IRBB, LAFB, first 
degree AVB, Nonspecific ST-T 
changes
Changes: 
RBBB (or with LAFB) iso-
lated VES, monomorphic, 
2nd degree AV block, T 
Changes, HR <40 bpm
Changes: 
Polymorphic or repetitive 
VES, Electrically inactive 
area, Sinus node 
dysfunction
Changes: 
NSVT, AF, 
CAB, LBBB
Individualized assessment 
(Clinic / age / labor demand) 
Echocardiogram, Stress test, Holter
Periodic 
reassessment
Evaluation 
LVEF on echocardiogram and 
arrhythmia evaluated by Holter or 
stress test
Without CHF                                                         With CHF
A 
Normal Eco
B1 
Altered 
Eco LVEF 
≥ 45%
B2 
Altered Eco 
LVEF < 45%
C 
Altered Eco 
Compensable 
HF
D 
Altered 
Eco refractory 
HF
 Without With Without With
 arrhythmia arrhythmia arrhythmia arrhythmia
Arrhythmia 
reassessment
Periodic 
treatment and 
reassessment
IRBB: incomplete right bundle-branch block; LAFB: Upper anterior fascicular block; AVB:  Atrioventricular block; ST-T: ST-T segment;  RBBB: Complete right bundle 
branch block; VES: Ventricular extrasystoles;  T: T-wave; HR: Heart rate; NSVT: Non-sustained ventricular tachycardia; AF: Atrial fibrillation; CAVB: Complete 
atrioventricular block; LBBB: Left bundle branch block;  LVEF: Left ventricular ejection fraction; CHF: Congestive heart failure; ECO: Echocardiogram;   HF: Heart failure.
FIGURE 4. Algorithm for evaluation of individuals with Chagas disease using conventional ECG.
Chagas disease, as shown in the following flowchart (Figure 4)(20). 
Cases with nonspecific ECG changes would not be diagnosed with 
CCC, but they should be re-evaluated according to the concomitant 
symptoms and changes found in additional tests.
Chronic Chagas cardiomyopathy staging
Presence of severe heart failure [functional class III and IV 
of the New York Heart Association (NYHA)] and left ventricular 
global systolic dysfunction are the most important prognostic 
factors in CCC(220) (221) (222) (223).
Echocardiography allows evaluation of both the overall and 
segmental myocardial function. It can also identify important 
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markers for staging the disease, such as size of chambers, 
alterations in segmental mobility, and presence of aneurysms 
and mural thrombosis. For these reasons, and because it is a 
noninvasive and inexpensive examination, echocardiography 
is of great value for the initial staging of CCC, in association 
with the functional NYHA classification. From a prognostic and 
therapeutic point of view, it is possible to identify five different 
subgroups of CCC, as shown in Figure 5(223) (224) (225) (226).
In addition to the impairment of myocardial function, rhythm 
disturbances and electrical impulse conduction abnormalities 
are significant changes in CCC; in some cases, arrhythmias may 
occur alone, without global ventricular dysfunction, or only with 
small regional dyskinesias(227) (228) (229) (230) (231) (232).
If possible, it is obligatory to perform a 24 hour-
electrocardiogram (Holter) in all cases with suspected arrhythmia. 
Less frequently, an ergometric test may be used instead of a Holter, 
to show ventricular arrhythmias during standardized physical 
effort. When possible, both tests should be performed, as they 
are complementary in the evaluation of these cases.
There is also a group of cases in the chronic phase of 
Chagas disease (not included in the classification above) that 
shows normal ECG findings, but presents changes  ̶  usually 
discrete and not associated with an increased risk of death  ̶ 
in other cardiac tests, such as echocardiography, myocardial 
scintigraphy, and magnetic resonance imaging. However, 
since the risk of progression of these cases to the cardiac form, 
classically defined, appears to be higher than that of cases of 
Chagas disease without these changes, they should receive 
regular clinical follow-up(231) (232).
Chronic Chagas cardiomyopathy prognosis
In a systematic review of studies that used multivariate 
analysis to evaluate the prognosis of patients with CCC(233), four 
independent prognostic variables were identified: functional 
class III/IV of NYHA, cardiomegaly on chest radiograph, left 
ventricular systolic dysfunction, and non-sustained ventricular 
tachycardia (NSVT) on Holter examination. By using these four 
variables in an integrated manner, it was possible to develop 
an algorithm capable of stratifying the prognosis of cases with 
CCC (Figure 6).
Stage Electrocardiogram Echocardiogram Heart failure
A Altered Normal Absent
B1 Altered Altered, LVEFa ≥45% Absent
B2 Altered Altered, LVEFa <45% Absent
C Altered Altered Compensated
D Altered Altered Refractory 
aLVEF: left ventricular ejection fraction.
Source: Adapted Xavier SS et al. 2005(223)
FIGURE 5. Initial staging of myocardial dysfunction in chronic Chagas cardiomyopathy.
It is important to highlight that the presence of functional 
class III or IV NYHA, per se, identifies high-risk cases, since 
virtually all these cases have ventricular systolic dysfunction 
(evident on echocardiography) and NSVT (detected by Holter). 
The combination of ventricular dysfunction with NSVT 
(regardless of functional class) already identifies a group with 
a risk about 15 times higher than cases without these two 
variables(222) (233) (234). 
Clinical manifestations of  
chronic Chagas cardiomyopathy
Clinical manifestations of CCC can be grouped into three 
syndromes: arrhythmic, heart failure, and thromboembolic. 
These syndromes may occur alone or in combination in the 
same case, and may be associated with megaesophagus and/
or megacolon(235) (236).
I - Arrhythmic syndrome
Ventricular arrhythmias
Ventricular arrhythmias are common in Chagas disease and 
are of various types, including ventricular extrasystoles, isolated 
and in pairs; NSVT; sustained ventricular tachycardia (SVT); 
and ventricular fibrillation(237). These commonly present in 
combination. Clinically, they present as palpitations, lipothymia, 
syncope, and sudden death(237) (238). Syncope and other symptoms 
of low output in cases with CCC should be quickly investigated, 
due to the risk of complex ventricular arrhythmias and sudden 
death.
Ventricular extrasystole is the most common arrhythmia. 
Initially uncommon, monomorphic, and isolated, it becomes 
polymorphic and repetitive with the evolution of the disease. 
Holter and ergometric tests are the methods of choice for the 
detection of ventricular arrhythmias and, when possible, should 
be performed in all cases with CCC, regardless of the presence of 
symptoms(42). Ventricular tachycardia may be sustained (duration 
≥30 sec or shorter than this when interrupted electrically or 
pharmacologically) or non-sustained (3 heartbeats or more and 
a duration <30 sec).
NSVT relates to the degree of ventricular dysfunction, 
occurring in about 40% of cases with CCC associated with 
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Patients with serological exam 
reactive to T. cruzi
Conventional electrocardiogramNormal
Abnormal FC III/IV 
(NYHA)
FC I/II
(NYHA)
Chest radiograph
Normal Cardiomegaly
Echocardiogram                                                                              Echocardiogram
Normal NormalReduced 
LVEF
Reduced 
LVEF
Holter                                     Holter                                                  Holter                                     Holter
Without 
NSVT
Without 
NSVT
Without 
NSVT
Without 
NSVT
With 
NSVT
With 
NSVT
With 
NSVT
With 
NSVT
Low risk Low riskIntermediate 
risk
High risk Intermediate 
risk
High risk
Source: Adapted from Rassi Jr. A et al., 2007(233)
FC: Functional class; NYHA: New York Heart Association;  LVEF: Left ventricular ejection fraction; NSVT: Non-sustained ventricular tachycardia.
FIGURE 6. Algorithm for risk stratification in patients with chronic Chagas cardiomyopathy.
regional changes in ventricular contractility, and in 90% of 
cases with left ventricular global systolic dysfunction associated 
with heart failure(222) (237). This may occur in cases with normal 
ventricular function(234). There is evidence that the frequency 
of ventricular arrhythmias is increased in heart failure due to 
Chagas disease, compared with other etiologies(239). SVT can 
occur spontaneously or be reproduced by electrophysiological 
study, which is indicated for cases whose history suggests this 
hypothetical diagnosis but for whom non-invasive methods have 
failed to confirm the diagnosis(240). Ventricular fibrillation is the 
leading cause of sudden death in CCC. It occurs more frequently 
in patients who have had previous episodes of ventricular 
tachycardia, although it may also be the first manifestation of 
the disease or its terminal event, especially in cases with severe 
ventricular dysfunction and chronic cardiac insufficiency (CCI ) (238).
Treatment of ventricular arrhythmias
Treatment of the arrhythmia has two main objectives: to 
control symptoms and to prevent sudden death(238). Simple 
ventricular arrhythmias (isolated and monomorphous ventricular 
extrasystoles) are not associated with an increased risk of death. 
Hence, they should be treated only if causing symptoms of 
functional impairment. If needed, suitable treatment consists of 
normal doses of amiodarone, sotalol, or beta blockers.
In cases of life-threatening arrhythmias (NSVT, SVT, and 
ventricular fibrillation), the most effective antiarrhythmic, 
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and the safer to use, is amiodarone(241). It is necessary to pay 
attention to the side effects of this drug – that are generally 
related to the cumulative dose – which can trigger serious 
bradyarrhythmias. In such cases, evaluation of the need for 
permanent pacemaker implantation is required. Extra-cardiac 
toxicity, thyroid dysfunction, and skin abnormalities are not 
uncommon, while severe pulmonary toxicity is rare(242). Periodic 
assessment of the thyroid function is recommended in patients 
treated with amiodarone. 
In turn, cases with SVT (a relatively common condition) and 
those who recover from cardiorespiratory arrest in an out-of-
hospital environment (a much rarer condition) are at high risk of 
death and deserve a rigorous evaluation. For these cases, there are 
not only antiarrhythmic drugs, but also arrhythmic focus catheter 
ablation techniques (or, rarely, surgical techniques) and, especially, 
implantable cardioverter-defibrillator (ICD) devices(237).
The treatment of ventricular arrhythmias in CCC is described 
briefly in Figure 7. Drug treatment and ICD recommendations 
are described in Figure 8 and Figure 9, respectively.
Supraventricular arrhythmias
Atrial fibrillation is the sustained supraventricular 
arrhythmia more frequently observed in CCC, found in 4–12% 
of cases(229). It tends to manifests later on and is often associated 
with marked cardiomegaly. Treatment consists in controlling the 
Ventricular arrhythmias in Chagas disease
NSVT 
(with frequent isolated or paired VES)
Sustained / malignant 
ventricular arrhythmias
Impaired LV 
function
Preserved LV 
function
Stable SVT
. Unstable SVT
. VF
. Syncope + induction 
  SVT
Amio 
(Class Ia/IIab)
Symptoms 
present
Symptoms 
absent
LVEF> 35%        LVEF< 35%     LVEF> 35%                LVEF< 35%
Individualized 
AA drug (Amio, 
sotalol, BB, 
class I)
No AA drug 
(except: >20% 
VES on 24h 
Holter)
 Amio (class I) 
ICD (class IIa)
 Amio (class I) 
ICD (class I)
 Amio (class IIa) 
ICD (class I)
Source: Adapted from Rassi Jr.A et al., Abordagem atual das arritmias Ventriculares na doença de Chagas. Cardios, year 16, n. 15 may - june 2013 
a Symptomatic
b Assymptomatic
NSVT: Non-sustained ventricular tachycardia; VES: Ventricular extrasystoles; LVEF: Left ventricular ejection fraction;  SVT: Sustained ventricular tachycardia; 
Amio: Amiodarone;  AA: Antiarrytmic drugs; ICD: Implantable cardioverter defibrillators;  BB: Adrenergic betablockers.
FIGURE 7. Interventions for treatment of ventricular arrhythmias in Chagas disease.
ventricular rate, which can be obtained through the use of drugs 
prolonging the refractory period of the atrioventricular node. If 
there is an associated heart failure, preference is given to digitalis 
and beta-blockers (metoprolol succinate, carvedilol, or bisoprolol). 
If ventricular function is normal, the use of conventional beta-
blockers (propranolol and atenolol) or calcium channel blockers 
(verapamil and diltiazem) is recommended for the initial control 
of the heart rate, with subsequent evaluation of the possible need 
for electrical or pharmacologic cardioversion. Anticoagulation is 
indicated when atrial fibrillation is associated with heart failure 
and cardiomegaly, CHA2DS2VASc score ≥2, or when there is 
evidence of intracavitary thrombosis or previous embolic episodes. 
The drug of choice is warfarin, in a dose sufficient to maintain 
the international normalization factor (INR) between 2 and 3(243). 
Bradyarrhythmias
The treatment of bradyarrhythmias in CCC does not differ 
from that recommended for other types of cardiomyopathies. It 
consists of the implantation of a permanent cardiac pacemaker in 
symptomatic or high-risk blockage cases. These recommendations 
are well defined in the Brazilian Guidelines for Implantable 
Cardiac Electronic Devices, published in 2007(244). 
The association between disorders of the heart conduction 
system and frequent and complex arrhythmias is common in 
CCC. In these cases, the effective pharmacologic antiarrhythmic 
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Recommendation class Indication Level of evidence
I Individualized antiarrhythmic medication for cases of isolated or paired VESa, symptomatic C
I Amiodarone for cases with symptomatic NSVTb C
I Amiodarone for recovered cases of cardiac arrest or with stable SVTc and EFd>35%  B
I Amiodarone for cases with stable SVTc C
I Amiodarone for reduction of shock in appropriate cases with ICDe  C
IIa Amiodarone for cases with asymptomatic NSVTb and LVf dysfunction B
IIa Routine amiodarone for cases with symptomatic SVTc who were treated with ICDe C
IIb Amiodarone for cases with asymptomatic NSVT and normal LVf function C
IIb Amiodarone for recovered cases of cardiac arrest or with unstable SVTc and EFd ≤ 35% C
III Antiarrhythmic drugs for cases with asymptomatic isolated or paired VESa C
aVES: Ventricular extrasystole; bNSVT: Non-sustained ventricular tachycardia; cSVT: Sustained ventricular tachycardia; dEF: Ejection fraction;  
eICD: Implantable cardioverter defibrillator; fLV: Left ventricle.
FIGURE 8. Recommendations and levels of evidence for the use of antiarrhythmic drugs in the treatment of ventricular arrhythmias in chronic Chagas 
cardiomyopathy.
Recommendation class Indication Level of evidence
I ICDa for recovered cases of cardiac arrest or with unstable SVTb, regardless of EFc C
I ICDa for cases with stable SVTb and LVEFd ≤35% B
IIa ICDa for cases with stable SVTb and EFc >35% C
IIb ICDa for cases with NSVTe and EFc ≤35% C
aICD: Implantable cardioverter defibrillators; bSVT: Sustained ventricular tachycardia; cEF: Ejection fraction; dLVEF: Left ventricular ejection fraction; eNSVT: Non-
sustained ventricular tachycardia.
FIGURE 9. Class of recommendation and levels of evidence for the use of CDI in the treatment of ventricular arrhythmias in chronic Chagas cardiomyopathy.
drug therapy may require permanent pacemaker implantation in 
order to prevent a possible AVB or high-risk bradyarrhythmia 
induced by antiarrhythmic. The choice of the pacing mode is, 
to date, the subject of controversy in the literature.
II - Heart failure syndrome
In the acute phase of Chagas disease, heart failure (HF) 
can occur due to severe myocarditis. Although the outcome 
may be death, in most cases, it is reversible, progressing to the 
indeterminate form of the disease. Approximately 30–40% of 
cases with the indeterminate form will progress to the heart 
form of the disease, usually after decades of evolution(42) (236).
The chronic heart form, characterized by the gradual 
appearance of electrocardiographic changes, is caused by 
the slow but steady destruction of myocardial fibers, caused 
by a continuous chronic inflammatory process, with intense 
reparative fibrosis and progressive ventricular remodeling(208).
In the early chronic stage of the cardiomyopathy, it is not 
uncommon that only the ECG findings are changed; individuals 
remain asymptomatic, capable of performing unrestricted, 
sometimes even extreme, physical activity. Therefore, they are 
included into NYHA class I(227) (230) (239). Rarely, in this group of 
cases, the first and only manifestation of CCC is sudden death(245). 
In most cases, a progressive reduction in the ability to perform 
physical activities is observed, followed by deterioration of 
contractile function of the left ventricle, initially in the form 
of regional dyskinesia and diastolic dysfunction, followed by 
a drop in the global systolic function of the chamber, due to 
several associated factors, such as the progressive destruction 
of cardiomyocytes, microvascular changes, the breakdown of 
the muscle structure and fibrosis(208) (236) (247). It is not common for 
cases with Chagas disease in the chronic phase to present with 
acute pulmonary edema. There are also many cases with CCC 
in whom the initial manifestations of heart failure are fatigue 
and edema, with minimal dyspnea(246) (247). In these cases there 
is the early involvement of the right ventricle, with impaired 
systolic function. In the more advanced stages of the disease, 
when heart failure is completely manifested, predominant 
symptoms and signs of systemic congestion may arise, but with 
little significant pulmonary congestion. Chest teleradiography 
shows a marked cardiomegaly, with little engorgement of 
the pulmonary vasculature. It is important to identify early 
signs of left ventricular systolic failure, since the treatment 
at this early stage could, in theory, delay the deterioration of 
contractile cardiac function(42) (227). In addition, left ventricular 
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systolic dysfunction is also the most important indicator of risk in the 
chronic phase of Chagas disease-induced cardiomyopathy(222) (224) (225).
Treatment of heart failure in cases with chronic Chagas 
cardiomyopathy
Treatment of heart failure aims to relieve the symptoms, 
slow the progression of ventricular dysfunction, and prolong 
survival(20). Treatment of heart failure due to Chagas disease, as 
well as other etiologies, should be comprehensive, starting with 
general measures, removing the factors that contribute to worsen 
heart failure, and treating the underlying syndrome(248) (249).
General measures
1. Diet: Obesity should be corrected and the ideal weight 
should be maintained, avoiding inadequate intake of 
sodium chloride and, in specific cases, alleviating the 
symptoms of dysphagia and constipation.
2. Controlling water retention: A balanced intake of salt (3–4g/
day of sodium chloride [mild to moderate disease], and ≤2g/
day [severe disease]). A simple and reliable way to evaluate 
water retention is daily assessment of body weight. Variations 
higher than 1kg/day are indicative of fluid retention. A gain of 
rapid and constant weight (1kg/day) is an indication that heart 
failure is worsening. People affected should be encouraged 
to monitor their weight daily in the morning (after urinating 
and fasting). In severe heart failure with hypervolemia and/
or hyponatremia, fluid restriction may be required.
3. Control of aggravating factors: The intake of alcohol 
and the use of anti-inflammatories should be avoided. 
Arterial hypertension, cardiac arrhythmias, anemia, or 
thyroid function disorders should be controlled. Other 
comorbidities may contribute to worsening heart failure, 
such as coronary artery disease and diabetes mellitus.
4. Individualization of the recommendations for rest or 
physical activity, in accordance with the degree of heart 
failure and the patient’s age.
5. Vaccination against influenza (annually) and pneumococcal 
23-valent (a booster after five years for those cases with 
compromised immune systems, or adults over the age of 
60 years who received the first dose before 65 years old) 
should be provided.
Drug treatment of heart failure  
caused by Chagas disease
At the time of finalization of this Consensus, the results 
of the BENEFIT study were published. This was a double-
blinded, multicenter, clinical trial that tested the hypothesis 
that trypanosomicide treatment with benznidazole, compared 
to placebo, could modify the prognosis of patients with 
Chagas disease chronic cardiomyopathy(250) (251). Overall, 
2,854 patients were evaluated. They were randomly assigned 
to receive benznidazole or placebo for up to 80 days, with a 
mean follow-up period of 5.4 years. A reduction in the parasite 
load was observed with benznidazole, but it had no effect on 
the progression of heart disease (estimated by complications 
occurring during clinical follow-up, such as death, ventricular 
arrhythmias, need for implanted devices, thromboembolic 
events, heart failure, or heart transplantation): 27.5% of patients 
in the benznidazole group and 29.1% of patients in the placebo 
group experienced complications, hazard ratio (HR) = 0.93; 
95% CI, 0.81–1.07; p = 0.31)(251). This result differed from the 
results of previous observational studies(252) (253). These results 
shift the focus of attention to treatment (of patients with CCC) 
with conventional anti-failure methods derived from other 
cardiomyopathies(254).
Long-term treatment of heart failure is usually based on 
a combination of the following classes of drugs: diuretics; 
ACE inhibitors or ARBs; adrenergic blockers (BB); and the 
aldosterone antagonists(254). Positive inotropic drugs (such 
as catecholamine or milrinone) have limited applicability 
in intensive care settings, and slightly prolonged cardiac 
decompensation. Digitalis, however, may be administered 
chronically in individuals without bradyarrhythmias to alleviate 
their symptoms and prevent cardiac decompensation and 
hospital admission, especially in patients with atrial fibrillation 
with rapid ventricular response(255).
Loop and thiazide diuretics may be used separately or in 
combination to relieve symptoms and signs of pulmonary and 
systemic venous congestion. When it is imperative to use high 
doses of loop diuretics, such as furosemide, one should be aware 
of the higher likelihood of hypokalemia and/or hyponatremia, 
which, in turn, can exacerbate or trigger serious arrhythmias(248).
In CCC with heart failure or asymptomatic systolic 
dysfunction (ejection fraction <45%), the chronic administration 
of ACE inhibitors is indicated to reduce the morbidity, mortality 
or ARB, when patients are intolerant to ACE inhibitors(256). With 
the same purpose, the use of spironolactone is recommended in 
cases with heart failure, in NYHA functional classes II–IV(248). 
Furthermore, it is thought that aldosterone antagonists can provide 
additional benefits when used in patients with CCC because 
of their antifibrotic properties (demonstrated in experimental 
studies). The combination of hydralazine and nitrates is a 
recommended alternative to treat cases in functional NYHA 
class II–III if a contraindication to the use of ACE inhibitors or 
ARBs (e.g., progressive renal failure or hyperkalemia) exists(248).
The use of adrenergic beta-blockers in addition to blockade of 
the renin-angiotensin-aldosterone system (with ACE inhibitors 
or ARBs) is recommended to reduce the morbidity and mortality 
associated with the disease. It is assumed that these drugs can 
help to prevent the worsening of the ventricular remodeling, 
development of malignant arrhythmias, and sudden death(257) 
(258). However, the use of an optimized dose of adrenergic 
blockers may be hindered in CCC, given bradyarrhythmias and 
frequent need of amiodarone administration for the treatment 
of tachyarrhythmias. To date, there is no consensus among 
experts about which drug, beta-blockers or amiodarone, should 
be prioritized in the management of Chagas disease.
Complementary forms of treatment for heart failure 
caused by Chagas disease
Heart transplantation is the treatment of choice for end-stage 
heart failure, despite the many limitations of medical and social 
nature that embargo its broader use in cases of Chagas disease. 
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The results obtained in a selected series of cases, compared with 
those observed in cases with heart failure due to other etiologies, 
show an even more favorable evolution in transplanted cases 
with Chagas disease. Among other possible factors, this is 
possibly due to the fact that, in this series, cases with Chagas 
disease were younger and had fewer comorbidities(259) (260). 
There is no definitive indication for prophylaxis; however, 
active control is recommended for possible reactivation the 
disease, especially in the first year after transplantation, when 
immunosuppression is more pronounced. Benznidazole, in a 
dose of 5mg/kg/day, should be promptly started and maintained 
for 60 days to obtain a good clinical outcome(100). 
There is no evidence to support routine indication of cardiac 
resynchronization therapy (CRT). In addition to the fact that 
there are no controlled studies exploring in a scientific and 
valid manner this therapeutic possibility, in CCC the complete 
block of the right bundle branch is frequent and, in the presence 
of this condition, evidence of the benefits of CRT, even in 
other etiologies of heart failure, are even more scarce and less 
convincing(203) (244).
Cell implant-based therapies were recently explored in a 
single study, properly controlled. The results did not show any 
benefit, even on surrogate outcomes such as the left ventricular 
ejection fraction(261). 
The recommendation classes and levels of evidence for 
treating heart failure in patients with CCC are summarized in 
Figure 10.
III - Thromboembolic syndrome
Systemic and pulmonary thromboembolic events are 
common in CCC. Pulmonary thromboembolism is certainly 
under-diagnosed when considering the results of postmortem 
Recommendation class Indication Level of evidence
I ACEIa or ARBb (intolerant to ACEIa) in cases with t reduced LVEFc, symptomatic or no C
IIb ACEIa or ARBb (in intolerant to ACEIa) in cases with normal LVEFc C
 and segmental dysfunction of LVd
I Spironolactone in cases with LVEFc <35% and FCe III/IV of the NYHA B
IIa Spironolactone in cases with LVEFc <35% and FCe II of the NYHA C
I Carvedilol, metoprolol succinate or bisoprolol in cases with reduced LVEFc,  C
 symptomatic or not, and with HRg>55 bpm
I Loop diuretics in symptomatic cases, with signs and symptoms of congestion C
I Combination of hydrochlorothiazide in cases resistant to loop diuretics  C
IIa Digoxin in symptomatic cases with reduced LVEFc (<45%) and sinus rhythm or AFh,  C
 despite optimized therapy with ACEIa and BBi
I Heart transplant in cases with refractory HFj C
aACEI: Angiotensin converting enzyme inhibitors; bARB: Angiotensin II AT1 receptor blockers; cLVEF: Left ventricular ejection fraction; dLV: Left ventricle; 
eFC: Functional class; fNYHA: New York Heart Association; gHR: Heart rate; hAF: Atrial fibrillation; iBB: Adrenergic beta-blocker; jHF: Heart failure.
FIGURE 10. Recommendations and levels of evidence for the treatment of heart failure in patients with chronic Chagas cardiomyopathy.
studies(262). Embolic events are favored by the combination of 
several factors. The most important are venous stasis, reduction 
in cardiac output, and intracardiac mural thrombus, favored 
by localized ventricular dyskinesias (e.g., apical aneurysm), 
dilation of the cardiac chambers, and atrial fibrillation in more 
advanced stages of the cardiomyopathy.
Prevention of thromboembolic complications in chronic 
Chagas cardiomyopathy
Embolic accidents in the central nervous system are the most 
severe form of thromboembolism in CCC and contribute to the 
high morbidity and mortality of the disease(263). The scientific 
basis for antithrombotic treatment in CCC is based on findings 
of a prospective cohort study of 1,043 cases, which assessed 
the risk and defined prevention strategies for cardioembolic 
stroke (CES)(264). In that study, the incidence of CES was 3.0% 
(or 0.56% per year), and the multivariate statistical analysis 
allowed the composition of a risk score for CES occurrence: 
The presence of left ventricular systolic dysfunction contributed 
2 points; while presence of apical aneurysm, primary alteration 
of ventricular repolarization in ECG, and age over 48 years 
contributed 1 point each. Warfarin may be indicated for cases 
with 4–5 points (in this subgroup, the incidence of stroke is 
4.4% vs. 2.0% of severe bleeding per year). In the subgroup 
with a score of 3 points, embolism rates and bleeding with oral 
anticoagulants are equivalent, and acetylsalicylic acid or warfarin 
may be indicated. In cases with 2 points, with low incidence of 
CES (1.22% per year), acetylsalicylic acid or no prophylaxis is 
recommended. Cases with 0–1 point, with an event incidence 
close to zero, do not require prophylaxis. Obviously, in cases 
with intracavitary thrombus, atrial fibrillation associated with 
CHA2DS2VASc score ≥2, and previous embolic accident, the use 
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of oral anticoagulants is always advisable, maintaining the INR 
between 2 and 3(264). Recommendations for oral anticoagulation 
in CCC are described in Figure 11.
Pregnancy approach in  
chronic Chagas cardiomyopathy
Chronic Chagas cardiomyopathy ranks second among the 
cardiomyopathies present in the pregnancy-puerperal cycle, being 
second only to rheumatic cardiomyopathy. Most pregnant women 
with Chagas disease are asymptomatic or oligosymptomatic, 
being carriers of indeterminate or initial cardiac forms.
The risks of pregnancy in women with Chagas cardiomyopathy 
depend on the cardiac functional status and the presence and 
severity of arrhythmias. Pregnancy should be discouraged in 
cases with heart failure and/or arrhythmias. Pregnant women 
with these conditions require monitoring and special care, due 
to the possibility of worsening during pregnancy. In the initial 
consultation of the pregnant woman with Chagas disease-
induced cardiomyopathy, in addition to routine tests, ECG and 
echocardiography (to assess cardiac dimensions and ventricular 
function) and a 24-hour Holter (in order to identify conduction 
disorders and arrhythmias) should be requested(265). The relative 
and absolute contraindications to the use of drugs acting on the 
cardiovascular system or with a teratogenic potential should 
always be observed. Pregnant women with CCC must be attended 
to at reference centers for high-risk pregnancy, as they may require 
high-complexity care. It is worth highlighting the importance of 
carrying out all recommended assessments during the prenatal 
period, including HIV testing(20).
Surgical risk in patients with  
chronic Chagas disease
The evaluation of surgical risk in patients with Chagas 
cardiomyopathy is based on available data related to other heart 
diseases. However, the unique characteristics of CCC, especially 
those related to autonomic dysfunction, complex arrhythmias, 
and intraventricular stimulus conduction disturbances, can cause 
different responses to surgical trauma(266). Cases with more 
severe myocardial damage (NYHA class IV heart failure or 
LVEF <30%; moderate systolic dysfunction, but with complex 
arrhythmia, atrial fibrillation, significant dilation of the left 
ventricle, total AVB and sinus node dysfunction) are more likely 
to have perioperative complications.
Asymptomatic sinus bradycardia in patients undergoing 
surgery under general anesthesia should be monitored by 
ECG during the procedure, which must be carried out where 
Class of recommendation Indication Level of evidence
I Atrial fibrillation with CHS2DS2VASc ≥2 C
I Intracavitary thrombus C
I Previous cardioembolic stroke C
IIa Risk score with 4 or 5 points B
FIGURE 11. Recommendations for oral anticoagulation in chronic Chagas cardiomyopathy.
there is the possibility of performing emergency pacemaker 
implantation. If bradycardia is symptomatic, preventive 
implantation of pacemaker should be considered.
Patients with atrial fibrillation with a high ventricular rate 
(>90 beats/min), regardless of the type of anesthesia, should 
be operated on under continuous ECG monitoring and prior 
scanning. In patients with atrial fibrillation with a ventricular 
rate <60 beats/min, the possibility of a marked decrease in 
the heart rate due to anesthetic agents must be borne in mind. 
In these cases, the surgical procedure should be performed 
under continuous ECG monitoring and in an institution able 
to perform emergency pacemaker implantation. The same care 
should be taken in relation to cases with AVB associated with 
bundle branch block, due to the possibility of developing full 
AVB during surgery due to the action of anesthetic agents(266).
Cases with complex ventricular arrhythmias should 
be evaluated by Holter and operated on after institution of 
appropriate antiarrhythmic therapy. The surgical procedure 
should be performed under continuous ECG monitoring and 
where there are defibrillators.
Preoperative evaluation of patients with cardiac pacemaker 
includes knowing the arrhythmia that lead to the implant, as 
well as generator characteristics. In addition to the clinical 
history, important data can be obtained from the card that 
cardiac pacemaker carriers receive and identifies the main 
characteristics of the device, such as the date of the implant, 
programmed heart rate, operating mode, and manufacturer.
The main risks associated with the presence of a pacemaker 
during surgical or diagnostic procedures consist of changing the 
unit’s operating threshold (by the action of drugs, changes in serum 
potassium levels, and changes in thoracic impedance for pulmonary 
ventilation), ventricular fibrillation (conduction of the electrical 
current from the electrocautery by the intracardiac electrode 
pacemaker) and, finally, damage, inhibition or reprogramming 
of the system by electrocautery, cardioversion, or magnetic 
resonance imaging. Whenever possible, biphasic electrocautery 
(bipolar) should be used, since the electric current remains 
confined between the region of the surgery and the electrocautery, 
reducing the risk of leakage and interference with the device(244) (267).
In any case, the use of electrocautery should be minimized. 
It should be used in short and irregular intervals, monitoring 
not only the ECG, but also the pulse by plethysmography or 
pulse oximeter. In the event of severe bradycardia or tachycardia 
during the use of the electrocautery, a magnet cover can be used 
over the pacemaker, which makes it work in its programmed 
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magnetic response. Attention should be paid to the fact that 
the placement of the magnet should be restricted to the short 
periods of electrocautery use. The patient should be advised 
postoperatively to return to the clinic for pacemaker follow-up 
for the assessment of its operation and eventual reprogramming 
of its generator(267).
In patients with a CDI, the presence of technician or specialist 
in the operating room is recommended. The antitachycardia 
function should be switched off, with staff prepared to treat any 
possible arrhythmias, including having to perform electrical 
cardioversion(244) (267). 
If electrical cardioversion is required in patients with 
pacemakers, the ideal would be to use adhesive pads in the 
anteroposterior chest position, as remote as possible from the 
generator, using as little energy as possible for resolution of the 
arrhythmia. Similarly, the thresholds and the functioning of the 
pacemaker should ideally be assessed after the procedure(244). 
Occupational health evaluation
Chronic Chagas cardiomyopathy is an important cause of 
incapacity to work in endemic areas. It should be the subject 
of surveillance actions for workers’ health, included in primary 
care. Careful clinical examination, with particular attention to the 
cardiovascular system, is the basic component of functional and 
occupational health evaluation in CCC(268). These assessments 
should take into account: the degree of ventricular dysfunction; 
the presence, magnitude and complexity of conduction and rhythm 
disorders; and the thromboembolism risk. It is also important to 
consider the characteristics of the labor activity performed by the 
worker, especially the need for intense or continued physical effort 
in the activity, as well as the degree of professional qualification of 
the worker and his/her ability to enroll in a vocational rehabilitation 
program. The age of the worker should also be considered, as the 
possibility of evolution of heart disease is greater for younger 
workers and vice versa. In general, the worse the LVEF and the 
greater the ventricular diameter, the worse the prognosis and the 
greater the inability to work(269). 
The presence of cardiomegaly and significant ventricular 
dysfunction implies incapacity to perform activities that require 
physical effort, and, when vocational rehabilitation is not 
possible, disability. In all functional assessments of prognosis 
and working capacity of an individual with Chagas disease, 
the great clinical variability of these cases should be taken into 
account, even when in the same stage of any classification of 
cardiac impairment. Often, but not always, advanced disorders 
of stimulus conduction are associated with the severity of 
myocardial damage, leading to the need for a complementary 
evaluation of the degree of myocardial dysfunction, especially 
in cases where the work requires intense physical activity and 
involves personal or social risk (e.g., aviation pilots)(270).
DIGESTIVE FORM OF  
CHAGAS DISEASE
The digestive form of Chagas disease can affect all organs 
in the gastrointestinal tract. However, from a practical point 
of view, it is manifested as involvement of the esophagus and 
large intestine, resulting in megaesophagus and megacolon, 
respectively(20). The association between megaesophagus and 
megacolon in cases that have an indication for surgery is 
approximately 92%. The association between megaesophagus, 
megacolon, and heart disease is 65%(271). A specific search for 
T. cruzi infection should be undertaken in patients with clinical 
syndromes consistent with those described below, who live 
in at-risk contexts and/or who have increased vulnerability to 
Chagas disease(20).
Diagnosis
Digestive manifestations in the acute phase of Chagas 
disease
Clinical manifestations are usually nonspecific, with 
practically imperceptible symptoms related to the gastrointestinal 
tract. However, there are reports describing the occurrence of 
gastrointestinal bleeding in cases of oral transmission and of 
dysphagia in rare cases of vectorial transmission(20). 
Digestive manifestations in the chronic phase of Chagas 
disease
Digestive manifestations of Chagas disease are concentrated 
in the esophagus and colon and are basically dysphagia 
and constipation, due to chronic alterations that can lead to 
megaesophagus and/or megacolon(20). However, as the disease 
causes autonomic nervous system injury throughout the 
gastrointestinal tract, anatomical and functional abnormalities 
of the salivary glands, stomach, extra-hepatic bile ducts, 
duodenum, small intestine, large intestine, and even of organs 
not belonging to the gastrointestinal tract, such as the ureter, 
can occur. The prevalence of Helicobacter pylori infection and 
of characteristic gastric endoscopic and histologic changes 
were similar in patients with and without Chagas disease. 
Furthermore, studies have shown that H. pylori is the main 
cause of gastritis in patients with Chagas disease(272). The most 
common symptoms and signs of the digestive system, in the 
chronic phase of Chagas disease, are described below.
Esophagus
Clinical diagnosis
Dysphagia is the main symptom of patients with severe 
impairment of the esophagus. Other dysphagia-related 
complaints occur in cases of megaesophagus, including 
ptyalism, hiccups, odynophagia, regurgitation, a sense of 
nocturnal choking, aspiration pneumonia, and malnutrition(20). 
In the early stages of the disease, the patient reports a feeling of 
obstruction at the level of the xiphoid after eating solids and, later, 
after fluid intake, especially cold fluids. Dysphagia progresses 
slowly and is well-tolerated for many years. Therefore, patients 
with achalasia often do not seek care in health services until 
the progressive dysphagia interferes with their lifestyle. It is 
observed that the patients themselves spontaneously change 
their eating habits to alleviate dysphagia. Patients with achalasia 
feed slowly, ingest large volumes of water to assist the food 
into the stomach, often bend the back, lift the chin, extend the 
neck, or walk to help esophageal emptying. Regurgitation of 
undigested food is common as the disease progresses, with a 
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risk of aspiration, which may lead to pneumonia, lung abscess, 
bronchiectasis, hemoptysis, and bronchospasm. Great distension 
of the dilated esophagus may lead to dyspnea, compression of 
the main stem of the bronchus or lung hilum.
Esophageal involvement occurs to varying degrees, with 
great variation in morphology and differences of esophageal 
motor behavior, ranging from minimal changes of esophageal 
transit to advanced forms of dolicomegaesophagus with 
an extremely prolonged esophagogastric transit time(20). 
Considering practical and therapeutic aspects, patients with 
megaesophagus can be classified into groups, depending on the 
degree of expansion of the organ, as shown in Figure 12(273).
Most cases of megaesophagus are found in groups II and III. 
The degree of megaesophagus does not necessarily reflect the 
duration of the disease. There are cases that rapidly progress 
to advanced forms, while others remain stable in the early 
stages. Lower esophageal sphincter dysfunction is greater in 
cases where the motor abnormalities of the esophagus are more 
Source: Rezende, 1982.(273) 
FIGURE 12. Radiologic classification of megaesophagus. (A) Group I: The esophageal diameter is within normal limits, without food stasis, but with an 
increase in food transit time from mouth to stomach. Functional motor disturbances predominate without corresponding dilation; (B) Group II: Moderate dilation 
of the esophagus with loss of motor control. Secondary and tertiary waves can be seen in the esophagogram. (C) Group III: More accentuated dilation than in 
group II, transit time more prolonged, and motor activity reduced. The esophagus behaves like an inert tube. (D) Group IV: Advanced form with massive dilation 
and stretching of the esophagus.
A=Group I; B=Group II; C=Group III; D=Group IV
Group I – Patients in this group present esophageal diameter within normal limits, without food stasis, but with an increase in food 
transit time from mouth to stomach. Functional motor disturbances predominate without corresponding dilation.
Group II – Patients present with moderate dilation of the esophagus e loss of motor control. Secondary and tertiary waves can be 
seen in the esophagogram.
Group III – More accentuated dilation can be observed than in group II, transit time more prolonged and reduced motor activity. The 
esophagus behaves like an inert tube.
Group IV – Consists of advanced forms with large dilation and stretching of the esophagus (dolicomegaesophagus).
A B C D
evident. Although there is a correlation between the degree of 
megaesophagus and the severity of dysphagia, it is common to 
find patients with bulky megaesophagus complaining  about or not 
even reporting dysphagia(273). Notably, the incidence of esophageal 
cancer in patients with idiopathic achalasia is 3.3%, 15 times 
higher than that of the general population without achalasia(274) (275).
Complementary examinations
• Plain radiography of the thorax (posterior-anterior or 
lateral views): In cases of megaesophagus grade III or IV, 
great dilation of the esophagus extending to the posterior 
mediastinum can be observed (Figure 13 A and B).
Contrast radiography of the esophagus: This shows not 
only the degree of esophageal dilation, allowing classification 
of megaesophagus, but also demonstrates functional changes, 
such as abnormal or missing peristaltic waves and the emptying 
time of esophageal contents into the stomach. The radiologic 
characteristics of megaesophagus in Chagas disease are: increased 
esophageal diameter and emptying time (Figure 14); a tapered 
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Source: Radiographs of a patient attended at the Hospital das Clínicas, Federal University of Minas Gerais (UFMG).
A B
FIGURE 13. Plain radiography of the thorax. (A) Posterior-anterior view and (B) lateral view, demonstrating the great dilation of the esophagus extending 
to the posterior mediastinum.
Note: Images taken 2 minutes (A) and 6 hours after ingestion of contrast (B). Note the pacemaker wires implanted in this patient due 
to AV block of concomitant Chagasic cardiomyopathy.
Source: Radiographs of a patient attended at the Hospital das Clínicas, Federal University of Minas Gerais (UFMG).
FIGURE 14. Contrast study of a patient with esophageal achalasia (group III ). Images taken (A) 2 minutes and (B) 6 hours after ingestion of contrast.
Note the pacemaker wires implanted in this patient due to AVB secondary to concomitant Chagas disease-associated cardiomyopathy.
A B
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distal third; retention of food debris; esophageal/mediastinal 
stretching; and reduced gastric volume.
• Esophageal electromanometry: This is a useful method 
to distinguish between the differential diagnoses of other 
diseases that develop due to motor dysfunction that present 
with dysphagia. In patients without dilatation, or with slight 
dilation of the esophagus (group I and II), uncoordinated 
pressure waves can occur in the body of the esophagus and 
incomplete or atypical relaxation of the lower esophageal 
sphincter (LES) can be observed. These findings precede 
radiologically demonstrated abnormalities(276).
• Endoscopy: Although endoscopy is not essential to confirm 
the diagnosis of megaesophagus, it should be performed to 
assess the degree of mucosal inflammation and to exclude 
the presence of neoplastic lesions in patients with dysphagia, 
varicose veins, and ulcers. This examination is useful in 
cases requiring forced balloon dilatation of the gastric cardia 
and in cases requiring botulinum toxin injection.
Colon
Clinical diagnosis
The main signs and symptoms of megacolon are constipation, 
paradoxical diarrhea (constipation interspersed by periods of 
diarrhea), dyschezia, abdominal distension, and fecaloma(20). 
Anorectal manometry is useful to diagnose internal anal sphincter 
achalasia. Colonic dilatation located in the rectum and sigmoid is 
better observed by contrast radiography studies and can be detected 
in up to 80% of cases. However, dilatation can occur only in the 
rectum, only in the sigmoid, or in the entire colon(277). It should 
be emphasized that the clinical picture of severe constipation in 
patients with idiopathic megacolon who are not infected with 
T. cruzi is indistinguishable from that induced by Chagas disease(278).
Complementary tests 
• Plain radiography of the abdomen: Bulky megacolons can 
be detected on plain radiographic films of the abdomen, 
especially if a fecaloma is present. Plain radiography is 
also useful in cases of suspected volvulus, since it can 
demonstrate rotation of the sigmoid and dilation of small 
bowel loops caused by obstruction (Figure 15).
• Contrast radiography of the colon (barium enema): This is 
the gold standard for the diagnosis of megacolon. It shows 
dilation and/or stretching of the colon, presence of fecaloma, 
and anatomic abnormalities of the sigmoid (Figure 16).
• Computed tomography and magnetic resonance imaging: 
These more modern imaging tests occupy a prominent 
place in the evaluation of patients with Chagas disease and 
are gradually replacing conventional imaging methods. 
Both methods are more sensitive in evaluating pericolonic 
and/or perisophageal  tissues; they can detect infiltration, 
not only visible masses and fecalomas detectable by 
conventional radiography. These modalities also provide 
greater detail than a barium enema (Figure 17 A, B and C).
• Digestive endoscopy: This is useful in cases of megacolon, 
to assess the degree of mucosal inflammation, detect 
ulcers, wall necrosis, perforation or bleeding, and to rule 
out the presence of associated lesions, particularly cancer. 
It is particularly important in cases of suspected sigmoid 
volvulus and can be therapeutic, since it might allow 
laparotomy to be avoided. If it is not possible to reduce the 
sigmoid volvulus by endoscopic examination, emergency 
surgery is absolute indicated.
Megaesophagus
Considering the impossibility of restoring normal physiology 
due to the irreversible changes caused by denervation, the goal of 
treatment is to act on the lower esophageal sphincter in a patient 
with achalasia, by removing the functional barrier to the passage 
of food into the stomach. The treatment, except if specific, does not 
cure the disease; it seeks only improve the symptom of dysphagia.(20)
Clinical treatment
This is indicated in patients with advanced age, with no 
history of complications, who are oligosymptomatic, are at 
high risk for surgical treatment, who refuse to undergo invasive 
treatments, or those treated in hospitals lacking adequate 
infrastructure to perform this type of surgery(20). The basis for 
the treatment is specified below.
Source: Radiograph of a patient attended at the Hospital das Clínicas, UFMG.
FIGURE 15. Simple radiograph of the abdomen in a case of sigmoid 
volvulus. Note the anomalous position of the sigmoid caused by the dilatation 
and the characteristic image of the small bowel loops secondary to the 
obstruction caused by the volvulus.
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Source: Radiograph of a patient attended at the Hospital das Clínicas, UFMG.
FIGURE 16. Radiograph of a barium enema examination revealing a 
hypodense image typical of a fecaloma.
A
B
C
Source: Computed tomography of a patient attended at the Hospital das Clínicas, UFMG.
FIGURE 17. Abdominal computed tomography, showing a megaesophagus with an air-fluid level formed by ingested contrast (A); megacolon with a large 
dilatation of the air-filled colon with a fecaloma in the rectum (B); and megacolon with a predominant image of a fecaloma in the dilated sigmoid (C).
1. Counseling and health education related to megaesophagus, 
in order to improve patient safety.
2. Adequacy of eating habits. It is recommended that the 
patient chew their food well; eat small amounts at a time; 
and consume liquid foods, pastes, and solids appropriate 
to their severity of dysphagia. Irritating foods, such as 
very spicy or hot foods or ice cream, aggravate dysphagia 
and should be avoided. Due to the risk of regurgitation 
and aspiration, food intake should be avoided before 
bedtime. Balanced enteral nutrition is indicated in patients 
with megaesophagus in Groups III and IV, malnourished 
patients, and candidates for surgical treatment. If the 
passage of a nasoenteric tube is not possible, parenteral 
nutrition can be administered via a central venous catheter. 
In both situations, the intervention is temporary.
3. Use of drugs: Medicines that relax smooth muscle fibers of 
the lower esophageal sphincter can relieve the symptoms 
of dysphagia. These drugs include:
• Isosorbide dinitrate, at a dose from 2.5mg to 5mg, 
administered sublingually, 15 minutes before each meal.
• Nifedipine, at a dose of 10mg, administered sublingually, 
30 minutes before each meal. The use of nifedipine 
should be performed with caution, considering the 
significant association of this condition with chronic 
Chagas cardiopathy; nifedipine may induce hypotension 
and shock.
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4. Botulinum toxin: Botulinum toxin type A, applied locally, 
blocks the release of acetylcholine from pre-synaptic nerve 
endings and leads to chemical denervation. The treatment 
is effective in 70% of patients, and the average duration of 
symptom remission is 16 months. Patients over 50 years 
of age respond better to this treatment(279) (280). Botulinum 
toxin treatment of megaesophagus has worse outcomes 
than those of dilation or surgery (level IIB). Although 
the effect is temporary, botulinum toxin injection may be 
indicated in selected cases, presenting the advantage that it 
can be repeated several times. The dose of botulinum toxin 
is 20 units injected into each of the lower quadrants of the 
esophageal sphincter. One of the limitations of this treatment 
is that the procedure should be guided by endoscopy.
5. Balloon dilatation: Pneumatic dilation is indicated for 
patients with group I megaesophagus, but can be performed 
in patients in groups II and III who have a contraindication 
to surgery. It can also be used preoperatively in patients in 
groups II and III who are candidates for surgical treatment 
of megaesophagus, aiming to improve their preoperative 
nutritional status. In patients in group IV, due to the risk 
of redundant esophageal perforation, dilatation is not 
recommended. The procedure is performed with a balloon 
coupled to gauge introduced endoscopically, which 
makes it the safest method. The result of megaesophagus 
treatment by balloon dilation relieves dysphagia in 71% 
of patients(280). However, the effect is transient, worsening 
over time with successive dilations.
Surgical treatment
1. Conventional surgery (laparotomy): This does not address 
the underlying cause of the disease, but restores the 
ability of the patient to swallow. Based on the knowledge 
gained about the pathogenesis and pathophysiology 
of megaesophagus, the cardiomyotomy known as 
Heller surgery(281), associated with some kind of partial 
fundoplication(282), is the most appropriate surgical 
procedure for cases of megaesophagus grades I to III. The 
response rate is about 90%(280), giving a more long-lasting 
and effective result than that achieved by pneumatic 
dilatation. For dolichomegaesophagus, there is still no 
consensus among surgeons; hence, different surgical 
techniques are still used.
2. Laparoscopic surgery: This technique was introduced in 
Brazil in the early 1990s, with simultaneous availability 
of modern surgical instruments, such as electronic 
scalpels and staplers. The experience of the surgeons with 
this technological innovation and its use in the treatment 
of cases of megaesophagus from achalasia related to 
Chagas disease, has reduced the morbidity and mortality 
associated with conventional surgery for megaesophagus 
induced by Chagas disease (level IA). Laparoscopic 
cardiomyotomy, associated with some type of antireflux 
valve, especially those made by partial fundoplication, has 
become standard surgery; it is virtually the standardized 
surgical procedure for patients with this condition(283).
3. Robotic surgery: Robotic surgery is probably the most 
advantageous of all the surgical options. However, the 
complexity of its implementation and the high associated 
costs hinder its routine application in practice(20). 
Megaesophagus treatment by myotomy associated with 
antireflux surgery carries a risk of esophageal perforation; 
this complication can be severe. Robotic surgery, by 
making scheduled and precise movements, will most 
certainly reduce the rate of this complication.
4. Endoscopic surgery: Technological advances and the 
increasing expertise of professionals has allowed myotomy 
to be performed as a totally endoscopic procedure. This 
surgery is now known by the acronym POEM (per-oral 
endoscopic myotomy). It uses the Heller technique, 
performed by transluminal endoscopic surgery through 
natural orifices [natural orifice transluminal endoscopic 
surgery (NOTES)]. This procedure was introduced by 
professionals from the Mayo Clinic Endoscopic division 
and, after testing on animals, the procedure was widely 
disseminated, being used in humans since 2012. The 
POEM technique seems to be a safe method, and is 
currently an effective alternative for the treatment of 
achalasia. 
5. The procedure is performed with the person in the 
supine position under general anesthesia, and consists in 
approaching the esophageal lumen with a high-definition 
gastroscope with frontal view. Saline stained with indigo 
carmine is injected to create a safety gap between the 
mucosa and submucosa of the esophagus. Then, a 2cm 
longitudinal incision of the mucosa is performed, at the two 
o’clock position, 10–15cm proximal to the gastroesophageal 
junction, to expose the submucosal layer. A tunnel is 
dissected in the submucosa, extending from the point of 
section to 2–3cm beyond the gastroesophageal junction 
(GEJ)(284). Myotomy of the lower esophageal sphincter is 
usually performed starting at 2cm distal to the opening of 
the mucosa to below the GEJ. As a rule, myotomy should 
have a minimum length of 6cm (on average, 8–10cm): 2cm 
in the esophagus, 2–3cm in the lower esophageal sphincter, 
and 2cm in the cardia. Dissection of the submucosal tunnel 
is performed in the plane before the muscle of the mucosa, 
and esophageal muscle section is performed only in the 
circular layer of the muscle, there is no need for longitudinal 
muscle layer section.
6. Data from 14 English language publications show that 
of 804 patients who underwent a POEM procedure, 
therapeutic success was documented in more than 80% 
(level A1)(285). The technique is less invasive and the 
patients do not experience gastroesophageal reflux, as 
observed in cases submitted to myotomy by conventional 
laparotomy or laparoscopy surgical technique. The 
familiarization of the endoscopist with the method enables 
secure closure of smaller perforations and adequate 
hemostasis (level B1)(286). If there is a more extensive 
perforation of the esophagus, or more intense bleeding, 
the assistance of a surgeon may be necessary.
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Megacolon
Clinical treatment
1. Health counseling and education related to 
megaesophagus, in order to improve patient safety.
2. Adequacy of eating habits: This should focus on a higher 
degree of self-care. Patients evacuated two to three times a 
week without reporting a fecaloma should be instructed to 
drink more fluids, and eat more fruits and vegetables. The 
use of a diet rich in fiber in these patients is controversial, 
because there is the fear that excess fiber may favor fecal 
impaction and the worsening of symptoms. The diet can 
be the patient’s usual diet, with restriction of constipating 
foods. Abundant water intake is recommended – a volume 
of at least 2L/day – as well as foods that favor intestinal 
functioning.
3. Regular defecation: It is necessary to systematically pay 
attention to the urge to defecate and to create the habit to 
evacuate at certain hours.
4. Laxatives: These are indicated for patients who do 
not adequately respond to dietary measures. Osmotic 
laxatives (20% mannitol or polyethylene glycol) are the 
most suitable. Mineral oil is also effective.
5. Avoidance of potentially constipating drugs: Opioids, 
diuretics, antidepressants, antihistamines, anticonvulsants, 
antiparkinsonians, among others, should only be 
prescribed under medical monitoring.
6. Removal of fecaloma: Fecalomas, located in the rectum, 
can be removed manually (under anesthesia) if they do 
not respond to dietary and drug measures.
7. Intestinal wash-out: Patients who do not respond 
satisfactorily to drug and dietary treatment, or those with 
significant fecalomas, should be treated with glycerin or 
saline enemas. Intestinal wash-out with 500–1,000mL 
twice a week is recommended for patients resistant 
to medical treatment. In patients with fecalomas, the 
procedure may be repeated two to three times a day, 
taking care not to use more than 3.5L of solution per day. 
Experience with these treatments shows that, with the 
removal of the fecalomas and normalization of bowel 
movements, the diameter of the colon tends to return to 
normal.
Surgical treatment
1. Elective surgery: Surgical treatment of megacolon is 
indicated for patients who have large dilatation of the 
sigmoid, repeated episodes of volvulus, prolonged 
retention of feces, recurrent fecalomas, and difficulties in 
applying enemas at home. Similar to the surgical treatment 
of megaesophagus, the goal of treating the megacolon is 
to improve or normalize the intestinal rhythm, since the 
predominant symptom is constipation. Except in cases 
of emergency caused by volvulus, bleeding, obstruction 
or perforation, in which emergency procedures must be 
adopted (colonoscopy or surgery), megacolon surgery 
is elective and should be well planned. The most 
commonly used conventional surgical techniques are 
the aforementioned rectosigmoidectomy and the surgery 
originally proposed by DuHamel for the treatment of 
Hirschsprung disease(287). With the advent and spread 
of laparoscopic surgery, the laparoscopic DuHamel 
procedure has become the gold standard for treatment of 
these cases(288).
2. Emergency surgery: The indications for emergency 
surgery to treat megacolon are:
• sigmoid volvulus not resolved by endoscopy; and
• ulceration, necrosis and/or perforation, due to volvulus 
or endoscopy.
3. The surgery to be performed will depend on the patient’s 
condition and anatomopathological situation. The surgical 
procedure may vary from a simple colostomy to fixing 
the part affected by sigmoid resection with primary or 
delayed anastomosis.
ANTIPARASITIC TREATMENT OF 
CHAGAS DISEASE
Although there is disagreement about the cure rates of the 
antiparasitic treatment of Chagas disease, there is consistent 
evidence showing its usefulness in both acute and chronic 
phases of the disease and in all clinical forms of chronic 
infection, as the organic lesions depend exclusively (acute 
phase) or at least in part (chronic phase) on the presence of 
the parasite. In addition, there is apparent suppression of the 
parasitemia with the current antiparasitic treatment(289) (290). 
In turn, the rates of cure and their confirmation depend on 
several factors, such as the phase and the duration of disease, 
the age of the patient, the tests used to evaluate therapeutic 
efficacy, the duration of follow-up after treatment, associated 
conditions, and the susceptibility of the specific T. cruzi strain 
to antiparasitic drugs.
Treatment in the acute phase
In the acute phase, treatment should be provided to all 
cases and as quickly as possible, regardless of the parasite 
transmission route (Class I, level of evidence B). Studies of a 
case series followed for over 20 years have shown cure rates 
above 50% at this stage of the disease(291).
Treatment of congenital Chagas disease
Patients diagnosed with congenital Chagas disease should 
receive antiparasitic treatment (more details on the specific part 
of vertical transmission)(20), regardless of whether the diagnosis 
has been made by parasitologic methods in the first weeks of 
life or by conventional serologic tests at least nine months after 
birth (Class I, level of evidence B).
Treatment of chronic phase
All children aged less than 12 years with chronic phase 
Chagas disease should be treated (Class I, level of evidence 
A). Prospective, randomized, double-blind, controlled studies 
with placebo, performed in asymptomatic school-aged children, 
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demonstrated therapeutic cure of T. cruzi infection in 58–62% of 
cases(292) (293). In an uncontrolled study involving Latin American 
countries(294), large regional differences were observed in 
treatment response rates: The seroconversion rate in Honduras 
was 92.7% for children aged 9 months to 12 years and 58.8% 
in a quarter of the study patients younger than 15 years. There 
were variations in Bolivia, from 0% in Sucre to 5.4% in Entre 
Rios. In the latter region this rate was higher in children younger 
than 5 years (24.4%) than in children aged 5–9 years (4.6%)(294).
For adolescents (aged 13–18 years) and adults with chronic 
infection, when it can be established that the acute phase 
occurred up to 12 years before (considered as recent infection) 
antiparasitic treatment is usually recommended(20) (294), although 
there is no consistent evidence from randomized studies 
justifying this (Class IIa, level of evidence C)(295).
For individuals with Chagas disease aged 19–50 years with 
no recent documented infection, antiparasitic treatment should 
be considered on an individual basis, whether in ICF(120) (252) 
(Class IIa, level of evidence B) or in the determined chronic 
form, without advanced cardiopathy(42) (120) (252) (295) (296) (297) (298) 
(Class IIb, level of evidence C). Specifically, treatment of 
chronically infected women of childbearing age, when provided 
before pregnancy, can reduce congenital transmission(104) (109). 
Some observational studies have shown that in this age 
group, antiparasitic treatment is able to prevent the onset or 
delay the progression of the disease in a significant proportion 
of cases(42) (120) (252) (295) (298). This would lead to a reduction in the 
complications of the disease, especially those related to heart 
disease. Classical experimental studies in mice have already 
documented total or partial regression of early myocardial 
injuries and the prevention of cardiopathy with antiparasitic 
treatment(299) (300). However, regression of inflammatory and 
fibrotic lesions, observed in experimental studies, has not been 
verified in the clinical context(20). 
A case series demonstrated cure in at least 20% of the 
cases treated in the late chronic phase(301). It should be noted 
that demonstrating cure depends on various factors, including 
follow-up of treated cases, which should continue for more than 
two decades for patients treated in the late phase. Increased 
seroconversion of cases showing no acute illness and without 
cardiac failure was also assessed(290). 
For individuals older than 50 years, without advanced heart 
disease, there are no studies justifying antiparasitic treatment. 
An observational study in elderly subjects infected with T. cruzi 
demonstrated that the disease is present and active – the percentage 
of patients with ICF decreases but the percentage with the heart 
form increases(195). Thus, these individuals should not be completely 
excluded from the etiological treatment plan of Chagas disease; 
treatment can be individualized (Class IIb, level of evidence C).
Antiparasitic treatment should not be given to patients with 
chronic phase Chagas disease with severe heart dysfunction, since 
there is no evidence of clinical benefit(251) (289) (291) (295) (296) (302) (303) 
(Class III, level of evidence C).
Recently, a series results from the BENEFIT study 
– a prospective, multicenter, randomized, double-blind, 
controlled study with placebo (placebo vs. benznidazole) – 
was published(251). This is the first study to evaluate the effect 
of a specific treatment for up to 80 days in relation to cardiac 
outcomes and T. cruzi infection. The effects of benznidazole in 
reducing morbidity and mortality among 2,854 patients with 
established chronic Chagas cardiopathy were evaluated(250) (251). 
After 5.4 years of follow-up, the results showed no statistically 
significant difference between the two groups in relation to 
the primary composite outcome that included death, sustained 
ventricular tachycardia, recent heart failure, implantation of a 
cardioverter-defibrillator or pacemaker, cardiac transplantation, 
resuscitated cardiac arrest, stroke, or other thromboembolic 
event(251). These findings, at first, seem to indicate a divergence 
of considerably lower rates of parasite detection by PCR in 
blood in the same study after treatment with benznidazole(303). 
In the BENEFIT study, the treatment with benznidazole in 
the protocol used probably has no significant preventive effect 
on the progression of heart disease in patients with advanced 
Chagas disease(251) (Class III, level of evidence B). However, 
the severity of Chagas disease is emphasized in this study, as is 
the resulting need for diagnosis and timely treatment, based on 
qualified management, especially of heart disease. In the study, 
503 patients died within 5 years (246 the in benznidazole group 
and 257 in the placebo group), and 63% of patients (in both 
treatment groups) developed a left ventricular ejection fraction 
<40%, one of the primary outcomes of the study(251). 
The study highlighted, therefore, the urgent need to structure 
a network of qualified health care to manage patients with 
Chagas disease comprehensively, without loss of diagnostic 
and treatment opportunities. Longitudinal clinical management 
is needed in terms of the various clinical forms of the disease, 
especially the advanced cardiopathy form, with protocols 
adjusted to local realities. In addition, the ability to create 
specific treatment opportunities for people with therapeutic 
indications based on more consistent evidence, is required(303).
Furthermore, the study draws attention to the lower 
frequency of serious adverse effects to benznidazole compared 
with previous study findings(251) (303). This reinforces the real 
possibility of including, in a more expanded form, the specific 
treatment of Chagas disease in the primary healthcare network 
(primary) not only in Brazil but also in other endemic countries.
The digestive form of Chagas disease is not a contraindication 
for antiparasitic treatment. Moreover, megaesophagus correction 
should be performed in order to ensure full transit of the drug and, 
subsequently, its absorption(20) (302) (Class IIa, level of evidence C).
Treatment of immunosuppressed cases
Cases with immunodeficiency, including patients taking 
immunosuppressive drugs to treat neoplasms, transplants, and 
other diseases, and patients with T. cruzi/HIV co-infection, 
can develop reactivation of Chagas disease(181) (184) (304). This is 
discussed, in themes, below.
Transplantation
In transplants in general, it is necessary to know if the 
donor or the recipient has Chagas disease, considering the risk 
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of transmission or reactivation of the disease. Thus, there are 
three possible scenarios:
• donors with Chagas disease and recipient without Chagas 
disease;
• donors without Chagas disease and recipient with Chagas 
disease;
• donors and recipient with Chagas disease.
Donor with Chagas disease and recipient  
without Chagas disease 
1. Guidelines for the donor with Chagas disease:  
• The candidate for organ donation who has positive 
serology for T. cruzi should be treated with antiparasitic 
drugs for 60 days before the procedure. In special 
situations requiring transplantation before completing 
treatment, the transplant can be performed, but if possible, 
not before 14 days of treatment has been completed (Class 
I, level of evidence C). 
2. Guidelines for the recipient when the donor is treated: 
a. Consider etiological treatment soon after transplantation, 
maintaining treatment for 60 days by means of intense 
immunosuppression (Class IIa, level of evidence C)(184).
b. Do not treat, but provide sequential clinical monitoring 
or parasitologic evaluation as follows: weekly direct 
search for T. cruzi in the peripheral blood, until 60 days 
post-transplantation; indirect parasitologic methods 
(blood and/or xenodiagnosis) of follow-up of the 
recipient during the period of immunosuppression; 
and serologic examination 30 and 60 days post-
transplant(181) (184) (305). In cases where monitoring is not 
possible, etiologic treatment is recommended. The 
following clinical and serologic examinations should 
be performed at 3, 6, 9, and 12 months of follow-up: 
direct/indirect parasitologic tests (blood culture and/or 
artificial xenodiagnosis at 3, 6, and 12 months) or PCR. 
Subsequently, the evaluation is repeated every 6 months, 
while there is persistent immunosuppression (Class 
IIa, level of evidence B)(181) (184) (305). It is noteworthy 
that, in some reference centers, PCR, but not indirect 
parasitologic examination, is performed. At any time, if 
an acute infection is detected through parasitologic or 
serologic tests, the conventional etiological treatment 
should be instituted. Out of the usual controls, any 
clinical signs suspicious of infection should be 
investigated through parasitologic examination, and 
positive cases should receive conventional treatment 
for the acute phase. Since 2009 in Brazil, organ 
transplantation laws have restricted the possibility of 
patients with Chagas disease being accepted as organ 
donors(183). In Brazil, Ordinance number 2,600, in 
2009, which approved the Technical Regulations of the 
National Transplant System, states that it is mandatory 
to perform serologic testing for T. cruzi infection 
in the following situations(183): I) for all donations, 
following the same algorithms used for screening 
blood donors; II) for registration purposes of potential 
organ recipients in a Single Technical Registry; III) 
for all potential deceased donor organs, tissues, cells, 
or body parts before the allocation of the grafts. It also 
establishes criteria for the classification of living and 
deceased donors as well as for potential recipients for 
the distribution of organs, tissues, cells, and captured 
parts. It does indicate that the team will decide whether 
the organ/tissue is acceptable for use or not regarding 
kidney, kidney/pancreas, pancreas, liver, and lung 
donations. In the order, the rejection of organs relates 
only to the heart. For ocular tissues, hematopoietic stem 
cells, musculoskeletal tissues, skin, and cardiovascular 
tissue, the issues related to T. cruzi infection are not 
mentioned(183).
3. Guidance for the recipient without Chagas disease: 
 In cases in which the donor with Chagas disease has not 
been treated or has received incomplete treatment, three 
possible actions may be taken in relation to the recipient:
a.  Start antiparasitic treatment soon after transplantation, 
for a 60-day period (class IIa, level of evidence C). This 
is recommended if the sequence monitoring indicated 
in item c below is not possible.
b.  Start treatment immediately after surgery, for an initial 
14-day period. Then, proceed to sequential monitoring 
with clinical, parasitologic, and serologic evaluation 
(Class IIa, level of evidence C or without evidence). If 
seroconversion occurs, introduce antiparasitic treatment 
for the acute phase.
c.  Do not treat, but proceed to sequential clinical monitoring 
and parasitologic evaluation (Class IIa level of evidence 
B)(181) (184) (305). Such evaluation consists of direct search 
for T. cruzi in the peripheral blood, every week, for 
up to 60 days, and indirect parasitologic and serologic 
examinations on days 30 and 60 after transplantation. 
Thereafter, clinical, serologic, and parasitologic (direct/
indirect/PCR) examinations should be performed every 
two months for up to one year of follow-up; then every 
six months, for as long as immunosuppression persists 
(time dependent on the mode and type of transplant). It 
is worth emphasizing that in some centers PCR, rather 
than indirect parasitologic examination, is performed.
d. At any time, if an acute infection is detected by 
parasitologic or serologic tests (IgM or seroconversion), 
conventional antiparasitic treatment should be started. 
Outside of the above-stated monitoring intervals, any 
clinical sign of suspected infectious condition should 
be investigated through parasitologic examination, and 
positive cases should receive conventional treatment for 
acute stage disease(20) (302). 
e. A few of cases have been reported of kidney transplant 
recipients without Chagas disease who were treated with 
antiparasitic prophylaxis for 14 days, as the organ donors 
had Chagas disease(308). In another work, prophylaxis 
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was provided for 60 days to recipients (without 
Chagas disease) who received livers from donors with 
Chagas disease(306) as usual strategy; seroconversion 
was not observed in the surviving recipients, as this 
may not occur in about 20% of patients in the post-
transplant period . Use of antiparasitic drugs in patients 
without documented infection (no identification of the 
parasite or evidence of seroconversion) is considered 
prophylactic use. In this text, even when the drug was 
administered for the same duration as the duration of 
treatment (60 days), the term prophylaxis has been used 
if the drug was used in the absence of a documented 
infection in the recipient. The works cited are not 
controlled and, in addition of having been carried out in 
a small number of cases in kidney and liver transplant 
recipients, these did not use the systematic monitoring 
of parasitemia, and the final results were based on the 
absence of seroconversion in patients who survived.
f. However, since 2009, the possibility of patients with 
Chagas disease being accepted as organ donors in Brazil 
has been restricted by transplant regulations(184), with 
systematic serologic screening limiting this type of 
donation in individuals with T. cruzi infection. However, 
these same organs can function as "marginal organs" in 
specific situations(184) (305) (307).
Donor without Chagas disease and recipient  
with Chagas disease
In these cases, the expected complication is the reactivation 
of Chagas disease in the recipient, due to the use of 
immunosuppressive drugs to prevent or treat rejections. With 
time, pre-transplant conventional antiparasitic treatment can 
be instituted. However, it should not prevent the realization of 
transplantation, as subsequent actions can be adopted (Class 
IIa, level of evidence C).
1. Prophylaxis of episodes of reactivation: In heart transplant 
recipients, antiparasitic treatment may fail(100) (307). 
2. Clinical and parasitologic monitoring of the recipient 
after transplantation should be carried out, as in the case 
with a donor with Chagas disease and a recipient without 
Chagas disease, and early conventional treatment of 
reactivation episodes should be provided(181) (184) (305). The 
monitoring during the post-transplant period in patients 
receiving cardiac transplantation is mandatory and must 
include monitoring of blood and tissues, due to the 
greater sensitivity of the methods in the reactivation site 
(myocardium).
Donor and recipient with Chagas disease
Both should be considered as carriers of the chronic form 
of Chagas disease and should be evaluated for antiparasitic 
treatment, as described for cases with the chronic form of the 
disease. After transplantation, the recipient should be monitored 
from a clinical and parasitologic point of view for the diagnosis 
of potential episodes of reactivation, such as in the case of a 
donor with Chagas disease and a recipient without Chagas 
disease. If reactivation occurs, conventional treatment for the 
acute phase should be provided (class IIa, level of evidence C). 
Episodes of reactivation can occur more than once and should 
be treated when documented. Hence, systematic parasitologic 
monitoring while immunosuppression persists, is recommended.
Coinfection Trypanosoma cruzi/HIV
Observational studies have shown that, in the presence of 
T. cruzi/HIV coinfection without AIDS, the natural evolution 
of both diseases occurs, and one should follow the guidelines 
for antiparasitic treatment of Chagas disease in its acute and 
chronic forms, or monitoring of parasitemia, quantitatively if 
possible(49) (159) (175) (Class IIa, level of evidence C) (see specific 
part of this Consensus). In patients with co-infection and 
AIDS, reactivation of Chagas disease might occur, and the 
following measures are recommended: Specific antiparasitic 
treatment is indicated for reactivation with a clinical syndrome 
of myocarditis, meningoencephalitis, or other; and parasitologic 
examination of the blood or cerebrospinal fluid yields 
positive results by direct microscopy; or characteristic lesions 
are demonstrated on histologic examination of tissue specimens(20) 
(49) (159) (Class I, level of evidence C). This therapeutic approach 
should also be adopted in cases without evidence of reactivation 
but with the associated clinical syndrome and a high level 
of parasitemia, as defined by Sartori et al. as the presence of 
more than 20% of positive nymphs in the same xenodiagnostic 
test (indirect parasitologic examination, quantitative PCR) or 
sustained parasitemia(49) (159) (175) (308) (Class IIa, level of evidence C).
Coinfection and prophylaxis
By analogy with other opportunistic infections in AIDS, 
secondary prophylaxis can be used for patients with reactivation 
of Chagas disease, who were treated for and achieved clinical 
and parasitologic remission, when the levels of CD4+ T 
lymphocyte were less than 200 cells/mm3 (IIa class, level of 
evidence C(20) (49) (159) (175). However, this recommendation needs 
to be validated in prospective studies, considering the low 
frequency of relapse observed in patients taking combined 
antiretroviral treatment. 
Immunosuppression in other diseases associated with 
Chagas disease
Clinical conditions such as neoplasms and collagen vascular 
disorders in carriers of Chagas disease might be associated 
with reactivation. The recommendations are the same as those 
for reactivation occurring in organ transplantation patients and 
patients with HIV coinfection(20) (49) (159) (175).
Accidental transmission
In accidents characterized as high risk for disease 
transmission, such as percutaneous injury or mucosal contact 
with biological material containing live parasites (samples 
for the culture of T. cruzi obtained from of patients with high 
parasitemia or necropsy material, vectors, and animals that 
are already infected), primary prophylaxis should be given. 
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Prophylaxis should be initiated immediately after the accident 
and should be continued for 10 days(309) (310) (311). (Class IIa, level 
of evidence C). Serologic tests should be performed before 
initiating treatment and after 20, 40, and 60 days post-treatment 
to monitor possible seroconversion. In the case of positive 
serologic results, conventional antiparasitic treatment should 
be provided, as described previously for the acute phase. 
In minimal risk situations, such as the contact with the blood of 
a patient with Chagas disease in chronic phase, drug prophylaxis 
is not indicated. Serologic tests should be performed immediately 
after the accident, and 20, 40, and 60 days post-infection. If 
seroconversion occurs, conventional treatment for acute phase of 
Chagas disease should be given, and post-therapeutic monitoring 
should be conducted as in the acute phase. If the serology remains 
positive after treatment, the therapeutic gap should be documented 
and repeat treatment provided, either with the same drug or with 
an alternative drug(20).
Treatment options, dosage, and type of administration 
The neglected character of Chagas disease is evidenced by 
the limited therapeutic options; only two antiparasitic drugs 
with established efficacy are available for specific treatment: 
benznidazole (a nitroimidazole derivative agent) and nifurtimox 
(a nitrofuran compound)(14) (19) (20) (38) (42) (293) (294) (296).
The drug of first choice for the antiparasitic treatment of 
Chagas disease in all the situations previously discussed is 
benznidazole(20) (38) (100) (294). Currently, this medicine is produced 
by a Brazilian pharmaceutical company, distributed by request 
to the Ministry of Health of Brazil, with no distribution to the 
general pharmaceutical market(20) (39).
Benznidazole is a well-tolerated drug(20) (38) (251). Children 
generally have fewer adverse effects than adults and can 
tolerate higher doses(104). In April 2013, the 19th Expert 
Committee on the Selection and Use of Essential Medicines 
of the WHO discussed and approved the addition of two new 
formulations of benznidazole in the essential drugs list for 
children(38). Benznidazole is being increasingly prescribed 
for the antiparasitic treatment of Chagas disease, not only the 
expansion of indications based on evidence, but also as a result 
of increased demand in endemic and non-endemic countries 
with better structure of their national surveillance and healthcare 
systems(38) (294) (295) .
Benznidazole (Class 1, level of evidence b) is produced 
as tablets of 100mg and 50mg (adults) and 12.5mg and 50mg 
(children)(20) (42) (104) (109) (122) (291) (296) (299) (302) (312) (313). In Brazil, only 
the 100mg and 12.5mg tablets are available in the SUS network.
• Adults: 5mg/kg/day, orally, in two or three daily doses, 
for 60 days. 
• The maximum dose recommended is 300 mg/day.
The 100mg and 50mg benznidazole tablets are distributed 
in Latin America by the Argentine Endocrine Laboratory 
(ELEA, Maprimed) and the PAHO Revolving Fund; in 
Spain, through the Spanish Agency for Medicines and Health 
Products; and the rest of the world through the ELEA and the 
WHO(38). In Brazil, it is acquired by the Ministry of Health, 
and distributed to State Health Secretariats (SES) upon request 
in the Information Strategic Procurement System (SIES). 
Benznidazole distribution flow (100mg) for regional and/or 
municipalities should be established for each SES, articulating 
Pharmaceutical Assistance, Epidemiological Surveillance and 
Primary Care. The distribution of benznidazole in doses of 
12.5mg is centralized, considering the small occurrence of 
cases of the disease in the recommended age for use of the 
drug. Therefore, to apply for a pediatric formulation, the Chagas 
Disease Technical Group, Communicable Disease Surveillance 
Coordination of the Secretariat of Health, Ministry of Health 
should be contacted(49).
• Children: 10mg/kg/day orally in two or three daily doses, 
for 60 days.
• In all cases, the dose should not exceed 300mg/day. When 
the daily dose exceeds 300mg, it is recommended that the 
treatment duration be extended to achieve the total dose 
calculated for 60 days.
The main advantage of the 12.5mg tablet is that it can be 
used to treat infants as young as 2 years of age, allowing proper 
dosing without the need to fragment and manipulate parts of 
larger tablets. In addition, the main advantage of 50 mg tablet 
is that it can be used to treat the rest of the pediatric population, 
including teenagers and young adults(38).
In addition to the specific treatment for T. cruzi infection, 
antiparasitic drugs can be used for prophylaxis in specific 
situations. Secondary prophylaxis should be considered after 
conventional treatment of reactivation in patients co-infected with 
HIV, and with evidence of AIDS (2.5 to 5mg/kg/day, orally, three 
times per week), but there is still no consistent evidence to validate 
the use of benznidazole prophylactically in this situation(49) (159) (175).
In turn, primary prophylaxis is indicated in situations where 
accidental exposure to T. cruzi has occurred. The recommended 
dose is 5mg/kg/day (adult) or 10mg/kg/day (child), orally, twice 
a day for 10 days, not exceeding 300mg/day. In cases where the 
inoculum has a high parasite load (≥107 trypomastigotes/mL), 
one should use conventional treatment for acute phase of Chagas 
disease for at least 60 days(310) (Class IIa, level of evidence C). 
In the case of children, one should use the pediatric formulation 
of benznidazole, that is now available. 
The adverse effects and toxicity of benznidazole, together 
with the respective actions to be taken, are shown in Figure 18. 
Thus, care should be taken before and during treatment to monitor 
these events. Before starting treatment, clinical examination 
and laboratory tests (complete blood count, evaluation of liver 
enzymes, and renal function tests) must be performed. This must 
be repeated 30 and 60 days after initiating treatment(20). 
In cases of intolerance to benznidazole, nifurtimox is a 
potential therapeutic option(20) (42) (119) (291) (292) (296) (312) (Class 1, level 
of evidence B). Nifurtimox comes as a 120mg tablet (adults) 
and a 30mg tablet (children).
• Adults: 10mg/kg/day, orally in three daily doses, for 60 
days.
• Children: 15mg/kg/day, orally in three daily doses, for 60 
days.
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The adverse effects and toxicity of nifurtimox are similar to 
those of benznidazole, except for a lower digestive tolerance, 
reflected in anorexia with weight loss, and psychological 
disturbances(20). In case of treatment failure with benznidazole, 
nifurtimox can be used, although cross-resistance between the 
two drugs has been observed.
It is necessary to remember that nifurtimox is not available in 
the pharmaceutical market of any country to date. In situations 
where the use of nifurtimox is essential, the drug must be 
requested via the PAHO and WHO offices. The Ministry of 
Health of Brazil, through the SVS Chagas Disease Technical 
Benznidazole
Manifestations/
adverse effects
Onset/
treatment 
period
Characteristics Localization Intensity Intervention Complementary 
measures
Dermatitis by 
hypersensitization is 
most frequent. NOT 
dose-dependent and 
NOT related to T. 
cruzi.
Recovery without 
sequelae.
10th day of 
treatment, may 
occur earlier or 
later
Non-bullous, 
pruritic, 
polymorphous 
erythema followed 
by scaling. 
Rarely oncolysis 
occurs 
Focal (restricted 
to part of 
the skin) or 
generalized 
Light (normally 
focal)
Continue 
treatment
Specific treatment 
for scaling and 
cutaneous 
desquamation, 
guided by a 
dermatologist
Hospitalize 
according to clinical 
presentation
Moderate (focal 
or generalized)
Continue 
treatment with 
low dose of 
corticosteroid 
(5 mg of 
prednisone 
or equivalent) 
Interrupt if 
worse
Severe 
(generally 
accompanied 
by fever and 
mphadenopathy)
Interrupt 
treatment
Use 
corticosteroid
Peripheral 
polyneuropathy. 
Dose-dependent, 
slow regression 
(months)
End of 
treatment
Pain and 
paresthesia
Plantar (more 
frequently) and 
palmar regions
Light to 
moderate
Interrupt 
treatment 
General treatment 
for peripheral 
polyneuropathy, 
guided by a 
neurologist
Ageusia End of 
treatment
Partial or total loss 
of taste
- - Interrupt 
treatment
-
Bone marrow 
depression
Between 
the 20th and 
30th days of 
treatment
Leukopenia with 
varying degree 
of neutropenia, 
may attain 
agranulocytosis
- Interrupt treatment General treatment 
for bone marrow 
suppression, guided 
by a hematologist
Digestive intolerance is rare (controlled with medication usually used for gastritis and peptic ulcers). Severe liver impairment is rare. Renal 
impairment has not been observed.
FIGURE 18. Adverse effects of benznidazole and recommended approaches for each situation.
Group, has the availability of nifurtimox to be dispensed under 
the conditions described above of benznidazole intolerance. 
Nifurtimox is acquired by the Ministry of Health via PAHO 
donation and is dispensed directly by the Chagas disease 
Technical Group of SVS(39). The product may be requested 
through a standardized protocol directed to this technical group 
by the Ministry of Health.
Other drugs, such as allopurinol and azole antifungals 
(ketoconazole, itraconazole, fluconazole, posaconazole), are 
recognized as suppressors of T. cruzi parasitemia and may 
be useful in some specific situations, such as reactivation 
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FIGURE 19. Summary of treatment situations, the recommendation class and level of evidence.
in immunosuppressed patients, when it is impossible to use 
benznidazole or nifurtimox(49) (159) (175) (Class IIa, level of 
evidence C). However, there is undeniable clinical evidence of 
proven therapeutic efficacy.
The antiparasitic treatment with benznidazole should not 
be imposed on pregnant women, or women of childbearing age 
who are not making a regular use of well-known contraceptive 
methods(20). As discussed in the specific section on vertical 
transmission of T. cruzi in this Consensus, there is evidence 
indicating the benefit of the antiparasitic treatment, with better 
evolution of Chagas disease(116) (119) (120) (121) (122), reduced risk of 
vertical transmission in future pregnancies(109) (116), and lower risk 
of vertical transmission and evolution to spontaneous abortion 
by reducing the parasitemia(103) (115). 
In the case of pregnant women for whom antiparasitic 
treatment is indicated, the risk-benefit ratio and available 
treatment options (in particular, acute phase and co-infection) 
should be considered in each case. The indication in patients 
with other serious disorders, such as hepatic and renal failure, 
must be carefully assessed case by case, according to the 
severity, as well as prior adverse events to drug components 
that may constitute relative contraindications(20) (38) (104).
Evaluation of cure of Chagas disease after antiparasitic 
treatment
Demonstrating serology becoming negative is considered 
the only method to determine cure following antiparasitic 
treatment of Chagas disease. The time required for this to 
Event Recommendation 
class
Level of 
evidence
Antiparasitic treatment in the acute phase of Chagas disease I B
Antiparasitic treatment in congenital Chagas disease I B
Antiparasitic treatment in the chronic phase of Chagas disease in children aged ≤12 years I A
Antiparasitic treatment in the chronic phase of Chagas disease with recent infection IIa C
Antiparasitic treatment in the chronic phase of Chagas disease with late infection, acquired in 
the indeterminate form
IIa B
Antiparasitic treatment in the chronic phase of Chagas disease with late infection and 
cardiomyopathy without advanced disease
IIb C
Antiparasitic treatment in the chronic phase of Chagas disease with advanced cardiac form of 
the disease
III C
Digestive form does not contraindicate antiparasitic treatment of Chagas disease IIa C
Antiparasitic treatment in an organ donor with Chagas disease I C
Antiparasitic treatment in an organ recipient without Chagas disease from organ donor with 
Chagas disease
IIa C
Monitoring of clinical and parasitologic events instead of antiparasitic treatment in an organ 
recipient without Chagas disease from an organ donor with Chagas disease
IIa B
Reactivation prophylaxis in transplanted person with Chagas disease IIa C
Monitoring of clinical and parasitologic events and prophylactic antiparasitic treatment for 
transplanted person with Chagas disease
IIa C
Coinfection Chagas/HIV without AIDS: antiparasitic treatment according to criteria in 
immunocompromised
IIa C
Reactivation antiparasitic treatment in coinfection Chagas/HIV I C
Antiparasitic treatment in coinfection Chagas/HIV without clinical events and high T. cruzi 
parasitemia
IIa C
Secondary prophylactic treatment after reactivation antiparasitic treatment in coinfection 
Chagas/HIV in individuals with CD4+ lymphocyte T count <200 cells/mm3
IIa C
Primary prophylaxis in laboratory accident with high risk of transmission of Chagas disease IIa C
Benznidazole as first choice drug for antiparasitic treatment of Chagas disease I B
Nifurtimox as a therapeutic option (instead of benznidazole) for the antiparasitic treatment of 
Chagas disease
I B
Allopurinol and azole antifungals as reactivation treatment in immunosuppressed patients when 
benznidazole and nifurtimox treatment are not possible.
IIa C (or unknown)
Serology as a criterion of cure and therapeutic failure after antiparasitic treatment for Chagas 
disease
IIa B
PCR as an alternative to indirect parasitologic examination (artificial xenodiagnosis and blood 
culture) as an indication of therapeutic failure after specific treatment for Chagas disease
IIa B
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occur is variable and depends on the stage and duration of 
disease, with one year for congenital infection, 3–5 years for 
the acute phase, 5–10 years for the recent chronic phase and 
>10 years (usually 20–25 years) for the chronic phase of long 
duration. The reduction in serologic test titers occurs gradually. 
The persistent and progressive decline above three dilutions 
of the titers of the serologic tests is suggestive that these will 
be negative. Parasitologic examinations are not mandatory 
for evidence of cure of Chagas disease, however, at any time, 
positive parasitologic tests indicate therapeutic failure. PCR is 
an alternative option to indirect methods (xenodiagnosis and 
blood culture) in the parasitologic evaluation as a treatment 
failure criterion after completing antiparasitic treatment(104) 
(313). However, there are still limitations on the availability and 
standardization of techniques in the health networks of endemic 
countries(313). 
Who and where to treat
Considering the operational specificities of national health 
systems, use of antiparasitic treatment for Chagas disease by 
doctors working in primary care who know the peculiarities 
of the drugs and Chagas disease(20) (303), is feasible, safe(20) (251) 
(294) (303) (312), and operationally possible(294). Depending on the 
severity of clinical conditions of each case, particularly cases 
with acute or reactivated and decompensated chronic forms, it 
may be necessary to refer certain patients to more specialized 
or reference units that have greater technological capability, or 
even for hospitalization.
Figure 19 provides an overview of potential situations for 
specific treatment, taking as reference the recommendation of 
class and the level of existing evidence. Figure 18 shows the 
adverse effects of benznidazole and recommended approaches 
for each given situation.
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Definitions of grades or classes of recommendations and 
levels of evidence1
Classes of recommendations
• Class I: conditions for which there is conclusive evidence, 
or, in its absence, general agreement that the procedure or 
treatment is useful and/or effective.
• Class II: conditions for which there is conflicting evidence 
and/or divergence of views on the utility/effectiveness and 
safety of the procedure or treatment:
• Class IIa: evidence and opinions favor the indication for 
the procedure or treatment; most professionals involved 
in specific management approve;
• Class IIb: utility/effectiveness and safety is less well 
established by evidence, with opinion divided; procedure 
or treatment is considered optional.
• Class III: conditions for which there is conclusive 
evidence and/or general agreement that the procedure/
treatment is not useful and/or effective, and may even be 
harmful in some circumstances.
ATTACHMENTS
Levels of Evidence
• Level A: data from several consistent and good quality 
randomized trials or robust meta-analysis of randomized 
clinical trials.
• Level B: data obtained from a single randomized clinical 
trial or from several non-randomized clinical studies, 
observational (less robust meta-analysis).
• Level C: data obtained from consensual opinions of 
specialists on the subject.
1Based on international publications and particularly endorsed in the First 
Latin American Guidelines for the Diagnosis and Treatment of Chagas Heart 
Disease.203
Evidence levels ranked as B or C cannot be interpreted as weak recommendations. 
There are many consensus-based recommendations, so with the recommendation 
of class I, level of evidence C (expert opinions). On the other hand, some 
indications considered controversial (recommendation grade II) may be 
grounded in randomized controlled trials (level of evidence A).
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